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Abstract
Mammary gland involution proceeds through massive, highly controlled epithelial cell
apoptosis and tissue remodelling. Thus the mammary gland represents an ideal
physiological environment in which to study apoptosis. Recently the Smad gene family
have been identified as mediators of TGF-(3 superfamily signalling and have been
implicated in mediating epithelial cell apoptosis. The Smad family of signal transduction
proteins focuses around a central mediator, Smad4, and this thesis reports a number of
analyses to investigate the potential apoptotic role of this and other Smad proteins.
To investigate the effects of Smad proteins in normal euploid cells, various Smads were
over-expressed in embryonic stem cells (ES cells). Analysis of lig2nd-specific Smads 1,
2, 3 and the central mediator Smad4, showed that only Smad4 could induce both a G1
arrest and apoptosis. This confirmed a role for Smad 4 in engaging apoptosis, and these
studies were then extended to an in vivo model of apoptosis, namely involution of the
mammary gland. This was undertaken using two transgenic approaches. First, a
mammary-specific Smad4 transgenic strain was created which utilised the ovine beta-
lactoglobulin gene (BLG) promoter to drive Smad4 expression to the mammary
epithelium during lactation. Remarkably, mice transgenic for Smad4 and characterised as
over expressing Smad4 throughout lactation and involution showed no overt phenotype.
This result may arise because levels of Smad4 are already limiting in the normal
mammary gland, because functional activity of Smad4 is being repressed, or even because
Smad4 does not mediate a central role in the apoptotic response in the mammary gland.
The second transgenic approach was to create mice with a conditional Smad4 allele using
the Cre-Lox system. A floxed targeting construct was successfully used to target ES cells
and these were then subsequently used to create chimeras. Germline transmission of the
floxed Smad4 allele and subsequent crossing to a BLG-Cre transgenic will generate a
powerful tool to investigate the requirement for Smad4 specifically within the mammary
epithelium. Finally, Smad-STAT interactions were analysed biochemically during
involution of the mammary gland. Other workers had previously demonstrated these
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pathways interact in vitro and this was confirmed in vivo with data suggesting a novel role
for STAT3 as an inhibitor of Smad activity during involution.
In conclusion this thesis has addressed the role of the Smad proteins, and especially
the role of the central mediator Smad4, in mediating apoptosis. I have shown that
Smad4 can mediate apoptosis in normal euploid cells in culture, but that over
expression of Smad4 in the mammary epithelium apparently fails to alter the
programme of involution. This result may arise as a consequence of interaction with
other pathways, as I have also demonstrated crosstalk between the Smad and STAT
signalling pathways in vivo. Finally, I have used Cre-Lox technology to create a
conditional Smad4 allele, which can now be used to facilitate detailed, tissue specific
analysis of Smad4 function in vivo.
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Chapter 1 - Introduction
1.1 The Transforming Growth Factor-B (TGF-B) Superfamily
The TGF-|3 superfamily comprises an extremely large number of structurally related
polypeptide growth factors, each capable of regulating a fascinating array of cellular
processes, including cellular proliferation, lineage determination, differentiation,
motility, adhesion and death. Expressed in complex temporal and tissue-specific
patterns, TGF-|3 and related factors play a prominent role in the development,
homeostasis and repair of virtually all tissues in organisms from fruitfly to human.
TGF-|3 and related factors are multifunctional agonists whose effects depend on the
state of responsiveness of the target cells as much as on the factors themselves.
Given this varied nature it is not surprising in retrospect that the gradual discovery of
these factors over the past years has been made through very disparate lines of
investigation. For example, the founding member of the family, TGF-fSl, was
identified as a regulator of mesenchymal growth (Heine et al, 1987) and, separately,
as an antimitogen in epithelial cells (Kurokowa, et al, 1987). The same is true of
other members of the family, for example Activins and Bone Morphogenic Proteins
(BMPs), and enforces the idea that members of this family can have varied effects
dependent on the situation or circumstance. This phenomenon of "multi-tasking"
ligands had remained unexplained for more than fifteen years until the discovery of
the Smad family of signal transduction/transcription molecules in 1996. However,
before this point in time much had been elucidated about the ligands themselves and
activation of their receptor families, and also about target genes which encode
immediate effectors of cellular responses, such as cell cycle regulators and
extracellular matrix components.
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1.1.1 Biological Actions of TGF-B
TGF-P and its related factors control cell fate by controlling proliferation,
differentiation and apoptosis and are therefore important for both the development
and maintenance of nearly all tissues (Hogan, 1996). TGF-p has a multitude of
actions, the most important of which may be to regulate genes whose products
contribute to the growth and stability of the extracellular matrix (ECM). Thus it
stimulates the production of collagen, fibronectin and other ECM components and
decreases the production of proteases that degrade the ECM. Since these early
discoveries, TGF-P has been demonstrated to be both a potent negative regulator of
growth for a wide variety of cell types, including cells derived from epithelial,
endothelial, neuronal, haematopoietic and lymphoid origins and a potent mitogen for
other cell types, for example mesenchymal cells. The growth inhibitory effect of
TGF-P is thought to be the molecular basis for many more of the global effects of
TGF-P including the regulation of immune responses, development and cellular
differentiation. In addition to its effects on cell proliferation and differentiation,
TGF-P also regulates many biological processes through its ability to
transcriptionally regulate a huge number of important cellular genes (Massague,
1990). For example, TGF-P regulates wound healing, cellular adhesion and
extracellular matrix deposition through its ability to co-ordinately control the
expression of extracellular matrix proteins and the proteases which degrade them.
TGF-P stimulates the anchorage-dependent proliferation of some cells and inhibits
the proliferation of others. Although the ability of TGF-P to affect different cell types
in opposite ways is puzzling, it may not reflect fundamental differences in the initial
cellular responses to TGF-P. Instead, the different types of cellular responses may
arise because TGF-P initiates a number of changes in all responsive cells, some of
which may lead to proliferation and others to proliferative arrest. Depending on the
individual responses of specific cell types and on the environment of the cells, the
balance of the effects of these changes could lead to cellular proliferation or
inhibition of proliferation. TGF-P is a cytokine commonly associated with
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differentiation of cells. For example in mammals it is found at highest concentrations
in the tip of the intestinal villus where it is associated with the most differentiated
cells (Murphy, 1998). This observation has given rise to the postulate that it is
involved in an "autocrine axis" that regulates the orderly progression of differentiated
cells not only in the intestine but also in the skin, perhaps explaining its vital role in
wound healing (Wahl et al, 1989). Other members of the family, especially the Bone
Morphogenic Proteins, are also very important in the healing processes that occur in
bone and cartilage (Bostrom and Asnis, 1998).
(a) TGF-B and the Immune System
TGF-j3 is produced by a wide range of immune cells including macrophages, NK
cells, T cells and B cells, and has both pro- and anti-inflammatory properties,
depending on its environment and concentration (reviewed in Wahl, 1994). Perhaps
the most important pro-inflammatory property of TGF-P is its ability to recruit
monocytes, T cells and neutrophils to the site of inflammation early in an infection,
through modulation of endothelial cell adhesion molecule expression. However, at
high concentrations TGF-P can have strong anti-inflammatory properties including
suppression of TNF-a and NO from macrophages (Alleva et al, 1994), inhibition of
IFN-y and TNF-a from NK cells (Bellone et al, 1995) and it can also antagonise
IFN-y-stimulated up regulation of major histocompatibility complex (MHC) class II
antigens (Nandan and Reiner, 1987). Antagonism of IL-4, IL-2 (Reugemer et al,
1990) and IL-12 by TGF-P is also well documented (Pardoux et al, 1997). The
importance of TGF-P in limiting inflammation is clearly demonstrated in TGF-p-
knockout mice, which die at weeks of age from a wasting syndrome associated
with multifocal inflammatory disease (Shull et al, 1992). Pathological examination
of null mice has revealed an excessive inflammatory response with massive
infiltration of lymphocytes and macrophages in many organs, but primarily in heart
and lungs. Many lesions in this model resemble those found in autoimmune
disorders, graft-vs. -host disease or in certain viral diseases (Kulkarni et al, 1993 (a)
and (b)). This mouse model is also characterised by a host of other symptoms which
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confirm the multifunctional nature of TGF-[3l. Evidence is constantly accumulating
which shows that TGF-J3 is a key cytokine which regulates immune function in vivo,
and that overproduction of TGF-(3 may be associated with immunosuppression.
Cytokines are known to be important mediators of immune regulation by regulatory
cells, and similarly the direct administration of cytokines can affect autoimmune
processes and influence the recovery from autoimmune disease. It has been shown by
Santambrogio et al. (1993) that the administration of TGF-(3 provides protection
against autoimmune encephalomyelitis (EAE), a condition which is thought to reflect
certain aspects of multiple sclerosis (MS) in humans, and can be induced in rodents
by injection of myelin antigens such as myelin basic protein (MBP) in complete
Freund's adjuvant. T-cell lines and clones that transfer EAE in the rat and mouse
produce the Thl cytokines IFN-y, IL-2, tumour necrosis factor-a (TNF-a) and TNF-
(3, and these cytokines are also present in the CNS of animals with active disease.
These authors found that injection of TGF-(3 on days 5-9 after immunisation was
highly protective and therefore concluded that the protective effect of TGF-(3 was
exerted at the level of the target organ and/or its vascular endothelium rather than
through a direct effect on lymphoid cells.
It thus appears that Th2-type cytokines like TGF-(3 are important regulators of
immune responses. Experiments (Rocken et al, 1994) have shown that the induction
of EAE in mice by the transfer of the Th 1 -like or pro-inflammatory cells can be
inhibited by the administration of IL-4 or TGF-(3 at the time of cell transfer and this
and other similar findings have been the basis for the current trend in gene therapy
experiments which have used myelin basic protein- specific T cells engineered to
express latent transforming growth factor-(3 in an experimental treatment of murine
EAE (Chen et al, 1998).
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(b) TGF-B and Wound Healing
One of the most exciting recent TGF-(3 discoveries is that TGF-(3 enhances wound
healing. When painted on a wound TGF-(3 has been found to increase both the
strength of the newly formed connective tissue and its rate of formation. This effect
is complex, involving both fibroblasts and macrophages and both are stimulated to
migrate to the site of a wound. Fibroblasts increase their synthesis of collagen and
fibronectin and decrease their secretion of proteases that tend to degrade the
extracellular matrix. Stimulation of secretion of the fibroblast mitogen, LL-1, by
monocytes has also been observed. The source of TGF-(3 at wounds may be platelets
which release TGF-p when they degranulate. In general, the release and activation of
TGF-P stimulates the production of various extracellular matrix proteins and inhibits
the degradation of these matrix proteins, although exceptions to these principles
abound. These actions of TGF-P contribute to tissue repair, which under ideal
circumstances leads to the restoration of normal tissue architecture and may involve
a component of tissue fibrosis. In many diseases, excessive TGF-P contributes to a
pathologic excess of tissue fibrosis that compromises normal organ function, a topic
that has been the subject of numerous reviews (Roberts and Sporn, 1989) but which
will be discussed succinctly here.
TGF-P is secreted by a variety of cells and serves multiple functions in tissue/organ
repair by increasing cellular production of ECM components, such as fibronectin and
collagen, and cellular expression of matrix receptor integrins. Furthermore, the
synthesis of Plasminogen Activator Inhibitor-1 (PAI-1) and Tissue Inhibitor of
Metalloproteases (TIMP) is also increased by TGF-p, while the expression of
coliagenase and Plasminogen Activator (PA) is decreased. This up regulation of
inhibitor synthesis and down regulation of protease synthesis further augments the
accumulation of ECM proteins induced by TGF-p, and is the basis for fibrotic tissue
formation caused by the action of TGF-P. The mechanism of receptor signalling
20
holds the key to TGF-P regulation of cellular responses and is one of the most
intensively studied areas of TGF-P research.
The use of in vitro systems has aided the identification and characterisation of many
of the components that interact during wound healing. For instance, there are many
compelling in vitro examples of the control of cellular gene expression through
the adhesive interaction of connective tissue cells with their surrounding ECM and
many of these interactions are mediated through cell adhesion receptors called
integrins (Hynes, 1992). Frequently, gene expression is regulated by cytokines and
growth factors, such as TGF-P, released from adjacent cells or the surrounding ECM
through limited proteolysis. Indeed, proteolytic degradation of ECM is an essential
feature of tissue repair and remodelling processes. The serine proteinases, including
plasminogen activator (PA)—plasmin and the matrix metalloproteinases (MMPs),
are the two major groups of ECM-degrading enzymes that interact and form a lytic
cascade for ECM remodelling. The major function of PA is to control the activation
of plasminogen into plasmin. Plasmin is not only the primary effective enzyme in
fibrinolysis, but it also participates in the breakdown of other ECM proteins, and
activates procollagenase into collagenase (a member of the MMP family) (DeClerck,
and Laug, 1996). Thus, the initiation of the proteinase cascade by PA leads to a
notable amplification of proteolytic activity. The complexity of this regulatory
system is increased by the fact that plasmin can release active TGF-P from its
latency-associated protein (Lyons et al, 1990). In turn, TGF-P regulates plasminogen
activator inhibitor 1 (PAI-1), MMPs, tissue inhibitor of metalloproteinases 1 (TIMP-
1) and genes encoding ECM components and their integrin receptors (Roberts and
Spom, 1990). TGF-P is the archetypal example of a growth factor involved in this
process because it is acknowledged to have the broadest range of activities, in both
normal and fibrotic repair injury. Many other growth factors such as epidermal
growth factor (EGF), fibroblast growth factor (FGF) and platelet-derived growth
factor (PDGF) also have substantial influence on the growth and differentiation of
keratinocytes, fibroblasts and endothelial cells during wound repair.
21
Mechanisms of foetal wound repair have attracted much attention in recent years,
owing to the observation that foetal wounds heal without scar formation. Foetal skin
contains abundant hyaluronic acid and does not become inflamed during repair.
Nevertheless, a key to foetal scarless healing seems to reside in the expression of
TGF-P. Whereas adult wound sites contain high and persistent levels of TGF-P 1,
TGF-P 1 is expressed transiently at low levels in foetal wounds (Martin et al, 1993).
An understanding of the mechanism of TGF-P expression and the mode of action on
cell proliferation/differentiation and ECM production/remodelling may ultimately
allow an understanding of the control of excess scarring in adult wounds.
(c) TGF-B and Development
Expression patterns of TGF-ps during embryogenesis as well as the activities of
these molecules in in vitro assays of biological processes relating to development
have suggested that TGF-Ps play an important role in embryonic development.
Embryonic induction, the process by which signals from one ceil population
influence the fate of another, plays an essential role in the development of all
organisms so far studied. In many cases, the signalling molecules belong to large
families of highly conserved proteins, originally identified as mammalian growth
factors, the largest of which is the TGF-P family. Genetic studies in Drosophilci on
the TGF-P related gene, decapentaplegic {dpp), have revealed the existence of
conserved mechanisms regulating both the expression of the protein during
development and the way in which it interacts with other signalling molecules to
generate patterns within embryonic tissues.
Recently, several groups have published exciting new data on the function of dpp in
Drosophila. These studies raise the possibility that dpp regulates and is regulated by
two other secreted growth factors, encoded by wingless (wg) and hedgehog (hh). As
both hh and wg -type (Wnt) genes exist in vertebrates, work on dpp in Drosophila
provides an important paradigm for the understanding of TGF-P related gene
function in higher organisms.
The dpp gene is necessary for several different morphogenetic processes during
Drosophila embryogenesis, including dorsal/ventral patterning of the embryo,
establishment of the proximo-distal axis of appendages, eye development, and
midgut morphogenesis (Spencer et al, 1982, Irish and Gelbart 1987, Panganiban et
al, 1990). In dorsal/ventral patterning, evidence suggests that the DPP protein acts as
a morphogen regulating dorsal cell fate (Ferguson and Anderson, 1992). Wharton et
al. (1993) have demonstrated that increasing the number of dpp genes in either
mutant or wild-type embryos results in the formation of an increasing number of
dorsal type cells in a dose-dependent manner.
During midgut development, DPP is made in the visceral mesoderm and induces
changes in gene expression in the adjacent endoderm, thus providing a model for
understanding epithelial/mesenchymal interactions in higher organisms.
Studies have shown that dpp transcription in the mesoderm is activated by the
homeobox gene Ultrabithorax (Ubx) and repressed by Abdominal-A (Abd-A) (Manak
et al, 1994). In both cases, regulation is direct and involves multiple DNA-binding
sites in a 5r upstream region of dpp (Capovilla et al, 1994 and Masucci and Hoffman,
1993). In the endoderm, DPP switches on the homeobox gene labial, which has a
DPP-response element in its 5' upstream region (Tremml and Bienz, 1992). These
studies clearly show that dpp acts during development both upstream and
downstream of homeotic genes.
Studies on eye morphogenesis demonstrate another key role for dpp during
Drosophila development (Heberlein et al, 1993). In this organ, dpp is expressed in
the morphogenetic furrow, a wave of organising activity that moves across the eye
imaginal disc. The extracellular signalling molecule encoded by hh regulates
transcription of dpp, and DPP induces morphogenesis in front of the furrow (Ma et
al, 1993). In the leg disc, dpp is also regulated by hh (Basler and Struhl, 1994) and
cooperates with wg in the regulation of the homeobox gene aristaless, which then
acts as an organiser for proximal/distal patterning (Campbell et al, 1993). In this
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case, at least three signalling molecules, hli, dpp, and wg, coordinate to generate
patterning in an epithelial sheet.
Several other members of the TGF-(3 family are also involved in early patterning of
the embryo: Vgl and members of the Xenopus nodal-related (Xnr) family (Lustig et
al, 1996) can induce dorsal mesoderm formation, the first step towards neuralisation.
In contrast, BMP4 acts as a mesoderm ventraliser (Jones et al, 1996); mutation of
cleavage sites yields BMP molecules that are incapable of maturation and leads to
dorsalisation of the early Xenopus embryo (Hawley et al, 1995).
These experiments support the concept that neuralisation of embryonic cells,
formerly attributed to a positive action of the Spemann organizer, occurs through a
default pathway opposed by members of the TGF-(3 family (Green 1994, Hemmati-
Brivanlou and Melton, 1997). Three articles published in the same issue of Cell
provide evidence that the Xenopus embryo derived Spemann organizer products
Noggin and Chordin interrupt Dpp and BMP signalling in Xenopus (Zimmerman et
al, 1996 and Piccolo et al, 1996) and also in Drosophila (Holley et al, 1996) by
binding Dpp or BMP-4, and so preventing them from reaching their respective
receptors. In keeping with this hypothesis, Noggin does not antagonise the effect of
constitutively active forms of the Dpp receptors (Holley et al, 1996).
These experiments also highlight the conservation of patterning molecules of the
TGF-J3 family between species; despite the large evolutionary distance between
insects and vertebrates, both Dpp and BMP4 act alike in Xenopus and Drosophila
(Jones et al, 1996). TGF-P family members also influence patterning in fish: a
constitutive form of a novel type I receptor is able to induce the most anterior dorsal
mesoderm in the zebrafish (Renucci et al, 1996).
During mouse embryogenesis, BMPs and their receptors are essential to mesoderm
development (Mishina et al, 1995). One of the most exciting findings in the field of
mouse embryogenesis is that Nodal is expressed asymmetrically in the mouse
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embryo and may be involved in the establishment of the left-right axis (Collignon et
al, 1996).
Three TGF-(3 family members — inhibin, MIS (also known as anti-Miillerian
hormone or AMH) and GDF-9 — are preferentially, if not exclusively, expressed in
the gonads. All three happen to be relatively remote members of the family, with
only 20-30% identity to the family ancestors Dpp/BMP and to TGF-j3 itself. MIS is
responsible for the regression of Miillerian ducts in male mammalian foetuses and
also in chick embryos (Behringer, 1994) and Neeper et al, 1996). As with all TGF-(3
family members, MIS requires cleavage at a proteolytic site to exert biological
activity. Work from the laboratory of Holly Ingraham (Nachtigal et al, 1996)
suggests that the processing enzyme couid be the kex2/subti!isin-like endoprotease
PC5. Co-expression of PC5 and MIS in transfected mammalian cells results in
efficient processing and PC5 is present in foetal testes, coincident with the beginning
of MIS expression.
Gene knockout experiments have revealed that MIS synergises with inhibin to
influence gonadal tumour development. Inactivation of MIS (Behringer et al, 1994)
or the genes encoding the MIS receptor (Mishina et al, 1996) leads to Leydig cell
hyperplasia. Male and female mice in which the inhibin genes have been inactivated
by gene targeting develop granulosa/Sertoli cell tumours, first detectable at around 4
weeks of age, followed by a wasting syndrome caused by activin signalling (Coerver
et al, 1996). Mice deficient in inhibins and either MIS (Matzuk et al, 1995) or the
MIS receptor developed testicular tumours in both the intratubular and interstitial
compartments earlier. Inhibin-deficient mice with concurrent inactivation of
gonadotropin-releasing hormone do not develop tumours at all (Kumar et al, 1996).
Mothers against Dpp (MAD) and proteins related thereto, have recently emerged as
key players in the signal transduction field. The Drosophila MAD protein is required
for any response to Dpp. Null alleles of MAD suppress the dominant phenotype of
constitutively active mutants of thick veins (tkv), which encodes a DPP type I
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receptor, proving that MAD is an essential component of the downstream signalling
pathway of Dpp (Hoodless et al, 1996). Homologues of the Drosophila MAD protein
have been cloned in C. elegans (Morita et al, 1999), Xenopus (Graff et al, 1996),
mouse (Baker and Harland, 1996) and human (Hoodless et al, 1996, Zhang et al,
1996 and Riggins et al, 1996).
A more distantly related protein, DPC4, which associates with mammalian MAD-
related proteins (MADR) proteins, is mutated in pancreatic cancers (Hahn et al,
1996). MADR proteins appear to be specific for a given member of the TGF-(3
family, suggesting that they are dedicated to transducing the signals for a specific
subclass of TGF-P ligands (Thomsen 1996). For instance, MADR2 (Smad2) is
phosphorylated by TGF-0 (Eppert et al, 1996) and activin (Baker and Harland, 1996)
and not by BMPs. In Xenopus, MADR1 (Smadl) specifies a ventral phenotype
similar to the one produced by BMP2 whereas MADR2 (Smad2) induces a dorsal
phenotype observed in TGF-(3 and activin signalling. In C. elegans, inactivation of
the MAD-related gene sma yields phenotypes similar to the one produced by the
mutation of DAF-4, which encodes a BMP receptor.
Drosophila is not the only system providing genetic clues to the biological
importance of TGF-(3 related genes. Important contributions are now beginning to
come from mice with mutations or targeted disruptions of genes in this family. The
short ear (se) mutant has deletions or rearrangements in the gene for BMP-5 that is
associated with loss of specific skeletal structures, indicating a role for the gene
product in skeletogenesis (Kingsley et al, 1992). In the case of the mouse mutation
413-d, studies have shown that it results from a retroviral insertion in the TGF-p
related gene nodal. During gastruiation, homozygous mutants are unable to form
axial structures, including organized dorsal mesoderm and notochord (Zhuo et al,
1993, Conlon et al, 1991, Varlet et al, 1997). Targeted disruptions of TGF-(3l,
inhibin, and activin/inhibin aB genes all result in aberrant phenotypes in homozygous
mutant mice. Mice that are homozygous null mutant for TGF-(3l are viable for a few
weeks before dying from a 'wasting' syndrome (Shull et al, 1992). These results
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indicate that the embryo does not need to produce TGF-P 1 for prenatal development,
although the mother may provide some TGF-P 1 protein in the uterus and milk. Mice
deficient for inhibin are also viable, but develop gonadal stromal tumours, suggesting
that one function of the protein is to regulate or suppress stromal cell proliferation in
this organ (Matzuk et al, 1992). Targeted disruption of the related gene encoding
activin/inhibin aB has also been reported (Vassalli et al, 1994). Homozygous null
mutants are viable, but females have reduced fertility, indicating a role for
activin/inhibin aB in reproductive function. However, the fact that some viable
offspring are born to these females eliminates activin aB from playing a role in
embryonic pattern formation.
Comparative studies on BMP-4 in Xenopus and mouse point to a conserved role in
specifying posteroventral mesoderm during gastrulation (Hogan et al, 1994). TGF-P
knockout mice can again confirm this essential role as mice lacking TGF-beta 3
exhibit an incompletely penetrant failure of the palatal shelves to fuse leading to cleft
palate (Proetzel et al, 1995). The fact that TGF-P 1 knockout animals are viable and
present with an immunological phenotype and not a severe developmental phenotype
has been explained in two separate ways as follows; 50% of the TGF-Pl conceptuses
die at mid-gestation from defective yolk sac vasculogenesis, a severe early
developmental defect. The other 50% are developmentally normal but die three
weeks postpartum from massive inflammation. It has been suggested that dichotomy
in TGF-p 1 lethal phenotypes is due to either maternal TGF-P 1 rescue of some, but
not all, TGF-P null embryos (Letterio et al, 1994) or is simply dependant on the
genetic background of the conceptus (Bonyadi et al, 1997).
In summary TGF-P appears to be a peptide that "gives form to things", e.g., it




Protein kinases play an important role in signal transduction by phosphorylating
specific amino acids of downstream substrates. Catalytic domains predict what kind
of residues will be phosphorylated by a given kinase. Many receptors for hormones
and growth factors are membrane-bound tyrosine kinases with reasonably well-
understood signal transduction pathways. In contrast, until relatively recently
serine/threonine kinase activity had been detected only in cytoplasmic proteins
downstream of receptor signalling. Starting with the Caenorhabditis elegans DAF-1,
a myriad of genes encoding transmembrane serine/threonine kinases have been
cloned; almost all act as receptors for members of the TGF-P family. As discussed
above, members of the TGF-(3 family are found in species ranging from Drosophila
to human and can be grouped in small clusters progressively diverging from
decapentaplegic (Dpp) and its human homologue, bone morphogenetic protein-2
(BMP-2). With the exception of glial cell line derived neurotrophic factor (GDNF),
all members of the TGF-(3 family in all species signal through a receptor complex
formed by two distantly related types of serine/threonine kinase proteins. Christened
type II and type I on the basis of their molecular weights, two such receptors (TR-II
and TR-I) have now been functionally characterised (Wrana et al, 1994).
Recombinant type II receptors bind their cognate ligand on their own, whereas type I
receptors do so only when co-expresscd with an appropriate type II receptor.
Dpp/BMP receptors exhibit somewhat different binding properties, insofar that type
II receptors bind ligand efficiently only in the presence of type I. which, in turn, can
bind free ligand (albeit weakly) in the absence of type II (Yamashita et al, 1996). The
kinase activity of TR-II is constitutive and its phosphorylation state is not modified
by ligand binding (Wrana et al, 1994). Ligand binding induces the formation of a
receptor complex, most likely a heterotetramer containing two molecules each of
TR-I and TR-II (Weis-C-arcia and Massague, 1996, Luo and Lodish, 1996, Ten Dijke
et al, 1996). The central event in ligand-induced TGF-P receptor activation is the
transphosphorylation of TR-I by TR-II at threonines and serines located in the GS
box, a conserved glycine/serine-rich domain located immediately upstream of the
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kinase consensus domains (Franzen et al, 1995). Absence of TR-I, or mutations
thereof leading to either loss of kinase activity or inability to be transphosphorylated
by TR-II, blocks the signalling response (Weis-Garcia and Massague, 1996). A
missense mutation of TR-II that blocks the recognition of TR-I as a substrate has the
same effect (Carcamo et al, 1995). In contrast, a mutation within the GS box of
several type I receptors yields a constitutively active molecule that signals in the
absence of ligand and receptor II (Wieser et al, 1995). Truncation of TR-II
immediately after the transmembrane domain produces dominant negative molecules
which bind to ligand and type I receptors but do not induce biological responses
(reviewed in Brand and Schneider, 1996). The model for activation of the TGF-(3
receptor complex has recently been extended to activin. Although it contains a
transmembrane domain, the type I receptor acts as a substrate and signal transducer
for TR-II, the primary receptor (Massague and Weis-Garcia, 1996). The composition
of the receptor complex, and more particularly the identity of the type I receptor,
determines the nature of the signal. Establishing which type I receptor associates
with which ligand/type II receptor complex is difficult because a given ligand may
signal through different receptor complexes and a given receptor can recognize
different ligands.
This family was initially discovered in 1991 with the cloning of the first activin
receptor (Mathews and Vale, 1991) now called ActR-II. Based on their structural and
functional properties, the TGF-P receptor family is divided into two subfamilies;
Type I receptors and Type II receptors and there are currently 12 members of the
Type 1 subgroup and 7 members of the Type II subgroup (Figure 1.1). Vertebrate
Type I receptors form three groups whose members have similar signalling activities.
In mammals these groups include 1) T(3R-1, ActR-lB and ALK7, 2) BMPR-1A,
BMPR-1B and 3) ALK1 and ALK7. In invertebrates Type I receptors include Thick
veins (Tkv) and Saxophone (Sax) which both act as receptors for Dpp in Drosophila,
and C. elegans has Daf-1, a Type I receptor for the BMP-like ligand Daf-7. The type
II receptor subfamily in vertebrates includes T(3R-II and BMPR-II, which bind TGF-












The Transforming Growth Factors-(3 (TGF-|3), activins and bone
morphogenic proteins (BMPs) signal through distinct sets of Type I and
Type II receptors and Smad proteins. Five distinct Type II receptors and
seven Type I receptors, also termed Activin-like kinases (ALKs) have been
identified. Type I receptors act downstream ofType II receptors
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Both the Type I and Type II receptors are glycoproteins of approximately 55kDa and
70kDa respectively with a relatively short extracellular domain and no singular
structural features in the transmembrane region. However, a unique feature of the
Type I receptors is a highly conserved domain preceding the protein kinase domain
called the GS domain. This region is so called due to the fact that it contains a
characteristic SGSGSG sequence and it has been proved to be a key regulatory
region that controls the catalytic activity of the Type I receptor kinase (Wrana et al,
1994). The kinase domain in both receptors is a typical serine/threonine kinase
domain (Matthews and Vale, 1991). Type I receptors have been shown to
phosphorylate their substrates, the Smads, on serine residues, while Type II receptors
phosphorylate themselves and Type I receptors on serine and threonine residues.
1.1.3 Receptor Activation
TGF-(3 and related family members activate signalling by binding to and bringing
together pairs of Type I and Type II receptors. Two general modes of binding iigand
have been documented. One mode, characteristic of TGF-(3 and activin receptors,
involves direct binding to the Type II receptor and subsequent interaction of this
complex with the Type I receptor, which then becomes recruited to the complex.
Here Type I receptors for these factors can recognise ligand that is bound to the Type
II receptors but not ligand that is free in solution. This mode of binding was
discovered using TGF-(3-resistant cell mutants - TGF-(3l can bind to T(3R-II in cell
mutants lacking T(3R-I but cannot bind to T(3RI in mutants lacking T(3R-II (Laiho et
al, 1990, Boyd and Massague 1989). The second mode of binding is typical of BMP
receptors and is co-operative, involving Type I and Type II receptors that bind ligand
with high affinity when expressed together but low affinity when expressed
separately (Liu et al, 1995).
The kinase activity of T(3R-II is constitutive and its phosphorylation state is not
modified by ligand binding (Wrana et al, 1994) Ligand binding induces the
formation of a receptor complex, most likely a heterotetramer containing two
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molecules each of T(3R-I and T(3R-II (Weis-Garcia et al, 1996, Luo and Lodish, 1996
and Ten Dijke et al, 1996) The central event in ligand-induced TGF-(3 receptor
activation is the transphosphorylation of T(3R-I by TPR-II at threonines and serines
located in the GS box (Franzen et al, 1995). Absence of T(3R-I, or mutations thereof
lead to either loss of kinase activity or an inability to be transphosphorylated by
TPR-II which then blocks signalling responses (Weis-Garcia and Massague, 1996).
A missense mutation of TPR-II that blocks the recognition of T(3R-I as a substrate
has the same effect (Carcamo et al, 1995). In contrast, a mutation within the GS box
of several type I receptors yields a constitutively active molecule that signals in the
absence of ligand and receptor II (Wieser et al, 1995). Truncation of T(3R-II
immediately after the transmembrane domain produces dominant negative molecules
which bind to ligand and type I receptors but do not induce biological responses
(reviewed in Brand and Schneider 1996). The model for activation of the TGF-(3
receptor complex has been extended to activin (Willis et al, 1996, Attisano et al,
1996 and De Winter et al, 1996) and although it contains a transmembrane domain,
the type I receptor acts as a substrate and signal transducer for TPR-II; the primary
receptor (Massague and Weis-Garcia 1996). The composition of the receptor
complex, and more particularly the identity of the type I receptor, determines the
nature of the signal.
Furthermore, given that type I and II receptors which probably do not associate under
normal cellular conditions may do so when over expressed in cell lines, binding data
alone are not sufficient to predict the existence of a functional signalling complex.
Demonstration of co-immunoprecipitation is more reliable as it requires high-affinity
association (Vivien and Wrana 1995); proof of the capacity of the receptor under
investigation to restore signalling in mutant cell lines is even more conclusive (ten
Dijke et al, 1994). The ultimate test, however, is the examination of the phenotypic
effects of inactivating the receptor during normal development. In man, mutations
have been described only for the anti-Miillerian hormone (AMH)/Mullerian
Inhibiting Substance (MIS) type II receptor (Imbeaud et al, 1995) and for the activin
receptor-like kinase-1 (ALK-1) (Berg et al, 1997). In the absence of natural
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mutations, the generation of mutated receptor molecules has proven very useful for
dissecting the signalling pathway for TGF-P family members, bone morphogenic
factors and their receptors in body patterning.
1.1.4 Latency of TGF-B
Like other members of the family, TGF-(3 is synthesised as the C-terminal domain of
a precursor form that is cleaved before secretion from the cell (Derynck et al, 1985).
However, the TGF-(3 propeptide, which is referred to as the latency associated
peptide or LAP, remains non-covalently bound to TGF-P after secretion, retaining
TGF-P in a latent form that cannot bind the receptors. Most cell types secrete TGF-P
in this biologically inert form (Roberts and Sporn 1990). In vitro TGF-p may be
activated by acid, alkali, heat or limited proteolysis (Miyazono et al, 1993). In tissue
culture activation of latent TGF-P may involve a combination of steps including LAP
proteolysis and cell-cell interactions, but the real physiological activation mechanism
remains to be defined.
1.1.5 Propagation of the Signal
Recent TGF-P receptor phosphorylation studies by Wrana et al. (Wrana et al, 1994)
have provided insights into the molecular mechanisms by which TGF-P receptors are
activated. TPR-II is a constitutively active kinase, the autophosphorylation of which
is not clearly up regulated upon ligand binding. After binding of TGF-P to TPR-II,
TPR-I is recruited into a stable complex and is phosphorylated by TPR-II on its
serine and threonine residues, which are predominantly located in the GS domain,
the 30 amino acid region preceding the kinase domain and conserved in type I
receptors for other TGF-P-reiated factors which contains SGSGSG repeats. (Wrana
et al, 1994). Phosphorylation of TPR-I is important for signal transduction, as
impaired responses are seen in cells with a mutation in TPR-II that renders its kinase
inactive (Wrana et al, 1992), or mutations of serine and threonine residues in the GS
domain of TPR-I (Wieser et al, 1995), or a mutation in TPR-II that inactivates its
33
ability to recognize T(3R-I as a substrate (Carcamo et al, 1995). Activated T(3R-1
does not autophosphorylate or phosphorylate T(3R-II (Wrana et al, 1994), but it is
phosphorylated by cytoplasmic kinases, albeit to a lower extent than is T(3R-II
(Weiser et al 1995). Recently, a constitutively active T(3R-I mutant (in which the
threonine residue at position 204 was replaced by an aspartic acid residue) was
described, and was shown to have an increased in vitro kinase activity and to signal
in the absence of ligand and T(3R-II (Weiser et al, 1995). Thus, T(3R-I functions as a
substrate for T{3R-II; its phosphorylation and activation by T(3R-II is essential and
sufficient for most TGF-(3 mediated signalling.
Using a yeast two-hybrid interaction screen with an intracellular type I receptor as
bait, FKBP-12 (Wang et al, 1996), a binding protein for FK506 and rapamycin, and
farnesyl protein transferase (Kawabata et al, 1995), an enzyme subunit involved in
farnesylation or geranylgeranylation of proteins such as Ras, Rac and Rho, were
isolated. Both proteins failed to interact with a kinase-defective type I receptor;
however, until recently their involvement in TGF-(3 signalling remained to be
established as no ligand dependence in receptor association or phosphorylation had
been demonstrated. FKBP12 is now known to interact with Type I receptors and
inhibits the phosphorylation of the Type I receptors by the Type II receptors (Wang
et al, 1996). Using the T(3R-II intracellular domain as bait, TBR interacting protein-1
(TRIP-1) was isolated (Chen et al, 1995). TRIP-1 is homologous to WD-domain-
containing proteins that are involved in various protein-protein interactions. The WD
repeat comprises a 44—60-residue sequence within many proteins although the exact
significance of this structure is unknown. The interaction and phosphorylation of
TRIP-1 is dependent on TpR-II kinase activity, but is independent of ligand and
TJ3R-I. The functional significance of TRIP-1 in TGF-(3 signalling remains to be
determined.
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Drosophila dpp signals via dpp type 1 receptors, thick veins and saxophone, and an
activin/dpp type II receptor, punt (Nelien et al, 1994, Penton et al, 1994, Brummel et
al, 1994, Letsou et al, 1995, Ruberte et al, 1995). Loss of saxophone or thick veins
activity results in phenotypes which resemble partial and complete loss of dpp gene
function, respectively (Nellen et al, 1994); thick veins may be required for all dpp-
specified cell fates, whereas saxophone may modulate responses at high
concentrations of dpp. Mutations that abolish punt activity show a similar phenotype
to that obtained with complete loss of dpp gene function. Thick veins and punt are
strictly required for dpp signalling, and their in vivo loss of function cannot be
compensated for by other receptors (Ruberte et al, 1995). A downstream component
in the rf/^-signalling pathway, schnurri, was recently found to encode a putative
zinc-finger-containing transcription factor that regulates the expression of dpp-
responsive genes (Arora et al, 1995, Grieder et al, 1995). Further genetic screens in
Drosophila will probably lead to the identification of additional genes that encode
components downstream of dpp receptors; mammalian homologues of these
components may act downstream of TGF-(3, activin and BMP receptors. Moreover,
inactivating mutations in daf-1 and daf-4, which encode Caenorhabditis elegans
serine/threonine kinase receptors, have been shown to lead to constitutive dauer
larvae development; genetically identified C. elegans genes that act downstream of
these receptors may have mammalian counterparts that participate in intracellular
signalling of TGF-(3 superfamily members (Estevez et al, 1993).
Signals emanate from a TGF-(3 Type I receptor when it is phosphorylated by its
activator, the Type II receptor. Ligand binding induces the formation of a
heteromeric complex of Type I and Type II receptors (Franzen et al, 1993) and
because the ligands are dimeric in nature each might contact one Type I and Type II
receptor resulting in a heterotetrameric complex. This is supported by data from 2-D
gel electrophoresis (Yamashita et al, 1994) and co-precipitation of receptor studies
(Weiss-Garcia and Massague, 1996). Formation of this ligand-induced complex
rapidly leads to phosphorylation of the Type I receptor (with TGF-(3 and activin
receptors) and this reaction is catalysed by the Type II receptor. Until recently this
marked the end of the known pathway of TGF-P signal transduction as substrates for
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the Type I receptor were unknown. A role of the Type I receptor as the downstream
signalling component in the receptor complex was originally inferred from the
observation that the kinase activity of T(3RI is required for signal transduction and
yet its substrate is neither T(3R-1 nor T(3R-II (Wrana et al, 1994). The proteins of the
Smad family are the first identified substrates of Type I receptor kinases and play a
pivotal role in the transduction of receptor signals to target genes in the nucleus.
1.2 Smads as Mediators of TGF-fi Signalling
The first identified Smad protein was the product of the Drosophila Mad gene
(,mothers against dpp). Mad was identified in 1996 as a maternally expressed
enhancer of the dpp phenotype in a screen for mutations that would exacerbate the
effect of weak dpp alleles (Raftery et al, 1995). Since that initial discovery many
related genes have been found in nematodes, Drosophila and vertebrates. Mad
homologues have been discovered in C. elegans and called sma-2, sma-3 and sma-4
because mutation in these genes causes small body size (Krishna et al, 1999 and
Morita et al, 1999). Homologues in vertebrates have been discovered through
screening EST (expressed sequence tag) databases and cDNA libraries. These
proteins have been named Smads (for sma/mad related) and the family currently
encompasses 10 members (for review see Ten Dijke et al, 2000).
Initial evidence that Smads function downstream of TGF-(3 receptors was the
observation that mutant Drosophila Mad genes could inhibit signalling by a
hyperactive thick veins (Tkv) receptor. The most compelling evidence came from the
observation that in response to TGF-(3 and related family members, Smads are
phosphorylated (Hoodless et al, 1996, Zhang et al, 1996), accumulate in the nucleus
(Hoodless et al, 1996, Baker and Harland 1996) and become transcriptionally active
(Liu et al, 1996). This evidence placed the Smads directly downstream of TGF-(3
receptors.
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1.2.1 Smad Families and Functions
Based on structural and functional considerations, vertebrate Smads fall into three
subfamilies; receptor-regulated Smads (R-Smads), the Co-Smad Smad4, and the
inhibitory Smads (I-Smads), Smad6 and Smad7 (for review see ten Dijke et al,
2000). The family is highly conserved and homologues of each of these classes have
been identified in Xenopus, Drosophila and C. elegans (Figure 1.2). The R-Smads
are activated and phosphoryiated only in response to specific ligands and this
phenomenon is important in maintaining specificity in TGF-(3 signalling. Thus, the
TGF-P and activin Type I receptors only activate Smad2 and Smad3, whereas the
BMP Type I receptors all target Smadl, Smad5 and Smad8 (Kretzschmar et al,
1997). Signalling by R-Smads requires the participation of a collaborating Smad or
Co-Smad. There is currently only one vertebrate Co-Smad, Smad4, although others
have been determined in Xenopus (Howell et al, 1999). Although Smad4 is similar to
the R-Smads in overall structure, it is not normally phosphoryiated in response to
agonists. Smad4 is generally required for Smad2 or Smad3-dependent growth
inhibitory responses in mammalian cells, and a dominant-negative Smad4 construct
interferes with Smadl and Smad2 signalling in frog embryos and mammalian cells
(Zhang et al, 1996 and Lagna et al, 1996). Smad4 therefore participates in TGF-(3,
activin and BMP signalling pathways as a shared partner of receptor-regulated
Smads. The Drosophila Medea and C. elegans sma-4 gene products are close
homologues and probably fulfil a similar function in these organisms.
In contrast to this the I-Smads function to block TGF-(3 and BMP signalling. These
Smads form stable complexes with the activated receptors and inhibit signalling by
preventing access and phosphorylation of the R-Smads. Vertebrate Smad7 inhibits
both BMP and TGF-P receptors whereas Smad6 appears to be more specific to the
BMP pathway only. Drosophila Dad inhibits Mad signalling (Tsuneizumi et al,
1997). Transcription of Smad6 and Smad7 is induced by TGF-P, activin and BMP,
providing a negative feedback mechanism for regulation of Smad signalling.
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1.2.2 Smad Structure
Smad proteins contain highly conserved N-terminal and C-terminal domains referred
to as MH1 and MH2.domains respectively and a middle linker region of variable
length and sequence which is proline-rich (de Caestecker et al, 1997). The MH2
domain contains SSxS motifs which are involved in receptor phosphorylation and
also mediate a large number of distinct protein-protein interactions which include:
association with the membrane-bound receptor (Macias-Silva et al, 1996), assembly
of heteromeric R-Smad-Smad4 complexes (Hata et al, 1997) and the association of
Smads with DNA binding proteins and transcriptional co-activators (Liu et al, 1997
and Chen et al, 1997). The MH1 domain has been suggested to auto inhibit the MH2
domain (Kim et al, 1997) and also has been shown to be capable of binding DNA
directly (Song et al, 1998 and Dennler et al, 1998).
The crystal structure of the MH2 domain of Smad4 has been analysed and found to
contain five a helices (HI to H5) and three loops (LI to L3) (Shi et al, 1997). This
structure has revealed that many of the mutations in Smad proteins identified in
cancers map to the protein-protein interface between R-Smads and Smad4 (Shi et al,
1997). Functional analysis of R-Smads has identified the L3 loop and HI region as
the important determinants controlling specificity over the R-Smad-receptor
interaction at the cell surface (Lo et al, 1998). A similar study with the Type I
receptor has shown that L45 region in the kinase domain specifies interactions with
the Smads (Chen et al, 1998, Feng and Derynck, 1997), thus Smad-receptor
interactions may be mediated by L3 on the Smad and L45 on the receptor (Figure
1.3).
The crystal structure of the MH1 domain of Smad3 has been analysed in the presence
of a short DNA fragment containing two of the known Smad binding sites called
Smad Binding Elements (SBE) (Shi et al, 1998). These elements consist of 5'-
GTCT-3' repeats and have been found in the promoters of various genes known to be
activated by Smads/TGF-(3. The MH1 domain is composed of four a-helices, six
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Figure 1.3
Crystal Structure of Smad2
The figure shows a stereo image of a Smad2 trimer. The crystal structure of
a number of Smad proteins has recently been elucidated and various groups
have identified a discrete surface structure in Smads 1 and 2 that mediates
and specifies their receptor interactions. This structure is the L3 loop, a 17
amino acid region that protrudes from the core of the conserved SMAD C-
terminal domain. On the figure above the L3 loop is represented in red on
the MH2 domains of Smad2. These studies have identified the L3 loop as a
determinant of specific SMAD-receptor interactions, and indicate that the
L3 loop, together with the C-terminal tail, specifies SMAD activation.
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short (3 strands and five loops and DNA binding is accomplished by a structure
composed of a (3 hairpin that contacts DNA in the major groove (Shi et al, 1998).
The linker region that connects the MH1 and MH2 domains is much less conserved,
but it also contains important peptide motifs which can control Smad activity. These
include a conserved proline rich PY motif that may be important for crosstalk with
the MAPK pathway (Kretschmar et al, 1997, 1999).
1.2.3 Signalling through Smads
In the basal state, Smads exist as homo-oligomers that reside in the cytoplasm. Upon
ligand activation of the receptor complex, the Type I receptor kinase phosphorylates
specific Smads, which then form a complex with Smad4 and move into the nucleus.
In the nucleus, these complexes either alone or in association with other proteins
activate target genes by binding to specific promoter elements.
Smads are serine-phosphorylated in response to agonists - Smadl in response to
BMP2 or 4 (Hoodless et al, 1996), Smad2 in response to TGF-(3 or activin (Eppert et
al, 1996) and Smad3 in response to TGF-(3 (Zhang et al, 1996). Although the kinetics
of this phosphorylation are relatively slow when transfected Smads are used (t>/2 ~ 5
minutes) Smads have been shown to be direct substrates of the receptors. Smadl is
phosphorylated by a highly purified BMPR-I kinase domain (Kretschmar et al,
1998), Smad2 by immunoprecipitated TGF-P receptor complexes (Macias-Silva et
al, 1996) and Smad3 by T(3R-I kinase preparation (Zhang et al, 1996). In vitro and in
vivo receptor mediated phosphorylation occurs at serines in the C-terminal motif
SSxS of Smadl and Srnad2. This motif is also present in the other R-Smads of all the
vertebrate and non-vertebrate Smads, but not the Co-Smads or I-Smads. This is in
agreement with the observation that Smads4, 6 and 7 are not phosphorylated in
response to ligand binding. Mutation of the serines in this sequence inhibits receptor-
mediated phosphorylation of Smads 1 and 2 in vivo and in vitro and their association
with Smad4, accumulation in the nucleus and mediation of transcriptional responses
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(Kretschmar et al, 1997), proving that phosphorylation of this motif is required for
Smad activation.
Interactions between receptors and Smads are a critical step in initiating the
intracellular signalling cascade. Recently a protein named SARA (Smad Anchor for
Receptor Activation) was identified in a screen for Smad2 interacting proteins and
has been shown to play a pivotal role in the association of the Smad with the receptor
(Tsukazai et al, 1998). SARA specifically binds unphosphorylated Smad2 and
Smad3 and contains a FYVE domain adjacent to its Smad-binding domain. The
FYVE domain is a double zinc-finger motif that in other proteins has been shown to
bind phosphatidylinositol-3-phosphate and can thereby anchor proteins to
membranes. In SARA, this FYVE domain is required for its proper subcellular
localisation into discrete areas. Furthermore SARA recruits Smad2 to these areas
where activation of TGF-P signalling causes Smad2 to dissociate from SARA.
Interestingly, these subcellular domains also contain the TGF-P receptors and SARA
can also associate with heteromeric TGF-P receptor complexes through a carboxy-
terminal region that is distinct from the Smad binding domain. Essentially this data
has shown that SARA can recruit Smads to the membranes and regions of the cell
where the activating receptor kinase is localised. The elucidated crystal structure of
the Smad2 MH2 domain bound by SARA has shown that the MH2 domain interacts
with an extended proline rich motif in the Smad binding domain of SARA. An
important asparagine residue (N381) has been identified and substitution of this
residue with a serine results in interference in the binding of Smad2 to SARA, a
failure of SARA to localise the Smad protein and loss of activity from reporter genes
(Wu et al, 2000). Thus SARA plays an important role in the initiation of TGF-P
signalling by controlling the localisation of the Smad substrate.
Smad2 and Smad3 become transiently and selectively associated with the activated
TGF-P receptor complex and the phosphorylation sites in the MH2 region of the
Smad become phosphorylated. This then facilitates Smad2 dissociation from the
receptor as shown by phosphorylation defective Smad2 mutants which have
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enhanced interactions with the receptors (Macias-Silva et al, 1996). This transient
nature of the Smad-receptor interaction is consistent with the role of Smads as
carriers of receptor signals into the nucleus.
Receptor-phosphorylated Smads associate with Smad4, which functions as a shared
partner required for transcriptional activation. Based on structural considerations and
the observation that mutations in the Smad4 L3 loop abolish the ability of Smad4 to
associate with Smad2, the L3 loop in Smad4 appears to mediate the association with
receptor activated Smads (Shi et al, 1997).
Nuclear translocation of receptor activated Smads occurs with kinetics that closely
follow these of the ligand-induced phosphorylation and association with Smad4.
Nuclear translocation of Smads 1 and 2 does not always require Smad4, as
determined using Smad4-defective cells and Smad4 is also translocated into the
nucleus in response to TGF-P or BMP; as this translocation requires the presence of
Smadl or Smad2 it appears that receptor activated Smads bind Smad4 in the
cytoplasm and carry it into the nucleus (Liu et al, 1997) (Figure 1.4).
1.3 Smads in the Nucleus
Initial studies on the function of Smads as transcriptional regulators have revealed
that Smads can bind directly to DNA. However, more recent work showing the
interactions of Smads with a diverse array of DNA-binding proteins have suggested
that the primary role of Smads is not to target specific genes through their DNA







The Smad Signalling Pathway
The Smad signalling pathway gives specificity to the myriad responses of
TGF-p/activin and bone morphogenic proteins bound at the cell surface.
Ligand binds at the cell surface inducing the formation of heteromeric
complexes of specific type I and type II serine/threonine kinase receptors.
The type I receptor is then phosphorylated and activated by the type II
receptor and this leads to activation of specific Smad proteins. Smads 1,5
and 8 are activated by BMPs and Smads2 and 3 are activated by TGF-P and
activins. These R-Smads then associate with a Co-Smad (in this case Smad4)
and the complex then translocates to the nucleus where together with other
proteins they direct transcriptional responses. A number of negative
regulators of this pathway exist including the I-Smads Smad6 and Smad7
and transcriptional co-repressors Ski, SnoN and TGIF.
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1.3.1 DNA Binding of Smads
In the nucleus, R-Smad-Co-Smad complexes are involved in transcriptional
regulation of target genes (Massague et al, 1998). The MH1 domains of Smad3 and
Smad4 were found to possess an intrinsic property to bind to specific DNA
sequences that contain 5'-AGAC-3' sequences, termed Smad-binding elements
(SBEs) (Yingling et al, 1997, Zawel et al, 1998, Dennler et al, 1998). Direct binding
of Smads to DNA was first described for Drosophila MAD which binds a GC-rich
element in the DPP-responsive vestigial gene - mutation of this site prevented dpp-
dependent expression of a reporter gene in vivo (Kim et al, 1997). Extensive studies
with Smad3 and Smad4 similarly established that these Smads bind DNA and, in
most cases, mutation of Smad binding sites in TGF-fYresponsive promoter elements
reduces activation of reporter constructs (for review see Derynck et al, 1998). These
studies suggest that Smad DNA binding is important for activating target genes,
however Smads appear to bind DNA with rather low specificity and affinity.
Selection of Smad3 and Smad4 binding sequences yielded a consensus-binding site
of two inverted repeats of GTCT (Zawel et al, 1998). The crystal structure of Smad3
bound to this sequence shows that MH1 monomers bind only to a single copy of this
core sequence (Shi et al, 1998). Further analysis has suggested that a GNCN repeat is
sufficient for Smad-DNA binding (Johnson et al, 1999). As this occurs frequently in
promoters, it suggests that Smad-DNA binding alone is unlikely to be sufficient for
Smad-dependent targeting of specific genes. Furthermore, Smad2 has a unique insert
in the MH1 domain that abolishes DNA binding (Yagi et al, 1999). These findings
suggest that interactions with DNA-binding partners are essential for Smads to
function in regulating specific transcriptional responses
1.3.2 DNA Binding Partners for the Smads
Assuming that Smad-DNA binding alone is not sufficient for gene activation, there
are now a growing number of examples in which Smads have been found to co¬
operate with DNA binding partners to regulate transcription. The most extensively
characterised of these is the FAST family of DNA binding proteins. Xenopus FAST
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is a winged helix/forkhead DNA-binding factor that binds to an activin responsive
element in the promoter region of the Mix.2 gene (Chen et al, 1996, Chen et al,
1997). Human and mouse homologues of FAST (FAST-1 and FAST-2) have been
identified (Labbe et al, 1998, Weisberg et al, 1998, Zhuo et al, 1998, Liu et al,
1999). In addition to regulating Mix.2, mouse FAST has been shown to bind a TGF-(3
activin responsive region of the goosecoid promoter (Labbe et al, 1998). In the
absence of signalling, FAST binds constitutively to these response elements, but is
unable to activate transcription. However, in the presence of TGF-(3 or activin a
complex containing FAST, Smad2 and Smad4 assembles on the DNA and
transcription is strongly activated (see previous references and Yeo et al. 1999).
Analysis of the complex shows that Smad2 interacts directly with FAST to recruit
Smad4 into the nuclear complex. The Smad4 MH1 domain then binds DNA at an
adjacent Smad binding element and this contact is essential to stabilise the DNA
binding by the Smad-FAST complex.
Smads can also co-operate with DNA-binding proteins which are involved in
mediating signals for other pathways. Several TGF-(3 responsive elements have been
found to contain API binding sites which are activated by heterodimers of c-jun and
c-fos. Over-expression of Smad3 strongly activates several API-containing
promoters and Smad3 can interact directly with c-jun via the MH1 domain and
indirectly with c-fos via c-jun (Zhang et al, 1998). In the absence of these two
proteins TGF-P and Smad3 only weakly induce API elements (Zhang el al, 1998,
Liberati et al, 1999) thus suggesting that Smads require active c-fos/c-jun dimers as
DNA-binding partners in order to stimulate API-containing elements.
The transcription factor ATF2 is a basic helix-loop-helix (bHLH) leucine zipper
protein which binds to cAMP response elements either as a homodimer or as a
heterodimer with c-jun. Both Smad3 and Smad4 have been shown to bind ATF2
through their MH1 domains and in transient assays, co-operate with ATF2 to activate
CRE-containing elements (Hocevar et al, 1999, Sano et al, 1999). Smads co-operate
with activated ATF2, which is a target of p38 kinase cascade, and blocking either
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ATF2 function or p38 activation also blocks the ability of Smads to regulate CRE
reporter genes. Thus Smads can regulate transcription through interactions with
ATF2 and like the Jun kinase cascade can crosstalk with the p38 pathway.
Another member of the bHLH-leucine zipper family of transcription factors, TFE3
binds to DNA through an E-box element. Smad3 and TFE3 together activate TGF-0
induced transcription by binding to adjacent sites in the PAI-1 promoter (Hua et al,
1999). Interestingly, any alteration in the spacing between the Smad-binding sites
and the E-box abrogates TGF-(3 induced transcription. Thus, proper positioning of
Smad-binding sites may be an essential feature for Smad-dependent regulation of
certain transcriptional targets, possibly preventing random activation of E-boxes by
Smad signalling.
The association of Smads with members of the polyomavirus enhancer binding
protein2/core binding factor (PEBP2/CBF) transcription factor complex was recently
described (Hanai et al, 2000). This complex binds to active forms of Smadl, Smad2
and Smad3 and although the biological relevance of these interactions has yet to be
determined it is important to note that DNA binding by both Smad3 and PEBP to
their respective sites was essential for TGF-(3-dependent activation of the promoter.
A similar situation has been described for vitamin D. Analysis of a vitamin D
response element (VDRE) linked to a reporter gene has shown that the VDRE was
responsive to TGF-(3, but importantly only in the presence of vitamin D (Yanagisawa
et al, 1999). Consistent with this Smad3 was found to act as a co-activator for the
vitamin D receptor through its ability to form a complex with the steroid receptor co-
activator-1 protein in a vitamin D and TGF-(3-dependent manner. A.gain this points to
Smad interactions with other pathways, in this case between the TGF-(3 and vitamin
D pathways.
One variation in the way that Smads might act as transcriptional regulators has been
described for the association between Smadl and Hoxc-8 (Shi et al, 1999). Hoxc-8 is
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a homeodomain transcription factor that may repress the osteopontin promoter and it
has been shown that Smadl expression may dislodge the inhibitory Hoxc-8 from the
promoter. A similar Smad-mediated relief of transcriptional repression has been
proposed for the reported interaction of Smads with Smad-interacting protein-1 (SIP-
1) (Verschueren et al, 1999). Thus relief of repression may represent another
mechanism for Smad-mediated transcriptional activation.
1.3.3 Activation of Transcription
Recent studies have shown that MH2 domains are responsible for mediating
transcriptional activation. Work from a large number of groups has shown that this
activation probably occurs through Smad recruitment of the transcriptional co-
activators p300 and CREB binding protein (CBP) to target promoters (for review see
Derynck et al, 1998). P300/CBP acts as a co-activator for a number of distinct
transcription factors including p53, p73, NFkB and members of the STAT family. It
works both by bridging transcription factors to the basal transcriptional machinery
and also through its intrinsic histone acetyltransferase activity. Enhancement of
Smad-mediated transcription occurs through the direct interaction of p300/CBP with
the C-terminus of Smadl, Smad2 and Smad3 and is enhanced by TGF-(3
phosphorylation (Pearson et al, 1999, Nishihara et al, 1998 and Janknecht et al,
1998). While association of p300/CBP has been documented for these R-Smads at
the C-terminal end of the protein, association of Smad4 with p300/CBP has shown a
novel function of the middle linker region of this Smad, which interacts with the
amino terminus of p300 (de Caestecker et al. 2000).
This interaction between Smads and p300/CBP has recently shown an interaction
between two major signalling pathways - Smads and STATs. In this case p300/CBP
is essential for the observed synergy between BMP and LIF in activation of GFAP, a
marker of neural cells (Nakashima et al, 1999). The cytokines LIF (leukaemia
inhibitory factor) and BMP2 signal through completely different receptors and
transcription factors, namely STATs (Signal Transducers and Activators of
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Transcription) and Smads. LIF and BMP2 were found to act collectively on primary
foetal neural progenitor cells to induce astrocytes. The transcriptional coactivator
p300 interacts physically with STAT3 at its amino terminus in a cytokine
stimulation-independent manner, and with Smadl at its carboxyl terminus in a
cytokine stimulation-dependent manner. The formation of a complex between
STAT3 and Smadl, bridged by p300, was therefore found to be involved in the
cooperative signalling of LIF and BMP2 and the subsequent induction of astrocytes
from neural progenitors (Nakashima et al, 1999).
1.3.4 Repression of Transcription
As well as activating target genes, Smads have also been shown to function as
transcriptional repressors. The earliest discovery of this phenomenon was in the
mouse goosecoid promoter. Here Smad2 was found to activate the gene in
cooperation with FAST2. whereas Smad3 was unable to activate the element and
actually blocked Smad2-dependent activation (Labbe et al, 1998). In contrast to this
the activin response element of the Xenopus Mix.2 gene appears to be activated by
both Smad2 and Smad3 thus showing that Smads can act as both transcriptional
activators and repressors depending on the promoter context. The mechanism behind
this is currently unclear.
The recent identification of TGIF (5'TG3' interacting factor), SnoN and Ski (Sloan-
Kettering avian retrovirus/ski-related gene) has also provided insights into how
Smads can act as transcriptional blocks. TGIF is a homeodomain protein which when
over-expressed blocks TGF-j3-dependent activation of target genes (Wotton et al,
1999). TGIF interacts with Smad2 and appears to repress target gene expression
through the recruitment of histone deacetylases to TGF-(3 pathway targeted
promoters. Binding of TGIF occurs via the MH2 domain and is mutually exclusive
with CBP/p300 interaction; the expression levels of TGIF versus CBP/p300 could
thus determine the intensity of TGF-P/Smad responses in a cell by affecting the
chromatin organisation through a balance between HDAC and HAT activity.
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Binding of the nuclear oncoproteins Ski or SnoN to Smad2 or Smad3 represses
transcription of Smad target genes and blocks the growth inhibitory effects of TGF-(3
(Luo et al, 1999, Sun Y et al, 1999, Stroschein SL et al, 1999, Akiyoshi et al, 1999).
This block of gene expression appears to occur through the recruitment of the
transcriptional co-repressor N-CoR which in turn has been described to recruit
histone deacetylases to targeted genes. As these co-repressor proteins are recruited to
genes that can be activated as a result of TGF-(3 treatment, these studies suggest that
induction of TGF-(3 target genes may be a balance between recruitment of activators
such as p300/CBP and repressors such as TGIF, Ski or SnoN. Interestingly, SnoN
and, to a lesser extent, Ski are rapidly degraded through cellular proteasomes upon
TGF-(3 treatment (Sun et al, 1999 and Stroschein et al, 1999) Thus Smads may
interact with different DNA binding factors and regulate transcription both positively
and negatively depending on the interacting partners.
Ubiquitin-mediated degradation of BMP R-Smads through specific interaction with
Smad ubiquitination regulatory factor (Smurfl) was recently shown to be another
mode by which the Smad pathway can be controlled (Zhu et al, 1999). Like other E3
ubiquitin ligases, Smurfl mediates the conjugation of ubiquitin to specific target
proteins. Increased expression of Smurfl leads to a selective decrease in BMP R-
Smad protein levels, thereby decreasing the cellular competence to BMP-mediated
responses.
1.3.5 Modulation of Transcription
The work to date on Smad control of transcription suggests that, as the nature of
these interactions appears to determine whether Smads positively or negatively
regulate activation of target genes, Smads should be considered modulators of
transcription. Smads may regulate transcription in two distinct ways; in the case of
the FAST-regulated genes, FAST binds DNA with high affinity and specificity but is
unable to activate target elements on its own. Transcriptional activation by FAST
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thus appears to rely solely on Smad activity and Smads may function as the primary
regulatory signal. Perhaps as FAST is only expressed during gastrulation, this
mechanism may be unique in playing a critical role in Smad signalling in patterning
in the early embryo.
Contrasting with this scenario, most other Smad partners identified can activate
transcription independent of the Smads. These often require input from other
pathways before the Smads can regulate their activity. Here Smads do not provide
primary signals, but rather act as secondary signals which can modulate the outcome
of these interactions.
1.4 TGF-B and the Mammary Gland
Programmed cell death (apoptosis) occurs during normal growth and development of
the mammary gland. One of the most dramatic examples of apoptosis is evident
during the remodelling of the breast that accompanies postlactational involution
(Strange et al, 1995). Transgenic mouse models have demonstrated that
overexpression of polypeptides such as transforming growth factor alpha (TGF-a)
and insulin like growth factor I (IGF-I) can block this remodelling, suggesting that
these growth factors may be acting as survival factors for the mammary epithelium
(Jhappan et al, 1990. Weber et al, 1998). In contrast, transgenic mice that
overexpress the growth inhibitor TGF-J3 show increased apoptosis in the mammary
epithelium throughout mammary development, suggestive of a mechanism working
to counterbalance the survival factors (Pierce et al, 1993, Jhappan et al, 1993).
Experiments with mammary epithelial cell lines cultured in vitro have confirmed that
these growth factors can indeed regulate apoptosis and survival in mammary
epithelial cells; EGF, IGF-I. and basic fibroblast growth factor (bFGF) act as survival
factors for mammary epithelial cells, while TGF-f) induces their death (for review
see Rosfjord and Dickson, 1999). In breast cancer, cytotoxic drugs and hormone
ablation increase the expression of TGF-(3, which may function to induce cell death
by either paracrine or autocrine mechanisms (Reiss et al, 1997). Together, these
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studies have begun to describe a complex dynamic pattern of pro- and apoptotic
factors that promote the development of the mature mammary gland and that rapidly
remodel the tissue after lactation.
1.4.1 Mammary Gland Structure and Function
Functional differentiation of the mammary gland is a crucial step in the reproductive
cycle of mammals. The development of the gland in mice proceeds in distinct
phases; in newborn mice a single primary duct is present which grows slowly during
the first eight weeks of life into a ductal tree which fills the fat pad until the onset of
puberty when pronounced ductal growth occurs. Development of the ducts continues
in cycling virgins leading to the formation of a ductal tree which fills the entire
mammary fat pad. Extensive ductal branching and alveolar growth occurs during
pregnancy and is largely completed at parturition. Terminal differentiation of the
alveolar epithelium is completed at the end of gestation with the onset of milk
secretion at parturition. After weaning, the entire alveolar epithelium undergoes
apoptosis and the gland is then remodelled. Within a few weeks the gland has the
appearance of that of a mature virgin (Hennighausen and Robinson, 1998) (Figure
1.5).
This repetitive cycling of the gland from full lactation through involution and back
again is a phenomenon that occurs in few other tissues and thus elects the mammary
gland as an ideal model to study highly controlled in vivo cellular apoptosis. Both the
role of systemic hormones and influence of the stroma on mammary epithelial cells
have been recognised for some time (Sakakura, 1991). However, only now through
the availability of knockout mice have we been able to dissect individual steps in the
pathways of the translation of hormonal signals into morphogenetic and
developmental events. Two unique aspects of mammary gland development have
greatly aided tn exploiting these knockout animals to elucidate the specific roles of
the epithelium and the stroma. First, the mammary gland develops predominantly in
the postpartum mammal. Therefore, an entire developmental program, mimicking
embryonic development of other organs, can be viewed and followed in postpartum
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Mammary Gland Development (H&E staining)
In newborn mice a single primary duct is present until the onset of puberty
when pronounced ductal growth occurs. Development of the ducts
continues in cycling virgins leading to the formation of a ductal tree which
fills the entire mammary fat pad. Extensive ductal branching and alveolar
growth occurs during pregnancy. Terminal differentiation of the alveolar
epithelium is completed at the end of gestation with the onset of milk
secretion at parturition. After weaning the entire alveolar epithelium
undergoes apoptosis and the gland is then remodeled. Within a few weeks
the gland has the appearance of that of a mature virgin
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animals. This characteristic has several ramifications; the tissue can be easily
manipulated, and reasonable amounts of tissue are available for analysis.
Furthermore, genetic manipulations whose consequences in other tissues would
result in lethality can be studied because mammary cells transplanted into the cleared
fat pad continue to grow and divide very effectively. Thus, normal virgin ductal or
lobuloalveolar cells will readily take, grow and fill the fat pad with mammary ducts
in virgin mice (or differentiate into alveolar cells if the recipient mice become
pregnant). In virgin mice or rats, the implanted cells take about 8 weeks to fill the fat
pad. The cleared fat pad also serves as a transplant site for preneoplastic and
neoplastic mammary cells. The ability to transplant into the fat pad allows one to
examine the morphogenic and tumourigenic capabilities of unknown cell
populations This is true for cells removed from the in situ mammary gland e.g. from
the mammary gland of a late embryonic lethal knockout animal and for cells grown
in vitro. Second, it is possible to generate chimeric glands composed of tissues from
knockout and wild-type animals. Alternatively, epithelium and stroma can be
separated enzymatically and recombined. The assembled tissues can also be grown
as grafts under the kidney capsule of appropriate hosts (Cunha, 1994).
The ductal growth observed in mouse mammary glands is known to be closely
controlled by ovarian steroid hormones (Daniel et al, 1987). Removal of the ovaries
results in mammary gland regression, a phenomenon which can be reversed with the
administration of oestrogen or progesterone (Mixner and Turner, 1942). Oestrogen
receptor (ER) knockout mice have confirmed that this hormone is absolutely required
for ductal outgrowth (Korach et al, 1996). Progesterone receptor (PR) null mice are
infertile due to a failure to ovulate so the role of the PR has been assessed using
ovariectomised mice. After hormone treatment control mice displayed extensive
ductal branching but this was virtually absent in the PR-deficient mice showing that
PR is also required for proper ductal growth of the gland. Prolactin is essential for
the proliferation and functional differentiation of the lobulo-alveolar structures
during pregnancy (Topper and Freeman, 1980). In the absence of the PR from the
mammary epithelium, ductal side-branching fails to occur. This defect can be
overcome by ectopic expression of the protooncogene Wnt-1 and transplantation of
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mammary epithelia from Wnt-4-/- mice shows that Wnt-4 also has an essential role in
side-branching early in pregnancy (Brisken et al, 2000). PR and Wnt-4 mRNAs
colocalise to the luminal compartment of the ductal epithelium where progesterone
induces Wnt-4 in mammary epithelial cells and is required for increased Wnt-4
expression during pregnancy. Thus, Wnt signalling is essential in mediating
progesterone function during mammary gland morphogenesis. Prolactin signalling in
the mammary gland also operates via the JAK/STAT pathway (Liu et al, 1997),
predominantly through the two STAT5 isoforms, Stat5a and Stat5b (STAT5 was
originally called mammary gland factor). Other factors including GH, epidermal
growth factor and erythropoietin also use STAT proteins to regulate the transcription
of specific genes through the JAK/STAT pathway (Schindler and Darnell, 1995).
The STAT pathway is activated through ligand binding triggering dimerisation or
oligomerisation of receptors. Receptor-associated tyrosine kinases (JAKs) cross-
phosphorylate each other as well as the tyrosine residues on the receptors.
Subsequently, SH2-containing latent cytoplasmic proteins from the STAT family are
recruited to the receptor complex and phosphorylated by the JAKs. Two STAT
proteins dimerise, translocate into the nucleus, and activate gene transcription by
binding to IFN-y activation sites in gene promoters (Figure 1.6).
The ability of individual receptors to activate overlapping but distinct sets of homo-
and heterodimerising STAT proteins is thought to contribute to their signal
specificity, in much the same way as the Smads. Animals deficient in STAT proteins
are known to have a number of defects including impaired mammary gland
development (Chapman et al, 1999, Akira, 1999, Udy et al, 1997). One of the most
exciting finds in recent months is the observation that this complex cytokine-
activated pathway can interact at the nuclear level with the Smad pathway
(Nakashima et al, 1999) and this finding forms the basis for my investigation into
Smad-STAT interactions within the mammary gland. Other important molecules
involved in mammary gland development are colony-stimulating factor-1 (CSF-1)
and oxytocin (OT). A natural mutant of the CSF-1 gene (observed as a consequence
of osteopetrosis homozygosity in a mutant mouse) has, amongst other things, a
severe lactational phenotype with a complete absence of milk secretion (Pollard and
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Figure 1.6
The Jak-STAT Signalling Pathway
The STAT pathway is activated through ligand binding triggering
dimerisation or oligomerisation of receptors. Receptor-associated tyrosine
kinases (JAKs) cross-phosphorylate each other as well as the tyrosine
residues on the receptors. Subsequently, SH2-containing latent cytoplasmic
proteins from the STAT family are recruited to the receptor complex and
phosphorylated by the JAKs. Two STAT proteins dimerise, translocate into
the nucleus, and activate gene transcription by binding to IFN-y activation
sites in gene promoters. Figure 1.6 above utilises IFN-y signalling via
STAT1 homodimers as an example of this signalling pathway.
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Heninghausen, 1994). OT knockout mice also fail to produce milk and this then leads
to a rapid involution of the gland (Young et al, 1996, Nishimori et al, 1996 and
Wagner et al, 1997). Because TGF-(3 is a potent inhibitor of epithelial cell
proliferation TGF-(3 is assumed to be important during the involution stage of
mammary gland growth and development. However, different TGF-f3 isoforms have
been implicated in other areas of mammary gland biology including in regulating
functional differentiation or the onset of milk secretion (Daniel and Robinson, 1992,
Robinson et al, 1991). The role of TGF-(3 in involution of the mammary gland has
been well characterised through a number of methods including in vitro work and
knockout and transgenic animals. At the time the work presented in this thesis was
initiated nothing was known about Smads in the mammary gland. However, recent
papers have shed some light on the role that Smads play in the mammary gland,
suggesting that these molecules are key players in this complex, dynamic tissue.
1.4.2 Smads and the Mammary Gland
The initial idea that Smads are involved in mammary gland biology derives from the
fact that they have been elucidated as the downsteam signalling components of the
TGF-P pathway, and because TGF-(3 has a clearly established role in mammary
gland involution.
The evidence to date that Smads are involved in mammary gland biology comes
from only a few published experiments showing that Smads are present in mammary
carcinoma cell lines (Pouliot and Labrie, 1999) and that expression levels of the
Smads become elevated and nuclear when mammary carcinomas are treated with
perillyl alcohol, an anti-cancer agent currently in trials. These results demonstrate
that the TGF-(3 signalling pathway was activated in the regressing carcinomas (Ariazi
et al, 1999). Taken together, the characterised interaction between Smads and STATs
- known to be important in mammary gland biology - and the clear role for TGF-J3 in
extracellular matrix modelling suggests therefore that it seems entirely reasonable
that the Smad family has an important role to play in normal mammary gland
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function and development, and further investigation into this formed the basis of this
research project.
1.5 Animal Models of Gene Function
Transgenic animal technology, and the use of germline manipulation for the creation
of targeted gene mutations, has resulted in a plethora of murine models for biological
research. Our understanding of some of the important issues regarding the
mechanisms controlling cell division, differentiation and death has dramatically
advanced in recent years through exploitation of these techniques to generate
transgenic mice. In particular, the generation of mice with targeted mutations in
genes encoding proteins of interest has proved to be a useful way of elucidating the
function of these gene products in vivo. Transgenic mouse models have provided
some insight into the complex events contributing to cellular dysregulation and the
loss of growth control that can lead to tumorigenesis. They have also helped
elucidate crucial roles for genes in development and normal tissue homeostasis.
The use of transgenic mice in biomedical research has now become widespread, and
numerous applications have been developed. Several general reviews have been
published, including those by Palmiter and Brinster (1986), Jaenisch (1988) and
Hanahan (1989). Two of the most common uses of transgenic mice have been for (1)
studies of tissue-specific and developmental stage-specific gene regulation and (2)
for experiments of the phenotypic effects of transgene expression. Most cloned genes
introduced into the mouse germ line have shown appropriate tissue-specific and
stage-specific patterns of expression despite their integration into apparently random
sites in the host genome. Gene transfer into the mouse embryo has therefore provided
the definitive experimental assay to define the cis-acting DNA sequences that dictate
specific patterns of transcription in the developing animal. In addition, the
characterisation of regulatory sequences through such studies has provided tools for
the second category of experiments in which the expression of gene products of
interest is directed to specific sites in the developing mouse.
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The first report of the direct introduction of new genetic material into the mouse
embryo actually predates the widespread use of recombinant DNA techniques. In
1974, Rudolf Jaenisch and Beatrice Mintz found that when purified SV40 DNA was
injected into the blastocoel cavity of mouse blastocysts, viral DNA sequences could
be detected in somatic tissues of many of resulting animals, suggesting that they had
integrated into the genome of embryonic cells. In addition, Jaenisch (1976)
discovered that Maloney murine leukaemia virus could be stably introduced into the
germ line by viral infection of pre-implantation mouse embryos. However, these
studies did not immediately lead to attempts to introduce cloned eukaryotic genes
into the germ line.
In 1980 it was reported that the microinjection of the cloned herpes simplex virus
(HSV) thymidine kinase (tk) gene into the nuclei of cultured fibroblasts led to the
stable incorporation and expression of the tk gene in 5-20% of the recipient cells
(Anderson et al, 1980, Capecchi 1980). This finding suggested that the
microinjection of DNA into the one cell mouse embryo might allow the efficient
introduction of cloned genes into the developing mouse and led a number of
investigators to test this possibility. Gordon et al reported the first successful
introduction of a cloned gene into mouse somatic tissues by pronuclear injection in
1980. Shortly thereafter, several groups were successful in introducing cloned genes
into somatic tissues as well as into the germ line by this technique (Brinster et al,
1981, Costantini and Lacy, 1981, Gordon and Ruddle, 1981, Harbers et al, 1981, and
Wagner et al, 1981).
1.5.1 Gene Targeting in ES cells
Our understanding of the signal transduction network has been aided by the
generation of mice that carry mutations in a cloned gene following homologous
recombination in embryonic stem cells (ES cells). This is a more directed approach
than the analysis of pre-existing mutants, as the molecule of interest has often
already been analysed in vitro. A significant advantage of this approach is the
identification of mutants that do not exhibit an overt phenotype, and which therefore
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would not have been identified by classical genetics. Homologous recombination in
ES cells is now a routine technique that is used to modify the mouse genome at any
chosen locus. The principles of this technique were developed in the 1970s in yeast
where contrary to the situation in mammalian cells, the majority of recombinations
between introduced vector DNA and genomic DNA occur by homologous
recombination as opposed to random integration.
Homologous recombination in mammalian cells between an artificial targeting vector
and an endogenous gene was first achieved by Smithies et al. (1985) for the (3-Globin
locus, albeit at very low frequency. In 1981 two groups (Evans and Kaufmann, 1981
and Martin 1981) derived pluripotent embryonic stem cell lines from mouse
blastocysts. Bradley et al (1984) were able to show that even after prolonged tissue
culture such ES cells have the capacity to colonise the germ line of chimeric mice
when injected into blastocysts. These experiments paved the way to altering the
mouse genome by homologous recombination in ES cells. This was first achieved for
the selectable hypoxanthine phosphoribosyl transferase (HPRT) gene locus
(Doetschman et al, 1987, Thomas and Capecchi 1987) and subsequently targeting of
non-selectable genes such as int-2 and c-abl (Mansour et al, 1988, Schwartzberg et
al, 1989) became possible after enrichment strategies for homologous recombination
had been developed. The first germline transmission in mice of a targeted allele
involved the corrected Hprt allele here in Edinburgh by Thompson et al in 1989.
ES cell lines are derived from pluripotent. uncommitted cells of the inner cell mass
of pre-implantation blastocysts and can contribute efficiently to both somatic and
germ line tissues after re-introduction into blastocysts. This capacity crucially
depends on culture conditions that keep the ES cells in an uncommitted,
undifferentiated state. These differentiation-inhibiting signals can be provided by
feeder cells that also serve as a matrix for ES cell adherence and/or by the addition of
leukaemia inhibitory factor (LIF) to the culture medium (Pease and Williams, 1990).
The genetic background of the majority of available ES cell lines is 129, a strain
from which ES cells lines are most readily established (Kawase et al, 1994). ES cells
have been well characterised since their discovery in 1981 and a variety of protocols
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exist to maintain their pluripotency throughout a gene targeting experiment. The key
to good, undifferentiated ES cell culture is the addition of LIF to the culture medium
- the first ES cells to be isolated were maintained on a feeder layer of mitomycin en¬
treated fibroblasts (Evans and Kaufmann, 1981 and Martin, 1981). However, the
presence of feeders can complicate the selection processes for isolation of genetically
modified cells (Hooper, 1987) and the discovery that medium conditioned by Buffalo
rat liver cells (BRL) can substitute for feeders greatly improved experiments (Smith
and Hooper, 1987). It has since been elucidated that an isolated, purified factor called
LIF (leukaemia-inhibiting factor) will also effectively maintain ES cell pluripotency
(Williams et al, 1988 and Smith et al, 1988).
The first step in a gene targeting experiment is to isolate a genomic clone or clones
containing the gene of interest. The targeting vector should be constructed from a
genomic clone of the same genetic background as the ES cells to be used, known as
isogenic DNA. Once the genomic clone has been isolated and characterised a
targeting vector must be built, usually one of two forms: a replacement vector or an
insertion vector. The replacement vector is the most commonly used type of
approach and is linearised in such a way that the vector sequences remain collinear
with the target sequences. Chromosomal sequences are replaced by vector sequences
by a double crossover event involving the flanking homologous region. The success
of this homologous recombination is dependent on several parameters; the total
length of the homologous region (0.5kb minimum, lOkb maximum for ease of
handling) (Hasty et al, 1991, Deng and Capecchi 1992), recombination rates can
increase with the use of isogenic DNA (te Riele et al, 1992) and absolute frequencies
of homologous recombination seem to be locus dependent. Normally a selection
marker is incorporated into the targeting vector in order to screen for successfully
targeted clones - the most commonly used marker is a cassette carrying the
neomycin resistance gene (neor) under the control of a strong promoter. However, to
enrich for clones that have undergone homologous recombination as opposed to
random integration a strategy termed "positive/negative" selection was developed by
Capecchi and co-workers (Mansour et al, 1988). A thymidine kinase (TK) gene from
HSV is inserted at the end of the linearised targeting construct. Cells that have
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undergone homologous recombination will have lost the TK gene, whereas cells in
which the construct integrated randomly can be eliminated using a toxic nucleoside
analogue such as ganciclovir. Enrichments using this technique are typically from 3
to 10 fold. Screening for correctly targeted clones is by either Southern Blot or PCR
with one primer derived from the newly introduced selection cassette and the other
primer hybridising to genomic sequences outside the targeting construct.
Although the generation of a simple knockout as described above can be a relatively
simple process it can also be one strewn with problems and pitfalls. Incomplete
knockouts can be created when coding sequences remain present in the genome and
form truncated or mutant forms of the protein. This can be caused by read-through
transcription through the inserted selection marker followed by initiation of
translation from downstream AUGs (for example see Tanaka et al, 1997) or splicing
which may lead to the expression of modified proteins (for example see Li et al,
1992). Removal of all coding regions or regulatory elements of genes can also cause
problems as it may lead to large genomic deletions resulting in the loss of regulatory
elements governing the expression of unrelated genes - this can be problematical
especially with clustered genes. Here different approaches to the targeting
experiment with the same gene can lead to a vast range in phenotypes dependant on
what regulatory factors were deleted at the same time (for example see Olson et al,
1996). Selection cassette interference may also cause problems as these markers of
recombination are almost always driven by strong promoters which may disrupt the
expression of neighbouring genes (for example see Fiering et al, 1995). Of course
one of the other major drawbacks with this technology can be that the phenotype of
the knockout is so severe that little biology can be interpreted other than the extreme
importance of the targeted gene at some point during development. However, many
genes are switched off after embryonic development or are limited to tissue specific
expression and so analysis by this means often proves fruitless. Recently strategies
exploiting site-specific DNA recombination have been incorporated into transgenic
and gene targeting procedures to allow in vivo manipulation of DNA in ES cells or
living animals. In other words it is possible to generate a deletion of the gene of
interest at a specific point in time and in a specific tissue.
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1.5.2 Cre-Lox Technology
Cre is the 38kDa product of the cre gene of bacteriophage PI (Sternberg, 1978) and
is a site-specific DNA recombinase. Within the bacteriophage Cre has two roles,
firstly to circularise the viral genome should this fail to be carried out by host cell
recombination machinery (Segev and Cohen, 1981) and secondly to maintain correct
unit copy segregation of the prophage by resolving any dimeric molecules into
monomers prior to cell division (Austin et al, 1981). Cre recognises a 34 base pair
site on the PI genome called loxP (locus of X-over of PI) and efficiently catalyses
reciprocal conservative DNA recombination between pairs of loxP sites (Austin et al,
1981). The loxP site consists of two 13 base pair inverted repeats flanking an 8 base
pair non palindromic core region (Hoess et al, 1982) that gives the loxP site an
overall directionality that, by convention, is depicted as an arrow. Cre mediated
recombination between two directly repeated loxP sites results in excision of the
DNA between them as a covalently closed circle (Figure 1.7). Unlike many other
recombinases no accessory factors or DNA topological requirements are required for
efficient Cre-mediated DNA recombination and this makes this system uniquely
suited to genomic manipulation of eukaryotic cells (Sauer, 1988). The strategy is
similar in many ways to that described earlier for conventional gene targeting - the
target gene is modified by homologous recombination in ES cells so that it is flanked
by two loxP sites. The correctly targeted ES cells are injected into blastocysts before
being introduced into pseudopregnant mice and animals containing the modified
gene (which are at this point phenotypically wild type) are then crossed with mice
expressing Cre in the desired target tissue and Cre-mediated excision results in a
tissue-specific gene ablation. This strategy was first demonstrated by Gu et al (1994)
using a mouse in which the promoter and first exon of the DNA Polymerase (3 gene
(polft) were flanked by loxP sites. When mated to a transgenic mouse that
specifically expressed Cre in T cells, the pol[3 gene was inactivated in the T cell















(a) Cre recognises a 34 base pair site on the PI genome called loxP (locus of
X-over of PI) and efficiently catalyses reciprocal conservative DNA
recombination between pairs of loxP sites. The loxP site consists of two 13
base pair inverted repeats flanking an 8 base pair non palindromic core region
that gives the loxP site an overall directionality that, by convention, is depicted
as an arrow. Cre mediated recombination between two directly repeated loxP
sites results in excision of the DNA between them as a covalently closed circle
(b) Correctly targeted ES cells are injected into mice and animals containing
the modified gene (which are at this point phenotypically wild type) are then
crossed with mice expressing Cre in the desired target tissue and Cre-mediated
excision results in a tissue-specific gene ablation
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A particularly powerful feature of a conditional gene inactivation strategy using Cre
is that the same loxP-tagged mouse can be used for gene ablation independently in a
large number of different tissues, or at different developmental times, by simply
mating it with a corresponding Cre transgenic that displays the desired tissue or
temporal specificity of expression. Thus the same genetically modified animal can be
used to answer a variety of different questions relating to the expression and function
of the target gene. Of course, crucial to the success of this strategy is the prior careful
evaluation of the pattern of expression of the cre transgenic animal. Mosaic
expression or exogenous tissue expression would defeat the purpose of the
experiment and so careful choice of promoter must be considered. There are
currently many Cre transgenic mice available ranging from oocyte-specific
(Lewandoski et al, 1997), mammary gland (Wagner et al, 1997 and Selbert et al,
1998), liver (Kellendonk et al, 2000) and pancreas (Ray et al, 1999). This method of
introducing Cre is tissue specific but relies very heavily on the availability of suitable
tissue-specific promoters and not all attempts at achieving tissue-specific expression
of Cre recombinase are successful; for example a transgenic mouse strain engineered
to express Cre under the control of the platelet endothelial cell adhesion molecule-1
promoter (PECAM-1) was predicted to express Cre only in endothelial cells (Terry et
al, 1997). However, when the PECAM-l/Cre mouse was crossed to a floxed mouse,
the progeny were seen to have undergone recombination in all tissues. The
conclusion from this work is that if the promoter is even briefly active during an
early stage of development this can be sufficient to induce floxing in a non-tissue-
specific manner. An attractive alternative to native promoters is to use synthetic
inducible systems to control cre expression. The elegant tetracycline-regulated
transcriptional systems (Gossen et al. 1992 and 1995) offer the possibility of
inducing cre expression at a desired time either by simply dosing an animal with
tetracycline or by withdrawing animals from tetracycline administration. A much
more rapid approach to the problem can be possible by viral-mediated gene transfer
of Cre recombinase (Anton and Graham, 1995). This uses a basic strategy where
sections of the wild type virus genome, such as sequences encoding the El and E3
genes are replaced with a Cre expression construct. Such recombinant viruses are
replication deficient but still capable of host cell infection. Many groups have used
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this approach successfully. As cultured cells can be exposed directly to the virus very
high efficiencies of infections can be achieved, more so than with standard
transfection efficiencies. For example infection of CV1 cells with adenovirus Cre
(AdCre) resulted in recombination mediated gene activation in up to 100% of the
cells (Kanegae et al, 1995). The technology has also been used successfully in vivo
where the commonest way of administering the AdCre is by intravenous injection
(IV), although this route does not lead to uniform infection of somatic tissues. Cre-
expressing adenovirus vectors can be administered by IV to loxP-modified mice and
cause high levels of recombination in the primary targets tissues of liver and spleen
(Wang et al, 1996 and Rohlmann et al, 1996).
The TGF-(3 superfamily is one of the most studied groups of proteins by gene
inactivation in animals. Knockout mice have been generated for TGF-(3l, (33 and
some of their receptors. Null mice have also been characterised for many of the
activins and their receptors and also the BMPs and their receptors (for review see the
Biomednet mouse knockout database at http://www.biomednet.com/db/mkmd.
Following the discovery of the Smads in 1996 there followed a spate of Smad
knockout mice including the embryonic lethal Smad4 (Sirard et al, 1998), embryonic
lethal Smad2 (Weinstein et al, 1998), colorectal cancer prone Smad3 (Zhu et al,
1998) and the embryonic lethal Smad5 (Chang et al, 1999). The high incidence of
embryonic lethality associated with Smad null mice suggests that they are very
important in the early stages of development. However, this fact has led to much
interest in producing conditional deletions of the Smads in order to learn more about
their tissue-specific roles in the mammai.
1.6 Aims of the Project
The broad aim of this project is to further understand the role that Smad4 plays in
normal mammary gland function and development. In order to achieve this goal
several approaches have been taken; the first part of the project examines how Smad
overexpression affects embryonic stem cells. These cells are known to not express
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various receptors for the TGF-J3 family until they become differentiated so they
represent a method of examining how overexpression of non-activated downstream
signalling components can affect the whole pathway.
The second approach has been to generate a mammary gland-specific Smad4
transgenic mouse. This mouse contains a stable transgene consisting of the BLG
promoter upstream of a FLAG epitope-tagged human Smad4 cDNA. This transgenic
should be useful in again addressing the question of what role Smad4 plays in the
lactation to involution progression and to what extent it is involved in the apoptosis
of the gland.
The third and possibly the most exciting has been the production of a "floxed"
Smad4 mouse. The embryonic lethality associated with conventional gene targeting
of the Smad4 locus has prompted the generation of a conditional targeting strategy
whereby Exon I of the Smad4 locus can be deleted in a tissue-specific manner in the
presence of Cre recombinase. This "floxed" mouse will be crossed to a BLG-
mammary gland specific Cre transgenic (Selbert et al, 1998) which has been
characterised to express Cre protein only in the epithelial cells of the gland during
pregnancy and lactation. This model will allow us to answer the question of what
role Smad4 plays in the massive epithelial cell apoptosis characteristic of involution
of the mammary gland.
The final approach has been an examination of Smad interactions with other known
signalling pathways in the gland. Here I have examined first the normal expression
pattern of Smads in the mammary gland and then gone on to characterise their in vivo
interactions with members of the STAT pathway, a group of proteins known to be
important in the mammary gland and known to interact with Smads in vitro.
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Chapter 2 - Materials and Methods
2.1 Preparation of DNA
2.1.1 Large-scale preparation of plasmid DNA - Maxiprep
Two 50pl aliquots of competent Escherichia coli cells (>2xl07 CFUpg pUCl9) of
the DH5a (Life Technologies) were removed from -70°C storage and thawed on ice.
lp.1 (approximately 1 pig) of DNA solution was added to one of the tubes of E. coli
cells and the tubes incubated on ice for 30 minutes. The cells were heat shocked at
42°C for 45 seconds and then placed on ice for two minutes. 800pl of LB medium
was added to the tube and the cells were incubated at 37°C for 1 hour in a shaking
incubator (Gallenkamp) (220 rpm). The transformed bacteria were plated out onto L-
amp plates (disposable 100mm bacterial culture dishes containing L-broth (See
Appendix A) supplemented with 50pg/ml ampicillin (Sigma) and 1.2% Bactoagar
and incubated overnight at 37°C.
The following day a colony was picked from the plate transformed with plasmid
DNA (the other control plate should produce no colonies) and was placed in lOmls
L-broth supplemented with ampiciliin and the cells grown for about 8 hours in a
shaking incubator at 37°C. This culture was added to a 500ml flask of L-broth
supplemented with ampicillin and incubated overnight in a shaking incubator at
37°C, 220rpm.
The following morning the cells were harvested by centrifugation at 6000xg for 10
minutes at 4°C. The supernatant was discarded and the cells lysed by resuspending in
iOmls Solution PI of the Qiagen maxiprep kit (Qiagen) (See Appendix A).
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10 mis of solution P2 (See Appendix A) was then added, the lysate mixed gently but
thoroughly by inversion and left to incubate at room temperature for 5 minutes
10 mis of chilled Solution P3 (See Appendix A) was added and the lysate mixed
gently by inversion before incubation on ice for 20 minutes
The precipitated proteins were removed by centrifugation at 20,000xg for 30 minutes
at 4°C and the supernatant containing the plasmid DNA removed promptly. A
Qiagen-tip was equilibrated with Buffer QBT (See Appendix A) and the plasmid-
containing supernatant was allowed to enter the column resin by gravity flow. The
Qiagen-tip was then washed twice with Buffer QC and then the plasmid DNA was
eluted with 15mls Buffer QF (See Appendix A).
The plasmid DNA was precipitated by adding 0.7 volumes of isopropanol, mixing by
inversion and incubating for 10 minutes at room temperature. The DNA precipitate
was recovered by centrifugation at 17000xg for 30 minutes at 4°C. The supernatant
was discarded and the pellet was washed with 5mls of 70% ethanol at room
temperature and then dried under vacuum. The plasmid DNA was resuspended in
200pl ddFLO and quantified by spectrophotometry (Genequant, USA). Plasmid
DNA was stored at -20°C.
2.1,2 Small-scale preparation of plasmid DNA - Miniprep
Isolation of plasmid DNA from bacterial cultures for the verification of plasmid
identity by restriction digestion was carried out using the QIAprep Spin Plasmid Kit
(Qiagen). Single colonies were picked from L-amp plates and inoculated into 5mls
LB medium containing the appropriate antibiotics (100pg/ml ampicillin) in Falcon
2059 tubes (Becton Dickinson). After an incubation period of 14-16 hours at 37°C in
an orbital shaker at 220rpm, a final 1.5 ml sample from each of the resulting late
logarithmic phase cultures was transferred to a microfuge tube and the bacteria
pelleted by microcentrifugation at 6500rpm for 5 minutes. The supernatant was
69
discarded and the bacterial pellets resuspended in 200pl Cell Resuspension Buffer
(see Appendix A), lysed by the addition of 200pl of Cell Lysis Buffer (see
Appendix A). This solution contains alkaline sodium dodecyl sulphate (SDS) and
this denatures bacterial proteins and the strong alkaline conditions used in this
procedure cause denaturation of both plasmid and chromosomal DNA. This was
mixed gently by inversion and then neutralised by addition of 200jul Neutralisation
solution (see Appendix A). This neutralisation caused rapid renaturation of circular
plasmid DNA whereas most chromosomal DNA, bacterial protein and SDS (as
potassium dodecyl sulphate) formed a white gelatinous precipitate which was
separated from the aqueous, plasmid-containing supernatant upon
microcentrifugation at 13000 rpm for 5 minutes. This supernatant (cleared lysate)
was promptly separated from the debris by pipetting into a clean Eppendorf
microfuge tube.
l-2pl samples of DNA purified from cleared lysates was digested with appropriate
restriction enzymes and analysed by agarose gel electrophoresis.
2.2 Manipulation of DNA
2.2.1 Restriction Endonuclease Digestion of Plasmid DNA
Plasmid DNA was digested in sterile Eppendorf microfuge tubes containing a
mixture of DDW, the appropriate restriction endonuclease and the recommended
correct ionic strength buffer. Boehringer or New England Biolabs supplied all
restriction enzymes. lOx stock buffer solutions were used diluted 1:10 in the final
reaction mix. Restriction enzymes were stored at -20°C in buffers containing 50%
glycerol and kept on ice while in use. Sufficient enzyme was used to ensure complete
digestion. 1 unit of enzyme being the amount required to digest lpg of pBR322
plasmid DNA to completion in 1 hour. The amount of enzyme was kept below 10%
of the final reaction volume as glycerol can interfere with enzymatic activity.
Digestion was carried out at 37°C for most enzymes for a minimum of one hour.
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2.2.2 Agarose Gel Electrophoresis of DNA
Agarose gel electrophoresis was carried out in order to confirm digestion,
characterise plasmids or purify restriction fragments. DNA molecules are separated
by electrophoresis according to size, conformation (supercoiled, nicked circular or
linear), agarose concentration and applied current. Tris-borate EDTA (TBE) was
routinely used as an electrophoresis buffer (See Appendix A).
Preparation of gels and electrophoresis in BioRad MiniSub cells was carried out as
described by Sambrook et al. (1989). Samples were loaded by adding 0.1 volume gel
loading buffer and applied to the wells of a gel submerged in electrophoresis buffer.
Fragment sizes were estimated with reference to a 1-kilobase ladder (Life
Technologies) See Appendix A.
2.2.3 Phenol: Chloroform Extraction and Etnanol Precipitation of DNA
These procedures were carried out as described in Sambrook et al. (1989) in order to
remove proteins and to concentrate DNA. The resulting DNA pellets were then
briefly air-dried and redisolved in an appropriate volume of double-distilled water.
2.2.4 Estimation of DNA Concentration and Purity
Two methods for the estimation of the concentration of DNA solutions were used: a
spectrophotomeric method and an ethidium bromide fluorescent quantitation method
(Sambrook et al, 1989). DNA samples from large and small-scale DNA preparations
were quantitated by ultraviolet spectrophotometry.
The optical densities (OD) of 1:100-diluted DNA solutions were measured in a
Genequant II RNA/DNA Calculator (Pharmacia) at X= 260nm. An OD260 of 1 was
taken to be equivalent to a concentration of 50p.g/ml of double-stranded DNA in the
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diluted sample. The ratio of the ODs at A=260nm and at A=280nm is a measure of
the purity of a DNA sample. Accordingly, OD260/280 ratios measured in the
Genequant were recorded for DNA samples.
The concentration of certain DNA solutions was estimated by ethidium bromide
fluorescence method. Small samples of DNA (e.g. 0.5p.l) and a range of serially
diluted kilobase ladder were spotted onto a plastic Petri dish containing 1% agarose
gel and 5|ag/'ml ethidium bromide. After 10-15 minutes to allow absorption of DNA
onto the gel, the plate was exposed on an ultraviolet transilluminator and the DNA
concentration was estimated by comparison of the fluorescent intensity of the sample
against that of the standards.
2.2.5 Isolation of DNA fragments from agarose gels
Digested DNA fragments were visualised by UV transillumination and then excised
from 0.7% agarose TBE buffered gels and purified using the QIAEX Gel extraction
kit (QIAGEN) according to manufacturers instructions.
2.2.6 Modification of the ends of linear DNA: dephosphorylation
1 unit shrimp alkaline phosphatase (SAP) (United States Biochemicals USB) was
added to 40p.l gel-purified DNA together with the appropriate dephosphorylation
buffer and distilled water up to a final volume of 50p.l. This reaction was incubated at
37°C for one hour and then the phosphatase was inactivated by heating to 65°C for
15 minutes.
2.2.7 Klenow reaction
The large fragment of DNA polymerase I, Klenow enzyme (United States
Biochemical) retains 5' to 3' polymerase activity but lacks any exonuclease activity.
This polymerase was used to blunt 5' overhangs of DNA generated by restriction
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enzyme cleavage when needed. The enzyme (1-5 units, depending on reaction
volume) and 0.1 volumes of 0.5mM dNTP mix can be added directly to a restriction
digest and incubated at 37°C for 30 minutes. If the blunted DNA was to be used in
subsequent ligations the correct size band was excised from the gel, purified and
SAP treated if necessary.
2.2.8 T4 DNA Polymerase
T4 DNA Polymerase catalyses the synthesis of DNA in the 5' to 3' direction so, like
Klenow fragment, can be used to fill-in 5' overhangs. However, T4 DNA polymerase
also has a 3' to 5' exonuclease activity that will remove any 3' overhangs generated
by certain restriction enzymes to leave blunt ends. As with Klenow, the enzyme and
other reaction components were added directly to restriction digests after they had
gone to completion. Each reaction contained 3 units of polymerase (New England
Biolab)/p.g of DNA, 0.1 volumes of ImM each dNTP mix (Pharmacia Biotech), 0.1
volumes of 0.5mg/ml BSA and 0.1 volumes of T4 reaction buffer
2.2.9 Southern Blot Hybridisation
lOpg of genomic DNA was digested with the appropriate restriction enzyme. The
sample was then run on a 0.7% agarose gel in 1 x TBE. The gel was then prepared
for blotting onto a nylon membrane. If the fragments of interest were predicted to be
larger than lOkb. transfer of the DNA to the nylon membrane was improved by
partially depurinating the DNA prior to transfer. This was achieved by soaking the
gel for 10 minutes in 0.2M HC1, followed by a rinse in ddw.
The DNA was transferred from the gel onto a positively charged nylon membrane,
Zeta-Probe® GT (Bio-Rad) according to the manufacturers instructions using 0.4M
NaOH as the transfer buffer. After blotting overnight the membrane was rinsed in 2 x
SSC and air dried. The nylon membrane was then baked at 80°C for 30 minutes and
stored between 3MM Whatman paper at room temperature until needed.
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UltraHYB™ (Ambion) hybridisation buffer was heated to 68°C to ensure complete
solubilisation of all components. lOmls was then removed and added into a
hybridisation tube containing the baked nylon membrane. The membrane and
UltraHYB™ buffer were then incubated at 42°C for 1 hour in a hybridisation oven
(Hybaid)
DNA probe fragments were gel purified and 20ng labelled with 50p.Ci, 3000Ci/mol
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[a- ~P]-dCTP (ICN) using High Prime random oligonucleotide premixed solution.
(Boehringer Mannheim). Unincorporated nucleotides were removed by passing
labelled probes down a Sepahdex G50 column (NICK column - Pharmacia).
Labelled DNA probe was denatured by boiling and then immediately diluted in
hybridisation solution overnight at 42°C. After overnight incubation the
hybridisation solution was discarded and the filters washed in twice in 2xSSC, 0/1%
SDS and twice in 0.1%SSC, 0.1% SDS. The filters were sealed in heat-sealable bags
and exposed to BIOMAX MS-1 film in an autoradiography cassette with intensifying
screens.
2.2.10 Dideoxynucleotide Chain Termination Sequencing of Plasmid DNA
Double stranded plasmid DNA template was prepared by the Qiagen maxi-prep
method as described and then alkaline denatured. For each sample, 5pg DNA was
diluted in 45p.l DDW and then denatured with 5pl 2M NaOH, 2rnM EDTA and
incubated at ambient temperature for 5 minutes. The solution was neutralised with
2M ammonium acetate (pH 4.6) and the DNA precipitated at -70°C for 30 minutes
with 185jctl absolute ethanol. The DNA was recovered by microcentrifuge at 13000
rpm at 4°C for 10 minutes and dried in a vacuum dryer for 5 minutes. The DNA was
resuspended in 6p.l DDW.
74
The resuspended DNA was annealed to 2pmol primer in IX Sequenase Reaction
Buffer (United States Biochemicals) in a final volume of 10pl by heating to 65°C for
2 minutes and then allowed to cool to 25°C slowly in a waterbath. The annealed
template/primer mix was then labelled at room temperature for 10 minutes with 5pCi
(lOOOCi/mmol) a-35S]-dATP (ICN) and terminated at 37°C for at least 5 minutes
with each of the four dideoxyribonucleotides using dGTP reagents and protocols
provided with the Sequenase Version 2.0 DNA Sequencing Kit (United States
Biochemicals). Each termination reaction was stopped using the provided "Stop"
solution, which also acts as a dye-containing loading buffer.
Processed samples were denatured by heating to 75°C immediately before loading
3pl into wells created by sharks tooth combs at the top of a pre-run 6% denaturing
polyacrylamide sequencing gels (See Appendix A). The gel was run using S2
sequencing apparatus (Life Technologies) and a model 3000 microcomputer
electrophoresis power supply (Life Technologies) at 70W in IX TBE.
2.3 Targeting Construct Preparation
2.3.1 Screening the A PS mouse genomic library
A mouse genomic APS library (MoBiTec) was screened as follows: A single colony
of the bacterial strain C600 (-Cre) was grown in 50mls of LB++ in a 250ml flask at
37°C overnight. Next day the bacteria were transferred to a sterile 50ml tube and
centrifuged to pellet the bacteria. They were then resuspended in 25mls of MgSCL
and stored at 4°C.
The viral library was prepared as serial dilutions and 300pl of the C600 bacteria was
infected with lpi of various dilutions and incubated for 30 minutes at 37°C. Plates
were prepared with LB/MgS04 and LB/top agar was added to infected bacteria and
poured onto the plates. These were left overnight at 37°C. The following day the
plaques were counted to calculate the exact titer of pfus of the library stock.
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The library was plated at 2xl06 pfu total and filter hybridisation was carried out
according to standard protocols. Positive plaques were purified by additional rounds
(usually 3) of plating and hybridisation. Single plaques were picked using a glass
pipette and then transferred into a reaction tube containing 500pl SM/20pl
chloroform.
The next step is in preparation of the Cre containing BNN132 cells (+Cre). From
BNN132 cells grown on kanamycin plates (25pg/ml) a single colony was transferred
into LB++ medium and prepared plating bacteria as described for the C600 bacteria.
20pl of the purified phage stored in SM/chloroform was added to 200pl of the
BNN132 plating bacteria. This generates automatic sub cloning from the addition of
Cre. This was incubated at 37°C for 30 minutes and then plated onto ampicillin
plates and incubated overnight. The next day a single colony was picked and grown
to saturation for maxiprep using standard protocols.
The result of screening the library was a 15kb genomic clone which encompassed
exonsl, 2 and 3 and upstream sequence from exon lof the mouse Smad4 locus.
LB/MgSOj Prepare LB agar plates as described before.
After autoclaving, add sterile 1M MgSCL to a final
concentration of lOmM. Pour plates and store at 4°C.
LB++ broth Prepare LB broth as described before. Add sterile
1M MgSCL (1:100/v: v) to a final concentration of
lOmM and 20% maltose (1:100/v: v) to a final
concentration of 0.2%. Store at room temperature.
SM (per litre) 5.8g NaCl
2.0g MgS04.7H:0
50ml 1M Tris-HCl, pH 7.5
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Autoclave, add 5mls of 2% gelatin solution
Store at room temperature.
LB/top agar Prepare LB broth as described before. Add MgSCL
(2.4g/L) to a final concentration of lOmM and agarose
(7.2g/L) and autoclave. Store at room tempretaure.
2.3.2 Creating the floxed Smad4-HPRT targeting vector
The floxed Neomycin/TK cassette has been described before (Potocnik et al, 2000)
and briefly consists of a neomycin antibiotic cassette and a thymidine kinase cassette
with single loxP sites on either side of the cassette in the same orientation. The
floxed Neo/TK cassette can be excised from its pBluescript backbone by restriction
digest with BamHI and Xhol.
The single loxP sites used in the creation of the floxed Srnad4 targeting construct
were designed with EcoRV and BamHI sites on either end. These sites aid in cloning
the loxP sites into the targeting vector and also help determine orientation of the loxP
site after cloning. Other than these adaptations the loxP sites used are standard and
do not contain any altered bases. The sequence of the loxP is:
►
GGATCCATAACTTCGTATAGCATACATTATACGAAGTTATGATATC
Dr Stefan Selbert at the Department of Pathology, Teviot Place, Edinburgh, created
the floxed Smad4 targeting construct. The strategy employed was to isolate an 8kb
BHI fragment from the original 15kb X clone which was determined by restriction
digest, southern blotting and sequencing to contain Exons I, II and III and some
upstream sequence of the murine Smad4 gene. A single loxP site, as described
above, was inserted into a unique Ncol site approximately 700bp upstream of Exon I.
The floxed Neo/TK targeting cassette was inserted into a unique Bin I site
approximately lkb downstream of Exon I. The final step in generating the targeting
construct was the introduction of an HPRT cassette into the NotI site of pBluescript
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i.e. outside the 3' region of homology. The HPRT cassette was excised from
pPOLYIII-Hprt using a Not I restriction digest. The pPOLYIII-Hprt cassette was a
kind gift of Professor David Melton, Edinburgh University. The pTarVec plasmid
was transfected into bacteria and grown to saturation so that maxipreps of the plamid
could be obtained. 150pg of Clal linearised plasmid DNA was used for
electroporation into ES cells.
2.3.3 Constructing the BLG-Smad4 transaene
The human Smad4 cDNA used in the BLG-Smad4 transgene was a kind gift of Dr
Rik Derynk, UCSF, USA. The cloning strategy employed to create the BLG-Smad4
vector was used by Dr Stefan Selbert, Medical School, University of Lubeck,
Germany. The human Smad4 cDNA has been described previously (Zhang Y et al,
1996). The flag-tagged human Smad4 cDNA was cut out of the full vector with the
restriction endonucleases Clal and Hpa I (New England Biolabs). The resulting
linear cDNA fragment was purified from a gel by the Quiaex Gel Extraction
(QIAGEN) kit as described previously. The BLG-pBS/SK+ plasmid has been
described previously (Selbert et al, 1998) and consists of the ovine beta lactoglobulin
(BLG) promoter sequence cloned into pBluescript. This vector was opened with
digestion with EcoRV (New England Biolabs) and the human Smad4 cDNA ligated
downstream of the BLG promoter using Ready-to-Go T4 Ligase (Amersham).
2.3.4 Preparation of Transqene for Pronuclear injection
The BLG-Smad4 transgene was removed from the vector backbone by restriction
digest with Xhol and NotI (New England Biolabs) and then purified by phenol
chloroform extraction and ethanol precipitation as described. An equal volume of
phenol: chloroform: isoamyl alcohol (25:24:1) was added to the sample and the
solution was mixed well then centrifuged at 13,000rpm for 1 minute. The aqueous
phase (upper layer) was pipetted into a clean microfuge tube, whilst the cloudy
interface, containing the proteins and the lower organic phase were discarded. An
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equal volume of chloroform was then added and the sample spun at 13,000rpm for 1
minute. The upper phase, containing the DNA was pipetted into a clean microfuge
tube and the organic lower phase discarded. The purified DNA was then
concentrated and sterilised by ethanol precipitation. For ethanol precipitation 2
volumes of ethanol and l/10'h the volume of 3M sodium acetate (pH 5) were added
to the DNA solution. The sample was placed at -20°C for at least 1 hour and then
centrifuged at 13,000rpm in a microfuge for 20 minutes. Ethanol was poured off and
the pellet washed with 1ml of 70% ethanol. The sample was centrifuged for 15
minutes and the wash step repeated. The transgene DNA was resuspended in sterile
injection buffer (lOmM Tris, O.lmM EDTA) at a concentration of lOpg/ml. The
resuspended transgene was then dialysed against a large volume of injection buffer
for 4 days at 4°C, the buffer being changed daily. Following dialysis the transgene
DNA was stored frozen in 20pl aliquots.
2.3.5 Collection of Fertilised Oocytes and pronuclear injection
This work was carried out by both Dr. Alastair Mackenzie in the MRC Transgenic
Facility, Edinburgh and Dr Roberta James at the CRC labs. Western General
Hospital, Edinburgh.
Fertilised oocytes were harvested from superovulated mice by standard methodology
and placed in M2 medium containing hyaluronidase solution (300mg/ml) to remove
the cumulus cells surrounding the fertilised oocytes, after a few minutes the oocytes
were transferred to a petri dish containing fresh M2 medium and cultured at 37°C
prior to injection.
The BLG-Smad4 construct was prepared and injected into the pronuclei of the
fertilised oocytes using a micromanipulator. Injected oocytes were then cultured
overnight at 37°C and the following day oocytes at the two-cell stage were selected
and transferred into the oviducts of 0.5-day postcoitum pseudopregnant mice.
Between 10-18 oocytes were transferred to each oviduct. For an in depth description
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and discussion on this technique see "Manipulating the Mouse Embryo: A
Laboratory Manual", 2nd Edition 1994 by Hogan, Beddington, Costantini and Lacy."
2.3.6 Extraction of DNA from Mouse Tails
Tail samples were taken from mice of 3 weeks of age and DNA extracted using the
following method. Tails were incubated shaking overnight in 500pJ of lysis buffer
(See Appendix A) with 30pl of Proteinase K (20mg/ml).
The DNA was purified by phenol extraction. 500pi of TE saturated phenol was
added and the tube shaken vigorously. The sample was then microfuged for 5
minutes and the aqueous phase carefully removed to a clean microfuge tube,
avoiding the lower phenol phase and material at the interface. This procedure was
followed again for 500p.l of phenol: chloroform (1:1) and then 500p.l of chloroform.
DNA was precipitated by the addition of 1/10th volume 7.5M ammonium acetate and
2.5 volumes of absolute alcohol. The samples were shaken and a glass rod was then
used to spool out the DNA. Excess alcohol was allowed to evaporate from the DNA
before it was transferred to 500pl of TE. DNA samples were stored at 4°C.
2.3.7 PCR protocol
PCR was carried out on the extracted DNA samples in Omnigene Thermal Cyclers
(Hybaid). PCR conditions were 95°C 5' minutes followed by 30 cycles 95°C, 57°C
and 68°C all for a period of 1 minute. The final extension was 68°C for 10 minutes.
The PCR utilised primers within the BLG promoter of the transgene;
BLG FORWARD 5' TCGTGCTTCTGAGCTCTGCAG 3'
BLG REVERSE 5' GCTTCTGGGGTCTACCAGGAAC 3'
The product of these primers is approximately 180bp and can be visualised clearly on
a 2.5% TBE agarose gel by electrophoresis.
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2.3.8 DNA Digestion and Southern Transfer
DNA from founder mice shown to be transgene positive was analysed by southern
blotting to determine transgene copy number. 20jug of DNA was digested with the
restriction enzyme Bgl II (New England Biolabs) and the DNA was then transferred
onto ZetaProbe™ hybridisation membrane as described elsewhere in this section.
2.3.9 Labelling DNA probes and Hybridisation of Southern Membranes
Transgene copy number was determined using a BamHI/SphI (New England
Biolabs) restriction digest product as a probe. DNA probe fragments were gel
purified and 20ng labelled with 50pCi, 3000Ci/mol [a-32P]-dCTP (ICN) using High
Prime random oligonucleotide premixed solution. (Boehringer Mannheim) This
method, first described by Feinberg and Vogelstein (1983) is based on the
hybridisation of random short oligonucleotides of 6 bases long to the denatured DNA
to be labelled. The complementary DNA strand is synthesised by Klenow
polymerase using the 3'OH termini of the random oligonucleotides as primers.
Unincorporated nucleotides were removed by passing labelled probes down a
Sepahdex G50 column (NICK column - Pharmacia).
Filters were prehybridised in a hybridisation oven (HYBAID) for at least 4 hours at
42°C in UltraHyb (Ambion). Labelled DNA probe was denatured by boiling and then
immediately diluted in hybridisation solution overnight at 42°C. After overnight
incubation the hybridisation solution was discarded and the filters washed in twice in
2xSSC, 0/1% SDS and twice in 0.1%SSC, 0.1% SDS. The filters were sealed in heat-
sealable bags and exposed to BIOMAX MS-1 film in an autoradiography cassette
with intensifying screens.
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2.4 General Cell Culture Techniques (Teviot Place Protocols)
2.4.1 Maintenance of Embryonic Stem (ES) cells
The ES cell line HM-1 (Magin et al, 1992, Selfridge et al, 1992) was characterised
by shape and size. Cells were small and light refractive when confluent and viewed
under light microscopy. ES cells were routinely cultured at 37°C in BHK-21 media
supplemented with 1% sodium pyruvate, 1% non-essential amino acids 5% (v/v)
foetal calf serum, 5% (v/v) new born calf serum (selected batches), 1.1 ml 50mM P-
mercaptoethanol and 1.9 ml LIF (Leukaemia Inhibiting Factor) upon gelatinised
tissue culture plates.
2.4.2 Defrosting ES cells
A 25cm2 (T25) flask was coated with 3 mis of 0.1% gelatin. The cells were taken
from liquid nitrogen and held in a water bath for a few minutes until defrosted. The
contents were transferred from the vial into a 15 ml centrifuge tube containing 4 mis
of warmed complete + LIF medium. The cells were then spun down at 1000 rpm for
5 minutes at room temperature. The supernatant was removed and the pellet flicked.
The cells were resuspended in 10 mis complete + LIF medium and transferred to a
T25 flask. They were then placed in a 37°C. 5% CCL incubator overnight. The
following morning the media was changed on the cells.
2.4.3 Gelatinisation of Tissue Culture Plates
Gelatin (Sigma) was made up to 1% in dHiO, double autoclaved and stored at 4°C
This is equivalent to a lOx stock solution. A Ix (0.1%) Gelatin solution was made
and sufficient volume added to cover entire base of tissue culture plate. The gelatin
solution was left on the tissue culture plate for a minimum of 30 minutes at room
temperature.
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2.4,4 Complete Media (CM)
500mls BHK-21 media (Gibco-BRL)
50mls Serum (25mls Foetal Calf Serum: 25mls Newborn Calf Serum)
5mls lOOx Non-Essential Amino Acids (Gibco-BRL)
5mls lOOx Sodium Pyruvate (Gibco-BRL)
5mls 200mM, lOOx L-Glutamine
1.9ml LIF (prepared and titred in lab as per standard protocols - see Smith et al,
1988)
1.1ml 50MM (3-mercaptoethanol solution (Gibco-BRL)
2.4.5 Trypsinisation of ES Cells
ES cells were routinely passaged 1 in 5 upon reaching approximately 70-80%
confluency. Medium was aspirated from cells and the cells washed once in warm
PBS. The appropriate volume of (IX) Trypsin-EDTA (Gibco-BRL) was added to
cover the entire base of the tissue culture plate. The cells were incubated at 37°C for
2-5 minutes, with occasional agitation of the plate. This provides sufficient time to
ensure that ES cells have detached from tissue culture plate and have formed a single
cell suspension. ES cell detachment was carefully monitored to avoid over-
trypsinisation, as this can result in cell lysis and a reduction in overall ES cell
viability. The trypsin was neutralised by addition of a minimum of 2 volumes CM.
ES cells were then ready for direct transfer to an area of gelatinised tissue culture
plate or for any of the further manipulations detailed in this section.
2.4.6 Freezing ES Cells
Following trypsinisation, ES cells were centrifuged at 1,100 rpm for 3 minutes.
The media was aspirated and the pellet resuspended in an appropriate volume of
Freezing Medium (FM).
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Plate area Volume of FM To Fill No. of Cryovials Area to Re-thaw
Into
24-we 11 800pl 1 24-weli
6-well 800pl 1 6-well
25cm2 1.6mls 2 6-well
75cm2 6.5mls 8 6-well
175cm2 13mls 16 6-well
lml of FM ES cell resuspension was aliquoted into an appropriate number of
cryovials as detailed in the above table and placed in a polystyrene container before
being placed in the -80°C as this helps to control the rate of cooling. Cryovials were
placed in a -80°C freezer overnight. The following day, the cryovials were
transferred to a liquid nitrogen store.
2.4.7 Freeze Media (FM)
80% CM
10% Serum (50% FCS: 50% NCS)
10% DMSO (Di-methyl Sulphoxide)
2.4.8 Electroporation of ES Cells
o
Following trypsinisation, ES cells were centrifuged in a volume equivalent to 10
cells at 1,100 rpm for 3 minutes. The pellet was resuspended in O.Srnls of PBS and
transferred to an electroporation cuvette (Bio-Rad) containing 150mg of linearised
vector DNA (suspended in lOOpl PBS (Gibco-BRL)). The volume of cells was
pipetted up and down in the electroporation cuvette once, to ensure good mix of cells
with DNA. A cap was placed on the cuvette and pulsed with a charge of 0.8kV, 3pF
capacitance, which results in a time constant of 0.1 seconds (Bio-Rad Gene-Pulser).
The cells were allowed to recover for 20 minutes before adding 20mls of CM. Cells
were plated on 10cm gelatinised plates (Nunc) in non-selective media at an
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appropriate density to permit selection the following day (lxlO6 per plate for G418
and ganciclovir selection)
2.4.9 G418 Selection and Picking of ES Cell Clones
24 hours after electroporation, the non-selective CM was replaced with selective CM
containing 200mg/ml G418 (Gibco-BRL) and 6-thioguanine (6-tG). G418 is a
neomycin analogue to which the bacterial neomycin phosphotransferase gene confers
resistance. Cells which have not incorporated targeting vector DNA (containing a
neo cassette), either by random integration or by homologous recombination, will not
be resistant to the G418 and will therefore die. Cells which have integrated the
targeting vector randomly as opposed to via homologous recombination will express
the HPRT selection cassette and as 6-tG is a guanine analogue and substrate for the
Hprt enzyme it undergoes a phosphoribosylation reaction to generate 6-thioguanine
monophosphate (6-thioGMP). High levels of 6-thioGMP within the cells inhibit the
biosynthesis of guanine nucleotides and this inhibition eventually results in the death
of all cells that express Hprt (Miech et al, 1967). Selective media on cells was
refreshed every 3 or 4 days until colonies of G418 -resistant clones became visible to
the eye (usually within 10-12 days post-electroporation). A 96 well plate containing
100ml of trypsin-EDTA in each well was prepared. Selective media was aspirated
from the 10cm plate, washed with lx in PBS and partially aspirated to leave a
residual volume of PBS sufficient to cover the base of the tissue culture plate. This
measure prevented dehydration of clones. A p200 (yellow) tip was placed over the
G418 resistant ES cell clone and gentle suction applied, thus taking the clone up into
the pipette. Clones were pipetted into a trypsin-EDTA containing well of a 96-well
plate and left for 2-5 minutes at room temperature. The contents of the well were
gently pipetted up and down once before transferring to a single gelatinised well of a
24-well plate, containing 1ml of non-selective CM. Non-selective CM media was
refreshed the following day.
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2.4.10 Thymidine kinase and Selection in Ganciclovir and Picking of ES cell
clones
After selection in G418 and 6-tG media to determine clones which have undergone
the correct homologous recombination event cells were transiently transfected with
Cre protein in order to remove the floxed Neo/TK cassette, hopefully leaving intact a
floxed Exon I. This was achieved using transient transfection of a circular plasmid
containing the Cre gene (pCre2 plasmid). Transient transfection was achieved using
the Tfx-50 lipid preparation (Promega) using the manufacturers protocols. Selection
of the correctly targeted clones was carried out using 2jaM Ganciclovir to select
against the presence of the Thymidine Kinase cassette. CM was prepared which
contained Ganciclovir.
2.4.11 Extraction of ES Cell DNA to Enable Subsequent Genetic Analysis
Following trypsinisation, ES cells were centrifuged at 1,100 rpm for 3 minutes. Cells
were washed once in PBS and re-centrifuged at 1,100 rpm for a further 3 minutes.
PBS was partially aspirated, leaving sufficient residual PBS to cover the pellet. The
side of the tube was flicked until the pellet was resuspended in this volume. 600ml of
Lysis Buffer was added and incubated at either 55°C for 3 hours, or at 37°C
overnight. 500ml of isopropanol was added and shaken on an orbital shaker for 15
minutes, whereby the DNA precipitate became visible. The DNA precipitate was
carefully removed using a fine glass hook made from a Pasteur pipette, and washed
once in 70% ethanol. DNA was transferred to an Eppendorf microfuge tube
containing 50pJ TE buffer. Evaporation of any trace residual ethanol and DNA
resuspension was achieved by incubation at 60°C for 30 minutes.
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2.4.12 Lysis Buffer




lOOmg Proteinase K per ml
2.5 General Culture of ES cells (NPU Protocols) - Differences in protocols
which may affect the outcome of gene targeting
2.5.1 Splitting ES Cells
Cells were fed 2-3 hours prior to splitting. The cells should be around 85-90%
confluent at this point. The medium was removed and the cells washed once with
PBS. Trypsin-EGTA (TEG) was then added at 1ml (T25), 1.5 ml (T75) or 2 ml
(T162). The trypsin was left on the cells for about 1 minute at room temperature.
The flask was hit sharply once to dislodge cells and once dislodged medium was
added to inactivate the trypsin - 5 ml (T25), 8 ml (T75) or 16 ml (T162). The cell
suspension was pipetted quite vigorously to obtain a single cell suspension. The
cells were spun down at 1000 rpm for 5 minutes and the supernatant removed. The
tube was rhen flicked to disperse the pellet and the cells resuspended in the required
amount of medium. The cells were transferred to a flask and placed in a 37°C, 5%
CO: incubator.
The flasks or plates should be gelatinised before using. 5 mis 0.1% gelatin per T25
flask, no less than 30 minutes before using. The gelatin is then aspirated before
adding medium and cells. Because ES cells divide every 18-24 hours the medium
should be changed everyday and the cells passaged every second or third day at a 1:4
split.
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Routine change of medium - amounts per flask:
Weekday Weekend
T25 5-7 mis 10 mis
T75 16-20 mis 25 mis
T162 40 mis 60 mis
2.5.2 NPU Protocol LIF Complete Medium
To a 500 ml bottle of Glasgow MEM (BHK 21) medium (GibcoBRL Life
Technologies) the following was added: -
5.7 ml 100 mM sodium pyruvate (GibcoBRL Life Technologies)
5.7 ml lOOx non-essential amino acids (GibcoBRL Life Technologies)
28 ml Foetal calf serum (Globepharm)
28 ml Newborn calf serum (Globepharm)
1.1 ml 50m M (3-mercaptoethanol (GibcoBRL Life Technologies)
4.0 mis NPU LIF - Batch 2 (7/7/99)
Sterility check all media by placing 10 mis in a sterile container in the tissue culture
incubator overnight. Always store at 4°C and use within 1-2 weeks.
2.5.3 NPU Protocol In Vitro Cre Targeting
Day 1
Cells: A T75 flask of first round targeted cells was washed and trypsinised and a cell
count performed to obtain 10'' cells. The cells were spun down (1000 rpm, 5 minutes
at room temperature) and the supernatant removed. The cells were washed once with
15 mis PBS and spun down again as before. The pellet was resuspended in a final
volume of 0.8 mis complete medium (minus serum).
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DNA: 25pg of pCre2 plasmid (see Appendix A) was used for each electroporation
Complete medium minus serum was added to make up a total volume of 80pl.
Electroporation: The cells and the DNA were mixed together and transferred to an
electroporation cuvette (EquiBio) (0.4 cm electrode, gap 50). The cells were
electroporated at 230V (0.23kV) and 500 pFd, pulsed twice (in a BioRad Gene
Pulser). This resulted in a time constant of approximately 7.0.
The cells were left to rest at room temperature for 15 minutes before adding
complete medium containing LIF. The cells were plated out at 104 cells per 10 cm
plate. The average number of plates set-up was 40.
Day 6 LIF complete medium containing 2p.M ganciclovir was added. The medium
was changed as required.
Day 15 Colonies were picked from media-covered plates using a Gilson P200 and a
yellow tip and briefly pipetted up and down before being transferred to a 24 well
plate containing normal complete media. 50 colonies were selected from the plates
and screened for the presence of the targeted allele.
2.5.4 LIF Complete Medium + G418 (250uq/ml)
To a 500 ml bottle of Glasgow MEM (BHK 21) medium (GibcoBRL Life
Technologies, Cat # 21710-025) complete media was added
5.7 mis G418 (25 mg/ml) (Promega)
G418 (25 mg/ml) = 0.5g G418 + 20 mis distilled water
This was sterility checked by placing 10 mis in a sterile container in the tissue culture
incubator. The G418 media was stored at 4°C and used within one week.
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2.5.5 Ganciclovir
The original vial of ganciclovir contained 500 mg (546 mg of Sodium Ganciclovir)
of Ganciclovir (MW 255). 5mls of sterile distilled water was added to make a 100
mg/ml solution. A 1:100 dilution in distilled water was made to make a 1 mg/ml
working stock solution. A bottle of LIF complete medium contains 569 mis;
therefore addition of 290 pi of the 1 mg/ml solution of ganciclovir means that the
final concentration is 2 pM.
2.5.6 LIF Complete Medium + 2uM Ganciclovir
To a 500 ml bottle of Glasgow MEM (BHK 21) Medium (GibcoBRL Life
Technologies) complete media was added:
290pl 1 mg/ml ganciclovir stock solution
This was sterility checked by placing 10 mis in a sterile container in the tissue culture
incubator overnight. The media was stored at 4°C and used within one week.
2.5.7 Freezing Cells
Cells were fed one hour prior to freezing down. The cells were washed once with
PBS and then 1.5 rnl (T75) trypsin-EGTA (TEG) added. This was washed over the
cells and left at RT for approximately 2 minutes. The cells were resuspended in 10
mis of complete + LIF medium and then transferred to a 15 ml centrifuge tube and
spun down at 1000 rpm for 5 minutes. The supernatant was removed and the pellet of
cells flicked gently to dislodge them. The cells were then resuspended in 2.5 mis
Freeze Mix A. 2.5 mis Freeze Mix B was then slowly dropped onto the cells and
pipetted up and down. The cells were then aliquoted into 1 ml cryotubes (labelled
with cell line, passage number and date). They were placed in polystyrene boxes in
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the -70° C freezers for at least 24 hours before being transferred to liquid nitrogen for
longer-term storage.
FREEZE MIX A FREEZE MIX B
8 mis complete + LIF medium 6 mis complete + LIF medium
2 mis FCS 2 mis FCS
2 mis DMSO
Freeze mixes should be used cold (from the fridge or on ice). The mixes can be
stored at -20°C but must be thawed and mixed well before use.
Flask size No. vials Vol Freeze mix A Vol freeze mix B
T25 1-2 0.5 ml - 1.0 mi 0.5 ml -1.0 ml
T75 4-5 2.0 ml - 2.5 ml 2.0 ml - 2.5 ml
T162 10-12 5.0 ml - 6.0 ml 5.0 ml - 6.0 ml
2.5.8 First Round Targeting of ES cells with a NEOMYCIN cassette
Day 1
Cells: The ES cells were trypsinised and a cell count performed in order to obtain 5
x 107 cells. The cells were then spun down at 1000 rpm for 5 minutes at room
temperature and the supernatant removed. The cells were washed once with 15 mis
of freshly prepared lx Hepes-phosphate buffered saline (FIBS) and spun down again
as before. The pellet was resuspended in a final volume of 0.8 mis lx HBS.
DMA: The targeting construct was linearised and kept in ethanol at -20°C. The DNA
was spun down at 13,000 rpm for 5 minutes at room temperature and the supernatant
removed. The pellet was washed in 75% ethanol before being spun down again. The
pellet was allowed to air dry and resuspended in a final volume of 80 pi lx HBS.
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Electroporation: The cells and the DNA were mixed together and transferred to a
cuvette (EquiBio) (0.4 cm electrode, gap 50). The cells were electroporated at 800V
(0.8kV) and 3 pEd - the time constant was always approximately 0.1. The cells were
then left to rest at room temperature for 15 minutes before adding complete medium
containing LIF. They were then plated out at 5 x 105 cells per 10 cm plate. 60 plates
were set up per experiment.
Day 2
24 hours after electroporation and once the cells have settled down the medium was
removed and G418 selection medium added. The medium was then changed every 2-
3 days or as required.
Day 15
By day 15 the colonies were now visible to the naked eye. Colonies were viewed
under the light microscope to check for morphology and size. Discrete colonies of a
medium size and shape were marked for picking. Colonies were picked in 200p! of
medium with yellow tips and are transferred to an Eppendorf microfuge tube where
they were pipetted gently up and down to disperse the cells. lOOp.1 of the cell
suspension was added to a 24 well plate for further analysis and the other lOOpl was
used for PCR or Southern analysis.
2.5.9 Karyotyping ES cells
Standard methodology was used to karotype ES cell clones. The ES cells to be
analysed were grown in a 25cm: flask to reach about 50% confluence on the days the
cells were to be harvested. 24 hours before the cells were to be harvested, they were
fed with fresh medium; a process which is known to cause partial synchronisation. 2
hours before harvesting colchicine was added to a final concentration of 50 pg/ml by
diluting into the existing medium (changing the medium completely at this point
upsets the partial synchronisation already achieved). Following a 2 hour incubation
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at 37°C the medium is removed and kept as mitotic cells tend to be lost into the
supernatant. The cells were then trypsinised as usual and the kept medium used to
neutralise the reaction. The cells were spun briefly at lOOOrpm for 3 minutes and
then resuspended in a hypotonic solution (0.075M KC1). The cells were incubated for
4 minutes at room temperature and then spun again. The supernatant was removed
leaving only a drop remaining and the cell resuspended in this drop of media. The
cells were placed on ice and fixed by drop-wise addition of ice-cold methanoi/glacial
acetic acid 3:2 v/v. As the fixative was added the tube was flicked sharply. lOmls
fixative was added in this way and then the cells spun again and resuspended in 5mls
fresh fixative. Again the cells were spun and this time resuspended in 0.5mls of fresh
fixative. Drop preparations were made from a height of about 30cm on to a
microscope slide washed in 70% ethanol, rinsed in water and removed from the
water just before use so that the upper surface remains wet. The slides were held at
45°C to the vertical and three drops of fixed cells dropped onto each slide. The slides
were dried thoroughly and the stained with Giemsa stain (Sigma).
2.5.10 10x HBS (Hepes-Phosphate Buffered Saline)
For 200 mis:
192mMHepes 10 g
1.37 M NaCl 16 g
50 mM KC1 10 mis of 1M stock
( = 14.91 g in 200 mis)
7.1 mM Na;HPC>4 (dihydrate) 2.8 mis of 0.5M stock
( =8.9g in 100 mis)
1% Glucose 2g
All the above reagents were dissolved in a volume of 180 mis of 18.2 mQ water.
The pH of this lOx stock solution was then adjusted to pH7.2 using concentrated HC1
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and the final volume made up to 200 mis. A lx HBS solution was made from the lOx
stock. The lx stock becomes pH 7.05 on dilution.
2.6 Animal Breeding
2.6.1 Floxed Stat3 mice
The floxed Stat3 mice have been described before (Chapman et al, 1999). Briefly,
they were generated by crossing mice with one null Stat3 allele and one floxed Stat3
allele (Takeda et al. 1998) with mice expressing Cre under the control of the /?-
lactoglobulin milk gene promoter (Selbert et al. 1998). Mice were maintained on an
outbred background and control BLG-Cre/Stat3floxA mice were obtained from the
same colony segregating for the same combination of genotypes.
2.6.2 BLG-Smad4 Transgenic mice
Founder mice were produced from pronuclear injection (described as in Chapter 3)
and were crossed to C57B1 mice to generate stably transmitting F1 progeny. The F1
mice were continuously crossed to C57B1 mice to generate colonies of expressing
transgenics.
2.6.3 Harvesting Mammary Glands
Mice were culled by cervical dislocation and an incision made in the midline through
the skin but not the body wall. The skin was peeled back on either side and pinned to
reveal the mammary glands. The glands were removed and either fixed in formalin
for paraffin embedding and histological analysis or snap-frozen in liquid nitrogen in
an Eppendorf microfuge tube for protein analysis.
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2.7 Mammary Gland analysis
2.7.1 Immunoblottinq
Mammary gland was harvested at various timepoints throughout lactation and
involution and snap frozen in liquid nitrogen. RIPA lysates were prepared as follows:
50mM Tris HC1, pH 7.5, 150mM NaCl, 1% Nonidet p40, 0.5% sodium
deoxycholate, 0.1% SDS. Anti-proteases were added immediately before use;
lOpg/ml aprotinin, lpM pepstatin, lpM leupeptin, ImM PMSF and ImM of the
anti-phosphatase sodium vanadate. Tissue was homogenised in RIPA buffer and
spun at 13,000rpm. The supernatant was collected and stored at -70°C. Prior to
loading, samples were mixed with denaturing sample buffer (NOVEX) and boiled at
95°C for 5 minutes.
Immunoblotting was carried out using NOVEX (Invitrogen) 10% Tris-glycine gels.
20pg of protein was added to an equal volume of 1 x sample buffer containing |3-
mercaptoethanol. Samples were then boiled for 5 minutes before being spun briefly
in a microcentrifuge and loaded on the gel. Gels were run at 125V for two hours or
until the markers had separated. Gels were then blotted in half strength Towbins
solution (20% methanol, 7.2g glycine, 1.45g Tris in 1L double distilled water). Blots
were blocked in milk buffer (TBS, 10% non-fat milk, 0.05% Tris) for 1 hour at room
temperature then primary antibodies were added overnight at 4°C. Antibodies used
were Smad4, Stat3 and p21 (Santa Cruz), Smadl, phospho-Smad2 and Smad2
(Upstate Biotechnology), Smad7 (gift of Dr C-H Heldin), PAI-1 (Chemicon), Statl
(NEB). After overnight incubation with primary antibodies blots were washed and
secondary anti-rabbit-HRP or anti-goat-EIRP (Santa Cruz) added for 1 hour at room
temperature. Blots were visualised with ECL (Amersham) and densitometry carried
out on three blots from different mice per experiment.
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2.7.2 Immunoprecipitation
Immunoprecipitation was carried out as follows; Cell lysates were pre-cleared by
adding lOOpl of 50% slurry of Sepahrose G beads to 500pl lysate (60pg protein) and
incubated for 10 minutes at 4°C. The beads were removed by centrifugation and the
supernatant incubated with the primary antibody overnight at 4°C. Antibodies used
were p300 (Santa Cruz), Stat3 (Santa Cruz), Smadl (Upstate Biotechnologies) and
Statl (NEB). After overnight incubation the immunocomplex was captured by
addition of lOOpl of 50% slurry of Sepharose G beads by shaking for 1 hour at 4°C.
The beads were then collected by centrifugation and washed three times with RIPA
buffer before the addition of sample buffer. NOVEX Tris-glycine gels were loaded
as described above
2.7.3 Electrophoretic Mobility Shift Assay
Nuclear extracts were prepared from mammary tissue as follows: cells were scraped,
washed once with PBS and resuspended in lysis buffer (20 inmol/L HEPES pH 7.9. 1
mmol/L EDTA, 10 mmol/L NaCl, 1 mmol/L dithiothreitol [DTT], 0.4 mmol/L
PMSF, 0.1 pg/mL leupeptin, 5 pg/mL antipain and 0.25% (v/v) Nonidet P-40). Cells
were incubated in this buffer for 10 minutes before being lysed by 8 to 10 passages
through a 26-gauge syringe needle. Nuclei were pelleted by centrifugation at 13,000g
for 20 seconds. Proteins were extracted from nuclei by incubation with RIPA buffer
at 4°C for 20 minutes with vigorous shaking. Nuclear debris was pelleted by
centrifugation at 13,000g for 5 minutes and the supernatant was collected and stored
at 80°C.
The nuclear extract was subjected to EMSA analysis as follows:
4pg of nuclear extract was mixed with equal volume binding buffer (50mM NaCl,
40mM HEPES, 3mM MgCL, lOpg/ml pepstatin, lOpg/ml leupeptin, 15mg/ml
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aprotinin, and 1 pig salmon sperm DNA) and 0.5ng of 3"P-labelled probe. Probes used
were SBE and a "mutant" SBE (both Santa Cruz Technologies).
SBE Consensus binding motif GTCTAGAC
"Mutant" SBE CATAGCGT
After incubation at room temperature for 30 minutes 0.05% bromophenol
blue/xylene was added and loaded onto 5% acrylamide gels and electrophoresed at
150V for 2-3 hours. For antibody supershift analysis 2pl of anti-Smadl, Smad2 or
Smad4 antibody (all Santa Cruz Technologies) was added for an additional 20
minutes before electrophoresis.
2.7.4 Histological analysis
Formalin fixed mammary glands were transferred to 70% ethanol before being
embedded in paraffin wax. 3pm thick sections were cut and floated onto vectabond-
coated slides. Slides were stained with haematoxylin and eosin for histological
analysis
2.7.5 immunohistochemistry
Immunohistochemistry was performed on 3pm thick paraffin embedded mammary
gland sections as follows. Smad4 immunohistochemistry was carried out on
mammary gland sections from day 10 lactation and day2, 3 and 6 involution samples.
Antigen retrieval used citrate buffer (lOmM, pH7.6) and the slides were microwaved
three times at 700Watts. The slides were then blocked using methanol and the
primary antibody was titrated and used at an optimal concentration of lin 200
overnight at 4°C (goat polyclonal, Santa Cruz). The secondary antibody is a biotin-
linked goat anti-rabbit and was used at 1 in 400 (DAKO Corp.). The staining was
visualised with an ABC-HRP (horse radish peroxidase) kit (Vectalabs) and then
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DAB (3,3 diaminobenzedene) (DAKO), a chromogen which undergoes a chemical
reaction leading to brown colouration in positive areas.
2.8 Transfection of ES cells and further analyses
2.8.1 Transfection of ES cells
HM-1 ES cells were grown in conditions as described above. Cells were cultured in 6
well plates until 50-60% confluency. At this point they were either treated by the
addition of PBS (1ml lx, Gibco) or TGF-(3 (lOng/ml, Sigma) or transfected with one
of either the CMV-LacZ reporter construct or Ig of the CMV-Smadl,2,3 and 4
constructs. Transfection was optimised for the Promega TfX-50 transfection system.
This is a mixture of a patented synthetic, cationic lipid molecule and L-dioleyol
phosphatidylethanolamine (DOPE). The reagent is supplied as a dried lipid film and
rehydrated according to the manufacturers instructions. The optimal ratio of
Lipid:DNA is 3:1 and once the lipid and expression construct DNA had been
vortexed thoroughly they were added to a small volume of serum-free media (0.5mls
for a 6-well plate) and left to incubate for 15 minutes before being added to the cells.
After 1 hour at 37°C normal media was added to the cells and then they were left
until being harvested at the various timepoints. Cells were washed twice and then
harvested into PBS by scraping.
Experiments were set up such that transfection efficiency was controlled for by
transfection of a CMV-LacZ expression vector (Ciontech, US). This vector contains
the powerful viral promoter and SV40 polyadenylation site which allows high-level
expression of the bacterial LacZ gene encoding the (3-galactosidase enzyme (Hall et
al, 1993). (3-galactosidase catalyses the hydrolysis of (3-galactoside sugars such as
lactose. The enzymatic activity in cells can be can be assayed in situ with various
specialised substrates, which when stained with the histochemical LacZ stain and the
compound X-Gal (X-gal is a substrate for the enzyme which gives a blue coloured
product) allows quantitation of positively stained cells by eye (Demeneix et al,
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1994). The procedure consists of washing the LacZ transfected cells once in PBS and
then fixing them in 0.05% gluteraldehyde for 5 minutes at 4°C. The cells were then
washed twice with PBS, each wash for 5 minutes before the LacZ stain (See
Appendix A) was added. The plates were then left at 37° to allow the stain to
develop before counting positively stained cells.
2.8.2 Annexin V Analysis of transfected ES cells
Harvested cells were washed once in PBS and then resuspended in lOOpl of Binding
Buffer. To this was added lOpl of fluorescein-conjugated annexin V reagent (R&D
Systems, Europe) and 10pl of propidium iodide. The cell mix was gently vortexed
and then incubated for 15 minutes in the dark at 20-25°C. Following incubation, and
without washing the cells of excess reagents, another 400pJ of Binding Buffer (See
Appendix A) was added to each tube. The cells were analysed on a Coulter Flow
cytometer within 1 hour of preparation.
2.8.3 Vindelov Analysis of transfected ES cells
Harvested ES cells were washed once in PBS and spun down in Eppendorf
microfuge tubes. The pellet was resuspended in lOOpl of citrate buffer and mixed
well. To this was added 450pl of solution A and the cells mixed gently by inversion
before incubating for 10 minutes at room temperature. After this time 325pl of
Solution B was added, mixed and incubated at room temperature and then 250pl of
Solution C was added, mixed and incubated on ice for 10 minutes. The samples were
then run through a Coulter Flow Cytometer and analysed on EPICS software for
DNA content.
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Chapter 3 - An in vitro analysis of Smad proteins
3.1 Introduction
3.1.1 TGF-B and Apoptosis
Transforming Growth Factor-(3 (TGF-{3) is a multifunctional cytokine which can
induce a variety of cellular responses, the most basic being opposing growth effects
on cells. This phenomenon depends on what lineage the cells derive from; cells of an
epithelial nature are considered to be growth inhibited by TGF-{3 whereas cells of a
mesenchymal nature are generally growth stimulated. The growth inhibition by TGF-
|3 on epithelial cells has been characterised extensively and, depending on the cell
system and the experiments themselves, has been shown to be concomitant with
apoptosis (Rotello et al, 1991 and Bursch et al, 1993), induction of CD95/Fas
(Ashley et al, 1998), down-regulation of c-myc and up-regulation of p27/Kipl (Kim
et al, 1998), down-regulation of NF-kB (Azuma et al, 1999), down-regulation of bcl-
2 (Tsukada et al, 1995), down-regulation of p21AVafl/Cipl and increased p53
expression (Yan and Sage 1998), induction of Bax (Teramoto et al, 1998), induction
of a G1 arrest (Motyl et al, 1998) and practically every other permutation of
responses and genes involved in cell cycle or cell death.
3.1.2 Smads and Apoptosis
Smads are a recently discovered highly conserved group of proteins which have been
shown to give specificity to the enormous array of cellular responses to members of
the TGF-P superfamily, including epithelial cell apoptosis (Brodin et al, 1999,
Yanagisawa et al, 1998. See section 2.1 of Chapter 1). The purpose of this thesis is
an examination of the role that members of the Smad family play in an in vivo model
of epithelial cell apoptosis, namely involution of the mammary gland, a process
characterised by proteolytic degradation of extracellular matrix and a loss of
secretory epithelial cells by apoptosis. TGF-|3 has been shown to be important in
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many aspects of mammary gland development (Kordon et al, 1995, Pierce et al,
1993, Jhappan et al, 1993) but its role in involution remains to be determined.
Previous work has suggested that the Smad proteins themselves are capable of
inducing apoptosis in a variety of cell types including kidney cells (Atfi et al, 1997),
liver cells (Chen et al, 2000) and breast cancer cells (Dai et al, 1999) and the first
aim of this project was to assess whether a number of different human Smad cDNA
expression constructs could induce apoptosis when over-expressed in ES cells.
3.2 Results
3.2.1 Smad Overexpression constructs
The Smad expression constructs were a kind gift of Dr Rick Derynck of the
Department of Growth and Development, Programs in Cell Biology and
Developmental Biology, University of California at San Francisco, California, USA.
The constructs consist of human Smadl, 2, 3 and 4 cDNA sequences cloned into the
pRK5 expression plasmid using the CMV promoter as the promoter of choice (Zhang
Y et al, 1996) (Figure 3.1).
E. coli DH5a cells were transformed with lpg of the plasmid DNA and plated out
onto L-amp plates followed by incubation overnight at 37°C. The bacteria were then
prepared as described in Chapter 2 (See Section 1.1.1) and the purified plasmid
DNA quantified both by Genequant spectrophotometry and on an ethidium bromide
plate. All the human Smad expression plasmids were prepared on the same day in the
same manner. A control CMV-LacZ plasmid for quantitation of transfection
efficiencies was also prepared in the same manner (Figure 3.2). The powerful viral
CMV promoter and SV40 polyadenylation site allow high-level expression of the
bacterial LacZ gene which encodes the (3-galactosidase enzyme (Hall et al, 1993). (3-
galactosidase catalyses the hydrolysis of (3-galactoside sugars such as lactose. The





























The CMV-humanSmad4 expression construct consists of the
cytomegalovirus (CMV) promoter upstream of a human flag-tagged
Smad4 cDNA in the pRK5 plasmid. The Smad4 vector is representative of
all the CMV-Smad expression constructs and was a kind gift of Dr Rik






























The CMV-LacZ expression plasmid is a commercially available vector
(Clontech, US) which allows quantitation of transiently transfected cells via
immunohistochemical staining. The vector is an ideal control plasmid for
these experiments as it utilises the same powerful viral promoter and SV40
polyadenylation site allowing high-level expression of the bacterial LacZ
gene which encodes the p-galactosidase enzyme (Hall et al, 1993).
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substrates, which when stained with LacZ histochemical staining, allows quantitation
of positively transfected cells by eye (Demeneix et al, 1994). This ability to assay in
situ expression and therefore transfection efficiency makes the CMV-LacZ plasmid
an ideal control.
In order to assess the effect that over-expression of human Smad cDNAs might have
on cell viability we chose to over-express the constructs in embryonic stem (ES)
cells. There are a number of reasons for this decision; ideally, since the project is
concerned with involution and associated epithelial cell apoptosis in the mammary
gland, mammary cells would be the model candidate for the in vitro work described
here. However, mammary gland cell lines often display strange characteristics such
as unstable karotype, gene deletions and oestrogen receptor anomalies (Medina et al,
1986 and Ormerod and Rudland, 1985). The model solution would be to use primary
culture of freshly isolated mammary glands but these are notoriously difficult to
transfect and this technique was not available at the time. In a compromise it was
decided to use ES cells as they are relatively "normal" (in terms of karyotype and
stability) but have one particular phenotype which makes them very interesting for
this particular experiment - they do not possess TGF-[3 type II receptors on their cell
surfaces (Goumans et al, 1998 and refs therein). This means that the cells cannot
respond to external TGF-B via binding of the ligand, although they do have activin
and BMP receptors, and thus they are a potentially interesting system in which to
examine over-expression of downstream components of the pathway, namely the
Smad proteins.
3.2.2 Embryonic Stem Cells
HM-1 ES cells have been described before (Magin et at, 1992, Selfridge et al, 1992)
and are embryonic stem cells derived indirectly from E14 cells (Hooper et al, 1987)
with a spontaneous deletion of part of the Hprt gene (Thompson et al, 1989). They
display the same morphological features as other embryonic stem cell lines, being
cobble shaped cells of approximately 20pm diameter with large nuclei and relatively
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little cytoplasm (Figure 3.3). Like other ES cell lines they require the addition of
Leukaemia Inhibitory Factor or LIF to maintain their pluripotency (Williams et al,
1988, Smith et al, 1988 and Moreau et al, 1988) and this characteristic allows these
cells to contribute to the germ line when injected into blastocysts for the purpose of
gene targeting experiments.
3.2.3 Annexin V analysis after over-expression of Smads in ES cells
HM-1 cells were grown in the presence of LIF in 6-well plates until they had reached
approximately 50-60% confluency. At this time they were then either exposed to
lOng/ml TGF-J3 or transiently transfected with lpg of the CMV-LacZ, CMV-Smad3
or CMV-Smad4 expression constructs. Immunohistochemistry with an anti-FLAG
antibody was used to show that the transfection of the CMV-Smad expression
constructs was possible (Figure 3.4). At various time points after this the cells were
harvested for Annexin V analysis via flow cytometry. All experiments were carried
out in triplicate and repeated on three separate occasions. All experiments were
normalised for transfection efficiency against that as determined by LacZ staining in
the control wells transfected with the CMV-LacZ plasmid (see Figure 3.5 for an
example of LacZ stained ES cells). Normalisation involved counting the numbers of
LacZ stained cells and, by assigning that figure as 100%, percentages of Annexin V
positive cells could be made relative to this figure. Annexin V is used as an early
indicator of apoptosis since during these early events a loss of membrane asymmetry
occurs when phosphatidylserine (PS) is exposed on the outer leaflet of the plasma
membrane. Annexin V preferentially binds to PS in the presence of salts and can
therefore be used as an accurate indicator of apoptosis (Zhang et al, 1997).
At all timepoints tested after treatment with TGF-f) the ES cells show very little
change in viability and remain intact, the treatment having no discernable effect on
the cells (Figure 3.6). At 12 hours after transient transfection with the expression
constructs CMV-LacZ, CMV-Smad3 and CMV-Smad4 there was a significant
increase (p<0.05) in the number of Annexin V positive cells to around 10% (resting
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(Kindly reproduced with the permission of E. A Aitchison, NPU, Edinburgh)
Figure 3.3
HM-1 ES cells
HM-1 cells are embryonic stem cells derived from El4 cells (Hooper
al, 1987) with a spontaneous deletion of part of the Hprt gene
(Thompson et al,1989). They display the same morphological features
as other embryonic stem cell lines, being cobble shaped cells of
approximately 20pm diameter with large nuclei and relatively little
cytoplasm. Magnification x 40.
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Figure 3.4
TRITC-anti-FLAG immunohistochemistry on CMV-Smad4-flag
transfected ES cells
Fixing and staining of Smad4 transfected ES cells shows that most of the
staining is localised to the nucleus. Magnification x 40.
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Figure 3.5
LacZ staining ofCMV-LacZ transfected ES cells
HM-1 ES cells were transfected with the control CMV-LacZ plasmid
and then stained using immunohistochemical techniques to visualise the
transfected cells. The overall efficiency of lipid-mediated transient
transfection in ES cells is generally quite low - transfection efficiencies
of greater than 30% are uncommon. Notably, transfection of
differentiated ES cells appeared to be much more efficient.
Magnification x 40.
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Annexin V analysis by flow cytometryof ES cells treated or transfected with


















Annexin V analysis by flow cytometry of ES cells treated or transfected with
various reagents (+/- SEM).
This graph shows the % ofAnnexin V positive cells after treatment with TGF-P,
or after transfection with the control LacZ plasmid or the Smad expression
constructs. Annexin V was measured at various timepoints after the
treatment/transfection and at 18 hours after transfection with CMV-Smad4
Annexin V levels peaked (-16%) compared to CMV-LacZ (-6%) at the same
time point. This increase is significant (P=0.001 using students t-test).
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cells display about 4-5% apoptosis) and this is probably indicative of the transfection
protocol itself which involves a one hour incubation in serum-free media. At 18
hours after the transfection there was a marked increase in the number of Annexin V
positive cells in cultures transfected with the CMV-Smad4 expression construct to a
final level of around 16% compared to around 5% after transfection with CMV-LacZ
at the same time point (p=0.001). Levels of apoptosis induced by Smad3 are also
significantly higher than those induced by transfection with the CMV-LacZ control
plasmid (p=0.004) These levels of apoptosis are not observed when ES cells are
transfected with either the control CMV-LacZ plasmid or for the CMV-Smad3
plasmid at this time point.
At 24 hours after transfection with the Smad3 and Smad4 expression constructs,
levels of viability had reduced but still remained significantly higher than LacZ
induced levels of apoptosis (p<0.05) and by 48 hours the transfected expression
constructs have no effect on cell viability at all.
3.2.4 Vindeiov Analysis after over-expression of Smads in ES cells
In order to determine if this increase in apoptotic cell number was associated with an
increase in the number of cells entering G1 (indicative of a G1 arrest) it was decided
to analyse cell cycle distribution via a Vindeiov analysis (Vindeiov et al, 1983). This
protocol prepares nuclei from cells which can be analysed by DNA content using
flow cytometry, thus quantifying the numbers of cells in each of the cell cycle stages.
Previous work by Dai et al (1999) and Atfi et al (1997) has shown that an induction
of apoptosis by Smad4 is accompanied by an increase in the number of cells in Gl.
Having previously shown that treatment of ES cells with TGF-(3 did not induce
apoptosis as determined by Vindeiov analysis this study concentrated on the effects
of Smad over-expression on cell cycle only.
HM-1 ES cells were grown in the presence of LIF in 6-well plates until they had
reached approximately 50-60% confluency. At this point they were then transiently
transfected with lpg of the control CMV-LacZ plasmid or the experimental CMV-
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Smadl, CMV-Smad2, CMV-Smad3 or CMV-Smad4 plasmids. Cells were harvested
at 18 hours after transfection and nuclei prepared as described in the Materials and
Methods section. The results show that 18 hours after transfection with the CMV-
Smad4 plasmid approximately 10% more cells have entered G1 phase of the cell
cycle (which could be indicative of a partial G1 arrest) than with transfection with
either the CMV-LacZ or CMV-Smad3 plasmids (P>0.05) (Figure 3.7). This result
correlates well with the previous published data and supports that concept that
Smad4 can induce apoptosis, perhaps through a cell cycle arrest mechanism, as has
been shown for TGF-(3 induced cell death (Bouchard et al, 1997 and Mazars et al,
1995)
3.3 Discussion
The aim of this work was to test the hypothesis that over-expression of Smads, and
especially of Smad4, can cause apoptosis. Although published evidence exists which
suggests this is the case these examples have utilised a variety of cell systems and
over-expression systems and it seemed prudent to test this hypothesis again using a
normal euploid cell, namely ES cells.
This data shows that ES cells do not respond to exogenous TGF-(3, presumably
because they lack the Type II receptor on the cell surface. This makes an interesting
system in which to examine the effects of over-expressing Smads as TGF-(3 cannot
play a role in activating the receptor-regulated Smads2 and 3 via binding to the
receptors. However, ES cells do possess activin and BMP receptors and so ligand-
binding signals could have conceivably come from these molecules instead.
The results show that Smad4 itself is capable of inducing a statistically significant
increase in Annexin V positivity compared with either Smad3 or a CMV-LacZ
control plasmid. This shows that over-expression of the Co-Smad, Smad4, can
induce apoptosis irrespective of TGF-(3 bound at the cell surface and suggests that
either the receptor activated Smads necessary for Smad4 translocation to the nucleus
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% of cells in G1 as determined by Vindelov analysis (+/-SEM)
This graph shows the number of cells in the G1 phase of the cell cycle at 18
hours after transfection with either CMV-LacZ, CMV-Smadl, CMV-Smad2,
CMV-Smad3 or CMV-Smad4. The increase in the number of cells in G1 after
transfection with CMV-Smad4 (-10%) is significant. P<0.05 (students t-test)
112
have been phosphorylated and therefore activated by another ligand bound at the cell
surface (e.g. activin or a BMP) or that they have been activated by some other means
currently not known. Either way, over-expression of Smad4 leads to nuclear
localisation of the Smad4 protein and subsequently to apoptosis. This data implies
that normal levels of Smad4 may be a limiting factor in this progression to apoptosis.
Immunohistochemical staining with an anti-FLAG antibody to test that Smad4 does
become translocated to the nucleus confirms that nuclear translocation occurs
(Figure 3.4). This process is only possible if Smad4 was bound to a phosphorylated
receptor-activated Smad, such as Smadsl, 2, 3 or 5. This scenario seems quite
possible
in a cell where TGF-p superfamily signalling is obviously tightly controlled until
differentiation when various receptors become highly expressed on the cell surface.
The amount of apoptosis induced by Smad4 over-expression seems relatively small
but, although transfection efficiencies between experiments have been normalised,
the overall efficiency of lipid-mediated transient transfection in ES ceils is generally
quite low - transfection efficiencies of greater than 30% are uncommon. Considering
then that perhaps only 30% of cells have been transfected, and that these 30% of
cells have not been selected for before flow cytometric analysis, the level of
apoptosis induced is fairly high and quite specific to Smad4.
The Vindelov analysis is a method of determining what proportion of the cells are in
the Gl, S and G2 phases of the cell cycle via DNA content on the flow cytorneter.
This is useful in determining if there is a block in the cycle, which may then lead to
apoptotic events, although a direct link of this nature has to date proved difficult to
establish. It remains entirely possible that cell cycle arrest and apoptosis could result
from parallel effects of the same stimulus, Therefore, it still remains uncertain how
cell cycle arrest can lead directly to apoptosis but it is known that TGF-p arrests the
cell cycle late in Gl (Laiho et al, 1990 and Geng and Weinberg, 1993) and that this
is accompanied by maintenance of RB in its underphosphorylated form (Laiho et al,
1990) - a phenomenon associated with cellular apoptosis (Dou et al, 1995).
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The results show that there is a statistically significant increase in the number of cells
in G1 of the cell cycle when transfected with the CMV-Smad4 construct. This
suggests that Smad transfection leads to a G1 arrest but the true extent of this
phenomenon is somewhat debateable. Again the small population of cells transfected
was not purified to identify the transfected population prior to flow analysis and
consequently the effect seen could be more dramatic if this was the case.
In conclusion I have shown here that overexpression of Smad4 in ES cells results in
apoptosis, and that this induction of apoptosis is concomitant with an increase in the
number of cells in the G1 compartment of the cell cycle. Future work in this area of
the project would definitely include either co-transfection of a GFP expression
plasmid with the CMV-Smad plasmids or the generation of a Smad-GFP fusion
protein plasmid so that the transfected population of cells can be purified by FACS
before Annexin V and Vindelov analysis. Co-transfection in ES cells is notoriously
difficult with transfection efficiencies of less then 20% and I would therefore favour
generation of the Smad-GFP fusion protein as the approach to follow. Cloning the
human Smad cDNAs from the expression vectors into a commercially available GFP
fusion protein plasmid should result in an experimental tool which would provide
more complete answers to the question of exactly how much apoptosis over-
expression of Smad4 can induce in ES cells and clarify whether this is truly
associated with a G1 arrest.
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Chapter 4 - Generation and Characterisation of a BLG-Smad4
transgenic line
4.1 Introduction
4.1.1 Transgenic Mouse Models
In order to investigate further the role of Smad4 in the mammary gland it seemed
appropriate to also attempt a transgenic approach to the problem. Applications
involving the phenotypic effects of transgene expression include studies of
developmental regulatory genes (Kessel and Gruss, 1990), hormones and receptors
(Palmiter et al, 1982), oncogenes (Adams and Cory, 1991), genes involved in
immune recognition and response (Hanahan, 1989; Goodnow, 1992) and viral genes
(Berns, 1991; Skowronski et al, 1993). In general, transgenic mice expressing novel
genes represent gain-of-function mutations, whereas loss-of-function mutations in
many of the same genes can be created only by gene targeting. However, dominant
negative mutants have been obtained through expression of transgenes (e.g. collagen;
Stacey et al, 1988), and in one case, the expression of transgenes encoding antisense
RNA has been successful in inhibiting the expression of endogenous genes (Katsuki
et al, 1988). A detailed description of the history and major advances in mouse
transgenic technology can be found in Chapter 1 of this thesis.
4.1.2 Mouse Models - the Pros and Cons
Mouse mutants provide a powerful but often complex resource with which to
understand the functions of genes during development of the mammalian embryo.
Although a number of genes which cause developmental disorders in humans have
been identified (Muenke, 1995), the underlying molecular and cellular pathways and
processes are poorly understood. In the mouse, access to every stage of
embryogenesis and beyond is not restricted and, therefore, the mouse has become an
important in vivo system for studying disease processes and for designing therapeutic
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strategies. The third edition of a book which catalogues, amongst many other
important aspects of mouse genetics, the naturally occurring mouse mutants, has
been published recently (Lyon et al, 1996 in Genetic variants and strains of the
laboratory mouse, edn 3. Oxford: Oxford University Press), indicating the continuing
and increasing importance of mouse models. Dense high-resolution genetic maps of
the mouse chromosomes are now available as a result of new classes of genetic
markers being coupled with the development of new types of mouse crosses for gene
and marker assignment (Dietrich et al, 1996) and these advances have led to recent
successes in using positional cloning strategies to identify some important
developmental mutations.
The ability to modify the mouse genome remains unsurpassed when compared with
our abilities with other mammalian models. Once candidate disease-related genes are
identified, modifying their expression by generating transgenic mice, via either
microinjection of mouse eggs or the use of embryonic stem cells, allows their role in
disease to be unambiguously deduced. A compendium of artificial gene-targeted
mutations has recently been published (Brandon et al, 1995, parts I, II and III),
reflecting the power and increased use of these techniques. The generation of
transgenic mice can allow the identification of new genes not considered previously
to play a role in the pathogenesis of a disease. Transgenic mice can also answer more
basic questions, such as determining the function of a poorly characterised gene or
confirming a give gene function in vivo.
The number of transgenic animals now available for study (see
htto:/7www.rodentia.com/wmc for a complete listing to date) is an indication that
most researchers feel that the benefits of producing such a model greatly outweigh
the numerous difficulties associated with this approach. These include problems with
germline transmission of the transgenic allele and the effects of uncontrolled copy
number and integration site, both of which can lead to unpredicted transgene
expression. Because the locus of transgene integration is usually random, the
transgene frequently inserts into other functional genetic sequences. Interruption of
the normal expression of an endogenous gene may be inconsequential or lethal. The
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timescale for generating transgene models is also of consequence, as these
experiments typically require one to three years to perform. However, it is generally
perceived that transgenic animal systems combine the virtues of cell culture and
congenic breeding strategies while avoiding the negative aspects of each system.
Using transgenic techniques, a characterised genetic sequence may be evaluated
within the specific genomic background of the whole animal. Therefore, transgenic
animals may be utilised to study both the function and the regulation of a specific
genetic sequence and as such this approach was deemed suitable for an investigation
into what role Smad4 plays in the mammary gland.
4.1.3 The Transqenic Approach
I decided to address this question via multiple approaches including both in vitro and
in vivo analyses - the latter consisted of two strategies; a tissue-specific conditional
deletion of the Smad4 gene in the mammary gland (see Chapter 5) and a tissue
specific over-expression of the Smad4 gene via a transgenic model. The aim of this
approach was to generate a line of transgenic mice which expressed higher than
normal levels of the Smad4 protein during mammary gland lactation and involution.
My hypothesis that Smad4 is an essential component of the initiation of the epithelial
cell apoptosis associated with involution of the gland suggests that over-expression
of Smad4, either before or during this period, may lead to an altered programme of
involution.
4.1.4 The Promoter
The first step in the design of a transgenic strain is to select a promoter which will
yield strong expression of the gene of interest in the desired target tissue at the
desired point in development. This essential component of the transgenic strategy
can often be overlooked resulting in an animal with inappropriate expression of the
target gene or inefficient expression. One illustration of how promoter differences
can influence the outcome of an experiment is given by experiments aimed at
generation of mammary gland-specific TGF-P transgenic mice. In 1993 Pierce et al
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published a TGF-P transgenic mouse where the transgene is driven by the MMTV
(mouse mammary tumour virus) promoter (Pierce et al, 1993). They showed that
expression of the transgene (as confirmed by in situ hybridisation,
immunohistochemistry and Northern blot analysis) was associated with marked
suppression of the normal pattern of mammary ductal tree development in transgenic
females. Reduction in total ductal tree volume was observed at 7 weeks, soon after
oestrus begins, and was most apparent at 13 weeks, as ductal growth in the normal
mammary gland declines. However, during pregnancy, alveolar outgrowths
developed from the hypoplastic ductal tree and lactation occurred. Therefore, all the
transgenic females could support normal litters. Unlike many other transgenic mouse
models in which expression of growth factors or oncogenes under control of the
MMTV promoter leads to mammary epithelial hyperplasia and increased tumour
formation, the MMTV-TGF-(3 transgene caused hypoplasia of the mammary ductal
tree and no spontaneous tumours were detected in these transgenic animals. In the
same year Jhappan et al (Jhappan et al, 1993) also published studies based on a
TGF-(3 mammary gland transgenic strain which used the porcine TGF-(3l cDNA
placed under the control of regulatory elements of the pregnancy-responsive mouse
whey-acidic protein (WAP) gene. Females from two of four transgenic lines were
unable to lactate due to inhibition of the formation of lobuloalveolar structures and
suppression of production of endogenous milk protein. In contrast with the Pierce
study, ductal development of the mammary glands was not overtly impaired. There
was a complete concordance in transgenic mice between manifestation of the
lactation-deficient phenotype and expression of RNA from the WAP/TGF-(3l
transgene, which was present at low levels in the virgin gland, but was greatly
induced at mid-pregnancy. TGF-(3i was localised to numerous alveoli and to the
periductal extracellular matrix in the mammary gland of transgenic females late in
pregnancy by immunohistochemical analysis. Glands reconstituted from cultured
transgenic mammary epithelial cells duplicated the inhibition of lobuloalveolar
development observed in situ in the mammary glands of pregnant transgenic mice.
These two papers clearly illustrate how promoter differences can definitely influence
the outcome of the phenotype.
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The expression patterns of MMTV and WAP are quite different, with WAP
expression tightly restricted to lactation compared to MMTV expression in the
pregnant and lactating gland and in other organs such as the salivary gland
(Hennighausen et al, 1994 and Muller et al, 1988). Although the consequences of
using different promoters is clear, it should also be noted that positional effects can
greatly influence the outcome of the transgenic phenotype. The classical example of
this is when the transgene influences the genome such that different founders from
the same experiment can have different phenotypes (Tanaka and Takeuchi, 1991).
4,1.5 Other Considerations
Several other factors are recognised to influence the efficiency of expression of the
transgene. This includes the debate about whether introns should or should not be
included in the transgene. Experiments have been designed to test the effect of
introns on gene expression in transgenic mice (Trudel et al, 1987). Four different
pairs of gene constructs, which were identical except that one member of each pair
lacked all introns, were compared for expression of mRNA after introduction into the
murine germ line by microinjection of fertilized eggs. The expression of two
chimeric genes, made by fusing either the mouse metallothionein I or the rat elastase
1 promoter/enhancer to the rat growth hormone gene, was assayed in foetal liver or
pancreas, respectively, while two natural genes, an oligonucleotide-marked mouse
metallothionein I gene and the human beta-globin gene, were assayed in foetal liver.
In each case there was, on average, 10- to 100-fold more mRNA produced from the
intron-containing construct. Moreover, mRNA levels were proportional to the
relative rates of transcription that were measured in isolated nuclei. However, when
the expression of the two mouse metallothionein I gene-based constructs was tested
after transfection into cultured celis, little difference was observed. These
observations suggest that introns play a role in facilitating transcription of
microinjected genes although this effect may be manifest only on genes exposed to
developmental influences.
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The method of introduction of the transgene into the nucleus has also been subject to
much testing with microinjection into the male pronucleus now routinely used. In
1985 Brinster et al showed that some of the more important parameters that influence
successful integration of foreign DNA into mouse chromosomes are the effects of
DNA concentration, size, and form (supercoiled vs. linear with a variety of different
ends) as well as the site of injection (male pronucleus, female pronucleus, or
cytoplasm) and buffer composition (Brinster et al, 1985). They showed that the
optimal conditions for integration entail injection of a few hundred linear molecules
into the male pronucleus of fertilized one-cell eggs and that under these conditions
about 25% of the mice that develop inherit one or more copies of the microinjected
DNA.
Finally, there has even been debate about the mouse strain used to generate the
transgenic animal. Brinster et al, (1985) also showed that the overall efficiency
depends heavily on the choice of mouse strains; for example, generating transgenic
mice that express foreign growth hormone genes is about eight times more efficient
with C57/BL6 X SJL hybrid mice than with inbred C57/BL6 mice.
4.1.6 The Beta-Lactoqlobulin Promoter (BLG)
In an attempt to circumvent some of the problems described above I decided to use
the promoter from the ovine beta-lactoglobulin (BLG) gene as the promoter of
choice. This gene has been characterised extensively and its promoter has
successfully been used in the past to target gene expression to secretory epithelial
cells of the mammary gland (Whitelaw et al, 1992, Farini et al, 1995, Archibald et
al, 1990 and Clark et al, 1992). The gene encoding the milk protein BLG in sheep is
expressed in the mammary gland in a tissue-specific manner during pregnancy and
lactation. Expression is induced mid-way through pregnancy, peaks in lactation and
begins to decline at the onset of involution (Gaye et al, 1986)) The unmodified sheep
gene behaves appropriately in transgenic mice, and it has been shown that many of
the cis-acting elements that mediate this pattern of expression are located in the
proximal 400 bp of the promoter (Clark et al, 1998). Expression patterns of the BLG
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are also well characterised and it has been demonstrated that BLG-driven
transcription is correctly initiated in mice and that BLG-driven synthesis is restricted
to the secretory epithelial cells of the mammary gland (Harris S et al, 1991).
The BLG promoter has also been illustrated to be less prone to erroneous expression
than other mammary gland specific promoters like whey acidic protein (WAP) or
MMTV. The major milk whey protein of sheep, beta-lactoglobulin (BLG), is
expressed specifically in the mammary gland in a developmentally regulated pattern.
Chromatin analysis of isolated sheep nuclei has showed that the promoter resides
within a DNAasel-hypersensitive region in the mammary gland but not in the liver.
BLG transgenes display a similar tissue-specific pattern of DNAasel hypersensitivity
in mice and this data has demonstrated an essential role of the proximal DNAasel-
hypersensitive sequences for position-independent expression of the BLG gene
(Whitelaw et al, 1992).
4,2 Results
4,2.1 Making the Smad4 Transqene
The 4.2kb-BLG/SK+ plasmid (Whitelaw et al, 1992) was a kind gift from Dr John
Clark at the Roslin Institute in Edinburgh (Figure 4.1).
The transgene of choice is the human Smad4 FLAG-tagged cDNA. This kind gift of
Dr Rik Derynk (UCSF) seemed an ideal candidate as it was conveniently tagged at
the C terminus with the 8 amino acid FLAG peptide sequence, DYKDDDDK, which
allows convenient tagging of transgene expression. The FLAG-tagged Smad4 human
cDNA in the pRK5 vector is shown in (Figure 4.2).
Dr Stefan Selbert devised a cloning strategy and working together we created the
BLG-Smad4 transgene. I excised the FLAG-tagged Smad4 cDNA from the pRK5
plasmid with Hpal and Clal restriction endonucleases. The restriction digest




This plasmid contains the 4.2kb ovine beta-lactoglobulin promoter within a
pBluescript backbone. This plasmid was a kind gift ofDr John Clark at the






























This plasmid consists of a FLAG-tagged human Smad4 cDNA positioned
downstream of the CMV promoter within the pRK5 backbone. This plasmid
was a kind gift ofDr Rik Derynck at UCSF, San Francisco, USA
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This shows the FLAG-tagged Smad4 cDNA schematically once it has been
excised from the pRK5 backbone using Clal and Hpal restriction





Hpa/Cla digest ofpRK5 Smads 1-4
This digest shows pRK5-Smadl, Smad2, Smad3 and Smad4 digested with
Hpal and Cla I to cut the FLAG-tagged cDNA out of the pRK5 backbone.
The digests were then run out on a 0.7% TBE gel.
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Smad4 cDNA fragment was then blunted using T4 DNA polymerase and then
purified using a QIAEX gel purification kit and 5pJ of the purified insert run on a
0.7% TBE agarose gel to check the fragment. (Figure 4.4(a)). The 4.2kb BLG/SK+
plasmid has been described elsewhere but consists of the 4.2kb ovine beta-
lactoglobulin promoter in the 2.9kb pBluescript SK+ vector (Figure 4.1 for details).
The BLG/SK+ plasmid was cut open with EcoRV restriction endonuclease to leave
blunt ends and the purified blunted Smad4 cDNA was ligated using Ready to Go T4
Ligase. An EcoRI restriction digest was performed to determine which clones had
the correct orientation of the Smad4 cDNA (Figure 4.4(b)). Bacterial clones carrying
the correct plasmid (Figure 4.5) were grown to saturation and the plasmid harvested
(as described in Chapter 2) and then prepared for pronuclear injection.
In order to prepare the transgene for pronuclear injection it is necessary to first
linearise the transgene. The BLG-Smad4 transgene was removed from the vector
backbone by Xhol and NotI restriction digest and then purified by phenol chloroform
extraction and ethanol precipitation. A final purification step was carried out using a
Qiagen purification kit prior to injection into the pronuclei of fertilised eggs (Figure
4.6). The linearised transgene was then injected by Dr Alasdair MacKenzie at the
Royal (Dick) Vet School in Edinburgh. UK and by Dr Roberta James at the MRC
transgenic unit.
4.2.2 Testing Founder Mice
A number of F1 founder mice were born and these were tail tipped in order to make
genomic DNA and the DNA then subjected to PCR to determine the presence of the
ovine BLG promoter (Figure 4.7). PCR positive mice EK4 and EK6 were mated to
C57/B1 mice in order to pass the transgene to the next generation. Founder mice were
also tested for the number of integration sites and the transgene copy number by
Southern blotting with a BamHI/SphI restriction digest probe against a Bgl II digest.
Bgl II cuts once within the Smad4 cDNA (1.6kb downstream from the ATG) and the
probe is a restriction digest fragment from the BLG promoter region. The linearised











This figure shows 5(4.1 of purified FLAG-tagged human Smad4 cDNA
after digestion from the pRK5 backbone run out on a 0.7% TBE gel. The
predicted band size ofhuman Smad4 cDNA is 2.2kb
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EcoRI digest to confirm Smad4 cDNA in BLG vector
This digest shows a number of EcoRI digests of the cloned Smad4
cDNA in the BLG/SK+ plasmid. The predicted band sizes after EcoRI
digest are 3.5kb, 3.1kb, 2.3kb and 600bp. Lane no. 5 has the correct







The pBS-BLG-Smad4 transgene vector
The complete transgene vector consists of the ovine beta-lactoglobulin
promoter upstream of a human FLAG-tagged Smad4 cDNA. Note the
BHI/SphI sites which were used to create a probe for testing founder lines by
Southern blot. Note also the single Bgl II site within the Smad4 cDNA, used to
linearise the transgene for Southern blot analysis.Also outlined are the EcoRI










Purified Transgene ready for injection
This gel shows the purified transgene after linearisation with digestion with
Xho I and Not I. This removes the vector backbone, leaving an intact
transgene. The transgene is then purified by phenol chloroform extraction
and ethanol precipitation before a final purification with a Qiagen kit just
prior to pronuclear injection
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Figure 4.7
Transgene BLG PCR
This gel (b) shows the result of the first BLG PCR of the first founder mice
obtained by pronuclear injection. The PCR (a) utilises primers designed to
amplify only a 250bp section of the ovine BLG promoter. Short red arrows
represent primers. Founder mice number 4 and number 6 are positive.
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approximately 7kb in length. Concatamers of the transgene will produce a 7kb band
of varying intensities between founder lines. The number of integration sites can be
determined from the other signal present on the autoradiograph as the number of
these bands (which may be smaller or larger than the transgene band size depending
on each site of integration) is indicative of the number of integration sites. Founder
mouse EK6 was tested in this way and was found to have a 7kb band of absolute
intensity value of 75.26 and one larger 9kb band with an absolute intensity value of
24.74. Comparison of the intensities between these bands can be used to determine
the copy number of the transgene. From this single digest analysis it is likely that
EK6 has a copy number of 4 and only one integration site (Figure 4.8).
A number of founder mice and wild type mice were also tested for expression of the
transgene by the expression of the C-terminal FLAG tag. Western blot analysis
showed that none of the PCR positive founder mice expressed the FLAG epitope
except for the progeny of EK6: EK62 and EK63 (Figure 4.9). The EK6 line was
therefore concluded to be the only line which expressed the transgene and the
offspring were mated to produce a cohort of both transgene positive and transgene
negative animals for further analysis. The timepoints for mammary gland harvesting
were day 10 of lactation, day 2 of involution, day 3 of involution and day 6 of
involution with the 6 pups per mother being forcibly weaned at day 10 of lactation.
Mammary glands were harvested (two glands each from the upper and lower lateral
regions) and immediately frozen on dry ice before being transferred to a -80°C
freezer for storage.
4.2.3 Analysis of the Mammary Gland Smad4 Transgenic Mouse Model
A cohort of animals was bred such that a number of animals for each time point and
each genotype could be analysed (n=2). Unfortunately time constraints limited the
analysis to two mice per genotype per time point. Wild type F1 animals were used as
controls for this analysis. The final cohort were genotyped for the presence of the
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Figure 4.8
Transgene Southern Blot with BamHI/Sph I restriction digest probe on a
Bgl II digest
This Southern blot shows the copy number and number of integration sites of
the BLG-Smad4 transgene as determined for founder mouse no. 6. The tail
tip genomic DNA is cut with Bgl II which cuts once in the Smad4 cDNA.
The BamHI/SphI probe is made from a restriction digest within the BLG
promoter. The resulting blot shows that founder number 6 probably has a
copy number of four and only one integration site (as determined by
phosphorimaging - values shown), although another restriction digest would
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Transgene anti-FLAG Western blot
This western blot was performed on whole mammary gland lysates from
animals at day 10 of lactation. The blot shows a number of transgene
founder mice and F1 progeny mice (EK63 and EK64, both progeny ofEK6)
after probing with a C-terminal monoclonal anti-FLAG antibody. Only
EK63 and EK64 (progeny of EK6) show the FLAG band at just above
60kDa. FLAG-tagged Smad4 should be approximately 60kDa.
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BLG PCR on data sets (a) and (b)
This figure shows the current state of the BLG-Smad4 transgene cohort with
a number of transgene positive animals (in red) identified for the various
timepoints. At the time of analysis there were limited numbers of transgene
negative F2 littermate and therefore F1 mice were used as controls. All the
BLG positive transgene mice were tested for FLAG positivity as a marker of
the Smad4 transgene expression (See Figure 4.11) and preliminary analysis
ofH&E stained mammary glands has been performed (See Figure 4.12).
133
western blot analysis to determine expression of the transgene (Figure 4.11). The
FLAG-tagged Smad4 transgene has a predicted size of 60-70kDa.
FLAG expression is seen in all timepoints from day 10 of lactation until day 6 of
involution. Some variability was observed between the glands, with EK295 showing
slightly less FLAG expression at day 10 of lactation compared to EK246.
H&E stained mammary gland tissues from F1 wild type control animals and BLG-
Smad4 transgenic animals were examined for differences in histological phenotype
(Figure 4.12). It should be stressed at this point that due to time constraints only two
mice per genotype, and per timepoint were examined and that this is considered sub-
optimal given some expected variance within different mammary glands.
Furthermore, time constraints have not permitted a full analysis of the histological
data e.g. an assessment of apoptosis rates and an accurate determination of changes
in the percentage fat contribution within the gland. However, it is possible to make
some general statements about the histology without over interpreting the data. At
day 10 of lactation there appears to be little difference between the wild type and
transgenic glands although it is possible that the transgenic glands contain slightly
more fat than might be expected at this point. By day 2 of involution the wild type
gland has begun to show the characteristic degradation of the gland with milk ducts
losing their tightly expanded appearance and cell death resulting in epithelial cell
loss. In transgenic EK2 this process appears to be slightly accelerated and many of
the ductal structures contain sloughed apoptotic fragments associated with this
process. In transgenic EK275 the gland seems more intact but there are numerous
apoptoses in the lumena of the ducts and in the epithelial layer of the ducts. By day 3
of involution the wild type gland has progressed such that the structure is even less
coherent. In transgenic EK64 many of the lumena have collapsed and there is an
increase in the amount of fat piesent in the gland and by day 6 of involution in both
the wild type and the transgenics the gland has nearly all collapsed. Both EK253 and
EK277 appear to have cleared slightly more of the residual gland than the wild type
sample which still retains pockets of parenchymal cells and debris.
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anti-FLAG western blots on BLG-Smad4 Transgene positive mice and F1
control mice
The western blots show expression of the FLAG-tagged Smad4 transgene
protein only in the EK mice which are positive by PCR for the presence of
the BLG promoter. The FLAG tagged Smad4 is about 60-70kDa in size
and is present throughout lactation and involution. (30pg protein loaded per
well)
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Figure 4.12
H&E stained mammary gland sections from wild type and BLG-Smad4
transgenic mice
These sections show representative areas ofmammary gland slides from both
wild type and transgene positive mammary glands (x 40 magnification).
Group (a) shows Day 10 lactation, (b) Day 2 involution, (c) Day 3 involution
and (d) Day 6 involution. Arrows indicate some of the apoptotic figures.
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4.3 Discussion
I have shown here the generation and initial analysis of a BLG-Smad4 transgenic
mouse model. The animals expressing the transgene are, at the time of writing, part
of a small cohort which cannot be used to produce statistically significant data.
However, it is hoped that over the next few months other workers will gather the
required iittermate control samples and other transgenic samples such that a coherent
set of experiments can be performed on a data set with an n = or greater then 3. Once
this data has been collected a thorough examination of the phenotype of the BLG-
Smad4 transgenic mice can be attempted.
The initial analysis of the H&E stained sections provide preliminary observations
which will be confirmed or refuted when the data set is complete. These observations
are as follows: throughout involution the transgenic mammary glands differ from the
wild type controls in that they show higher levels of apoptosis and generally
accelerated involution. Assuming that collection of the final cohort samples is
completed there are a number of studies which would be required to be undertaken in
order to confirm this phenotype These include a further analysis of the progression of
the gland from the H&E slides which would be undertaken using microscopy to
count the relative areas of fat per field and number of apoptoses per field. Other
markers of gland progression are the matrix-associated proteins such as Matrix
Metalloproteases (MMPs) and Tissue inhibitors ofMatrix Metalloproteases (TIMPs),
and markers of immunological clearance such as the macrophage associated antigen
marker CD68. Immunohistochemical stains for these markers could be earned out, as
could protein analysis by Western blotting. A biochemical analysis of the tissues will
be undertaken to investigate what downstream and related genes are expressed when
Smad4 is over expressed in the mammary gland. Western blot analyses will include
Smadl, Smad2, phospho-Smad2 and Smad7 levels and an examination of the known
downstream markers of Smad activation, p21 and PAI-1. Western blot analysis for
markers of apoptosis-associated genes such as the Bcl-2 family will also provide
information on what other signal transduction pathways are involved. It will also be
interesting to examine protein levels of the STAT family of signal transduction
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Transgene expression levels compared to endogenous expression levels
This figure shows (a) human Smad4 cDNA transgene protein levels as
determined by Western blotting compared to (b) endogenous mouse Smad4
protein levels
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molecules as their interaction in Smad signalling in the mammary gland has become
apparent during the course of my PhD (see Chapter 6 for details).
It is useful to note at this point that levels of the transgene expression are perhaps not
as high as might be expected and, when compared to endogenous levels of Smad4 in
the mammary gland (Figure 4.13), it appears that transgene expression levels might
be quite low. This is a hard comparison to make for a number of reasons - without
the full data set and densitometry analysis of western blot gels it is difficult to assess
levels of protein expression, and use of different antibodies to detect FLAG (rabbit
polyclonal) and Smad4 (goat polyclonal) makes for very difficult comparisons.
However, as only one line of BLG-Smad4 mice have been tested (from EK6) it
remains a possibility that this particular line does not express very high levels of the
transgene and may therefore not show a particularly strong phenotype. Reasons for
poor expression will be discussed in more detail in Chapter 7 but could include the
lack of 3' UTR sequences, position effects and the use of a cDNA transgene as
opposed to a genomic construct.
It will be interesting to observe what the final phenotype of these Smad4 mammary
gland transgenic animals is. If indeed the preliminary phenotype is confirmed then
this will have established an in vivo role for Smad4 in initiating apoptosis within the
involuting gland, and it is hoped that the information assembled from this particular
model will be of help in our understanding of what role Smad4 plays in mammary
gland progression.
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In order to dissect the functions of individual components of complex biological
systems it has become almost routine to engineer some type of transgenic mouse.
This approach can yield immense amounts of information regarding the functions of
the molecule in question and can also answer questions pertaining to redundancy and
compensation. However, there are risks related to the use of this approach and these
include not least the time involved to generate the transgene, the requirement for
exclusive experimental mouse stocks and then the final analysis. Compared to
standard in vitro techniques this can therefore be a long term, high-risk approach.
However, it is often the only option to fully understand the role that a particular
molecule plays in an in vivo context and, combined with the other analyses described
in this thesis, it was an approach which seemed entirely appropriate for this project. I
addressed what role Smad4 plays in the mammary gland in two ways utilising mouse
transgenics. First, the generation of a mammary gland transgenic mouse which over-
expressed Smad4 (see Chapter 4 for details) and second, the generation of a
"floxed" Smad4 allele. This chapter will deal with the production of the floxed
Smad4 mouse.
The ability to disrupt any gene by homologous recombination has led to new
approaches in the study of gene function in vivo. The derivation from
preimplantation embryos of murine embryonic stem cells (ES cells) that retain
totipotencv even after gene targeting has allowed the generation of intact animals
harbouring the desired genetic alteration (Hooper (1992) in "Embryonal Stem
Cells"). This technology has been used extensively in recent years to generate
"knockout" animals- that is animals in which the desired gene or locus of interest has
been ablated from the chromosome, either in a heterozygous or homozygous manner.
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These studies have always been of mixed usefulness with some null animals
providing great insight into the role that a particular gene plays through exciting or
surprising phenotypes for example the TGF-(33 knockout (cleft palate amongst other
phenotypes) and the Smad3 knockout (intestinal tumourigenesis) (Kaartinen et al,
1995 and Yang et al, 1999) and others, simply by a phenotype of embryonic
lethality, demonstrating that the gene is of great importance during early embryonic
development; like the FGF-4 knockout or certain of the BRCA gene knockouts
(Feldman et al, 1995 and Ludwig et al, 1997). Of course a knockout which results in
embryonic lethality is not a failed experiment - it predicts that the gene or protein of
interest is extremely important at a certain stage in development and, depending on
the lethal phenotype observed, much can be learned from this result - however, it
tells little about the gene function in adult tissues.
Often in conventional knockouts other genes will compensate for the null locus
resulting in unexpected phenotypes. This phenomenon results from several factors
which may complicate the interpretation of a specific phenotype. For example,
defects in early development may indirectly also compromise functions in the adult.
Conversely, developmental plasticity may compensate for an early loss of gene
function. This may occur at the single gene level, the genetic pathway level or
involve systemic adaptive mechanisms. Within gene families, related proteins may
functionally compensate for deficits associated with the loss of one family member,
for example the COX-1 knockout (Reese et al, 1999) where COX-2 compensation
occurs in the absence of COX-1. and the resulting phenotypes fail to fully address the
questions being asked.
5.1.2 Cre Lox Technology
Recently, strategies have evolved which have the potential to overcome this problem
by allowing in vivo manipulation of DNA in ES cells or animals. This can be
achieved through site-specific DNA recombinases; molecules originally described in
yeast and bacteria which have the ability to catalyse efficient DNA recombination at
sequences of from 25 to 150bp in length, a size sufficiently large that these
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recognition sequences are not expected to naturally occur in the mammalian genome.
The relative simplicity and efficiency of Cre recombinase from temperate phage PI
has made it particularly useful for this purpose (Sternberg and Hamilton, 1981 and
Hoess et al, 1982). Placement of recombination sites into the genome and subsequent
targeted expression of recombinase have allowed the development of genetic
switches that can either ablate or turn on any desired gene in transgenic or gene
modified mice.
The Cre-Lox system is described in detail in Chapter 1 but some of the most
important features concerning this application shall be briefly reiterated here.
5.1.2 (a) The Cre-Lox Reaction
Cre is the 38kDa product of the cre gene of bacteriophage PI (Sternberg, 1978 and
Sternberg et al, 1986) and is a site-specific recombinase of the Int family. Cre
recognises a 34-bp site on the PI genome called loxP (locus of crossover of PI) and
efficiently catalyses reciprocal conservative DNA recombination between pairs of
loxP sites (Hoess and Abremski, 1985). The loxP site consists of two 13bp inverted
repeats flanking an 8bp non-palindromic core region that gives the loxP site an
overall directionality, that by convention is represented as an arrow (Figure 5.1 (a
i)). Cre mediated recombination between two directly repeated loxP sites results in
excision of the DNA between them as a covalently closed circle (Figure 5.1 (a iij).
Breaking and joining of the DNA is confined to discrete positions within the core
region and proceeds one strand at a time by way of a transient phosphotyrosine
DNA-protein linkage with the enzyme. Although the enzymatic details of the early
steps involved in these recombination reactions differ, and are in some cases not yet
well understood, each case involves a common four-way branched DNA
intermediate known as the Holliday junction (Holhday, 1964). A Holiiday junction
(HJ) is formed when a single strand from each of two duplex DNA segments
involved in recombination is exchanged in a region of sequence homology to yield a
branched structure that has four duplex arms. The ultimate fate of HJs in vivo is











Cre recognises a 34 base pair site on the PI genome called loxP (locus ofX-
over of PI) and efficiently catalyses reciprocal conservative DNA
recombination between pairs of loxP sites, (a) The loxP site consists of two 13
base pair inverted repeats flanking an 8 base pair non palindromic core region
that gives the loxP site an overall directionality that, by convention, is
depicted as an arrow. Cre mediated recombination between two directly
repeated loxP sites results in excision of the DNA between them as a
covalently closed circle, (b) Correctly targeted ES cells are injected into mice
and animals containing the modified gene (which are at this point
phenotypically wild type) are then crossed with mice expressing Cre in the
desired target tissue and Cre-mediated excision results in a tissue-specific
gene ablation
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5.1.2 (b) The LoxP sequence
Not all 34bp are essential for efficient recombination; the first 4 bp of either of the
13bp-inverted repeats can tolerate some modification with little if any loss of
recombinatorial proficiency or fidelity (Sauer et al, 1988 and Sauer 1996). Modified
loxP sites might possibly be helpful in the design of genetic switches as the internal
8bp non-palindromic section contains two ATG translational start signals in one
orientation (ATGTATGC) but not in the other. It has been hypothesised that it might
be important that the loxP sites be oriented such that there remains no false ATG
start that could interfere with downstream transgene expression after exclusive
recombination. However, there is currently no evidence in support of this, although it
has been suggested that loxP sites should be routinely modified such that there is no
longer an ATG present. A second potential problem is that because of its palindromic
structure, the loxP sequence will form a hairpin structure in transcribed RNA that
can, if present in the 5' leader, decrease downstream gene expression (Kozak, 1986
and Sauer and Henderson, 1989). This potential problem can be minimised as
already mentioned by introducing a recombinatorially neutral alteration of one or
more of the outer 4bp into one of the sites inverted repeats.
5.1.3 Applications of Cre Lox Technology
The exciting potential of the Cre/loxP system became apparent when it was shown
that the enzyme would catalyse recombination in the absence of ATP, co-factors or
topoisomerase activity (Abremski and Hoess, 1984). Most importantly, the system
will also function in eukaryotic cells (Sauer and Henderson, 1988). These
observations have subsequently been extended in vivo using transgenic mice and it
was this work which first demonstrated the potential application of this system to
conditional gene targeting (Orban et al, 1992 and Lakso et al, 1992).
Applications of the Cre-lox system are varied and include cell-restricted, site-specific
recombination (as utilised in this project) where regulatory DNA sequences are
engineered to be flanked by loxP sites which can be introduced into ES cells via
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homologous recombination. Once correctly targeted ES cells have been selected
(usually via drug selection for an incorporated positive/negative drug selection
cassette carrying flanking loxP sites) Cre can be transiently expressed in order to
remove the selection cassette. These ES cells are then capable of generating
heterozygous mouse lines via blastocyst injection which can then be crossed to lines
with one null allele to generate mice with either one WT allele and one floxed allele
or one null allele and one floxed allele. Crossing these mice to a transgenic mouse in
which Cre protein expression is regulated by a tissue or cell-type specific promoter
then results in excision of the intervening DNA resulting in a tissue/cell-specific
deletion of the DNA of interest (Figure 5.1 (b)). This application was first
demonstrated by Rajewsky and co-workers (Gu et al, 1994) when they deleted the
polfi exon 1 from thymocytes by using a T-cell specific Cre transgenic via the
tyrosine kinase Ick promoter.
Control of protein expression in vivo has also been demonstrated using inducible
promoters, although problems such as high basal level of expression, toxicity and
poor induction have limited their usefulness to date. Recent modifications of the
tetracycline-responsive regulatory system now provide an effective inducible
promoter in vivo (Hennighausen et al, 1995 and St-Onge et al, 1996). Combining
site-specific Cre-lox recombination with inducible promoters offers perhaps the
ultimate flexibility in designing experiments to generate conditional alterations, not
only in a particular tissue/cell type but also at varying times, oveicoming the
increasingly problematic limited availability of tissue and stage-specific promoters.
The elegant potential of the Cre-lox system was chosen as an attractive approach to
examining the role of Smad4 in the mammary gland for two main reasons;
conventional knockout technology at the Smad4 locus had resulted in embryonic
lethality (Sirard et al, 1998) and mammary gland (3-iactoglobulin-Cre transgenic
mice were readily available which have been weil characterised (Selbert et al, 1998)
and would allow a thorough investigation into the role that Smad4 might play in the
epithelial cells of the mammary gland.
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5.2 Results
5.2.1 Screening the A library
In order to generate a targeting vector for use in homologous recombination in
embryonic stem cells (ES), it was necessary to first isolate a genomic clone that
contains part if not the entire murine Smad4 locus. The initial part of this work (the
cloning and majority of the characterisation of the genomic clone) was carried out
together with Dr Stefan Selbert at the Department of Pathology, Teviot Place-
Edinburgh University. It was decided to isolate a murine Smad4 genomic clone from
the mouse genomic APS library (MoBiTec), a eukaryotic genomic library created in
the vector system APS. This system was chosen as molecular cloning of a given locus
not only requires the screening of the library, but also the subsequent characterisation
of the phage recombinants, and as this latter stage can be quite complex (purification,
restriction mapping and subcloning) this method was selected as it circumvents many
of these problems. It features an automatic plasmid subcloning facility of insert
fragments and therefore combines the advantages of large insert genomic libraries
with the convenience of working with high copy plasmids (Figure 5.2). APS is a
replacement vector of lambda origin which can accommodate DNA inserts of up to
20kb. This allows the complete representation of complex genomes in a reasonable
number of recombinants. The linear vector contains two loxP sites in direct
orientation flanking high copy plasmid backbone and the insert. Recombination
between these two sites is mediated by Cre recombinase, leading to excision of the
multi-copy plasmid from the phage genome. Hence, this is termed automatic
subcloning. It can be achieved by transferring the phage into the Cre-expressing E.
coli strain BNN132.
The library was plated at 2xl06 pfus total and filter hybridisation was carried out
using a previously generated murine Smad4 cDNA probe.

















Structure of the APS vector
AJPS is a replacement vector which can accommodate DNA inserts of up
to 20kb. The linear vector contains two loxP sites in direct orientation
flanking a high copy plasmid backbone and the insert. Recombination
between these two sites is mediated by Cre recombinase, leading to
excision of the multi-copy plasmid from the phage genome.
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DPC4 (1) 5' -GATGTGTCATAGACAAGGTGG-3'
DPC4 (2) 5'-CAATTCCAGGTGAGACAACCC-3'
These primers were designed to amplify the murine MH1 region of the Smad4 gene
and gave a product of approximately 2kb (Figure 5.3).
Positive plaques were purified by additional rounds (usually 3) of plating and
hybridisation (Figure 5.4) and purified phage added to the Cre-containing BNN132
cells, resulting in automatic subcloning of the positive genomic clone.
The result of screening the library was a 15kb genomic clone which was then
mapped extensively to identify suitable sites for the insertion of the single loxP site
and the floxed Neo/TK cassette. The mapping of the 15kb genomic clone consisted
of a number of approaches including single and double restriction digests. Southern
blot hybridisation to the digested DNA using PCR probes and dideoxynucleotide
chain termination sequencing into the DNA .
I designed primers based on the known human cDNA sequence of DPC4 (Genbank
Accesssion No. U44378) to the MH1 region (5'), the proline-rich linker region and
the MH2 region (3') as follows:
DPC4 (1) 5' -GATGTGTCATAGACAAGGTGG-3'
DPC4 (2) 5'-CAATTCCAGGTGAGACAACCC-3'
DPC4 (3) 5'-GTTCACGACTTTGAAGGACAGC-3' ^











DPC4 1/2 PCR product
Primers 1 and 2 amplify the 5' MH1 domain of the Smad4 gene. This
product is approximately 2 kb in size and was used as a probe for





Typical filter from screening the X library
This photograph shows positive plaques after hybridisation of the
filter with the Smad4 PCR product 1/2. A number of positive plaques
can be seen. The positive plaques were picked and screened in
subsequent rounds.
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5.2.2 Creating the floxed Smad4-HPRT targeting vector
Using these techniques the 15kb genomic X clone was mapped (Figure 5.5) such that
it was possible to isolate an 8kb BamHI fragment and this was then subcloned into
the MCS of pBluescript II (KS+) (Genbank Accession No. X52327, Stratagene) for
further analysis (Figure 5.6 and Figure 5.7). This 8kb fragment was also subjected
to restriction digest and then probed with the Smad4 cDNA probes described above.
Southern blot analysis confirmed that the 8kb genomic clone contained only the 5'
MHI region of the Smad4 gene and sequencing from the pBluescript vector into the
8kb clone confirmed the presence of exon III at the 3' of the DNA and exon I at the
5' end. It was therefore used as the basis of the floxed targeting construct as it was
found to contain exons 1, 2 and 3 of the murine Smad4 gene (Figure 5.7).
The floxed Neomycin/TK cassette was a kind gift of Professor Reinhard Fassler and
has been described before (Potocnik et al, 2000). Briefly this cassette consists of a
Neomycin antibiotic gene and a Thymidine Kinase gene with single loxP sites on
either side of the cassette in the same orientation. The floxed Neo/TK cassette can be
excised from its pBluescript II (KS+) backbone by restriction digest with BamHI and
Xhol (Figure 5.8).
The floxed Neo/TK cassette was cloned into the single Bin site of the 8kb fragment
which had already been determined by sequencing as being approximately ikb
downstream of exon I and about lkb upstream from exon II of the murine Smad4
gene (Figure 5.9). A single loxP fragment (Figure 5.10) was then cloned into the
Nco I site of the 8kb genomic clone, a site determined to be 700bp upstream of exon
I. LoxP fragments were engineered to have EcoRV and BamHI restriction sites at
either end of the 34bp palindromic loxP sequence in order to aid in cloning and to
help determine orientation of the loxPs by restriction digest. The final step in
generating the targeting construct was the introduction of an HPRT cassette into the
NotI site of pBluescript i.e. outside the 3' region of homology. The rationale behind











Intron 1 Intron 2
Exon 3 Muni (10,000)
BamHl (80 3) BamHl (11,800)
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15kb/_ clone restriction digest map
Figure 5.5
15kbX. clone restriction digest map
This figure shows a map of the 15kbA, clone as determined by restriction
digest, southern blot and sequencing. The BamHl sites which were used as
the basis of the 8kb subcloned fragment are outlined in red text. The 2.2kb
BamHI/Mun I fragment used as a probe for 3' southern blots is outlined as a
pink bar. The map also shows the sites intended for insertion of the single
loxP sites (Ncol site outlined in blue) and the floxed Neo/TK cassette (Bin I
site outlined in blue). The Apa I site used in the 3' Southern blot strategy to
detect correctly targeted ES cell clones is shown outlined in pink.
152



















Subcloning the 8kh BamHT fragment from the 15kbA. clone
These figures show (a) BHI/Clal digest of the 15kb A, clone showing that
there is an 8kb fragment. Figure (b) shows the purified 8kb band before it
was subcloned into pBluescript. Figure (c) shows uncut 8kb plasmid and
plasmid cut with Ncol I. This single site within the 8kb BHI fragment was
used to insert a single loxP.
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BHI 8kb X genomic DNA
I
I (2541) Exon 1
Figure 5.7
The BHI 8kb X. clone
(a) An 8kb BHI fragment was sub cloned into pBluescript from the original
15kb X clone. The 8kb clone was mapped and found to contain Exons I, II
and III of the Smad4 gene. This 8kb fragment then became the basis of the
targeting construct. The cloning strategy was devised by Dr Stefan Selbert
and involved insertion of the single loxP site into the Ncol site upstream of
Exon I and insertion of the floxed Neo/TK cassette into the Blnl site between
Exons I and II, thus placing loxP sites on either side of Exon I. (b) This
figure shows the sub cloned 8kb X fragment containing Exons 1, 2 and 3 of
the murine Smad4 gene in pBluescript.
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Floxed Neo/TK cassette vector
This figure shows the floxed Neo/TK cassette (a kind gift of Professor
Reinhard Fassler) before it was cut out of the vector backbone and ligated


















Inserting the floxed Neo/TK cassette into the 8kb fragment
This figure shows where the blunted BHI/Xho fragment of the floxed
Neo/TK cassette was cloned into a blunted Blnl site in Intron I of the BHI








This diagram shows a single loxP site with EcoRV and BamHI sites on
either end. These sites aid in cloning the loxP sites into the targeting vector
and also help determine orientation of the loxP site.
EcoRI (5203) ffl (25)
Pi/1 (2632) Ava I (2103)
Figure 5.11
I (2119)
pPOLYIII - the HPRT cassette
This figure shows the pPOLYIII-HPRT cassette before being excised from
the backbone and cloned into the Smad4 pTarVec targeting plasmid. Note
the NotI sites in bold which were used to liberate the Hprt gene from the
pPOLYIII backbone.
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recombination) then the HPRT cassette would remain present in the DNA and could
be selected against using the drug 6-thioguanine (6-TG). 6-TG is a guanine analogue
and substrate for the Hprtenzyme it undergoes a phosphoribosylation reaction to
generate 6-thioguanine monophosphate (6-thioGMP). High levels of 6-thioGMP
within the cells inhibit the biosynthesis of guanine nucleotides and this inhibition
eventually results in the death of all cells that express Hprt (Miech et al, 1967) If
homologous recombination occurs then the HPRT cassette will be lost and selection
against the presence of it will result in a higher proportion of correctly targeted
clones. This strategy of counter-selection works only with embryonic stem cells
which are already HPRT-deficient as HM-1 ES cells are. The HPRT cassette can be
excised from the pl'OLYlll/Hprt vector (a kind gift from Professor David Melton)
by NotI restriction digest (Figure 5.11) and this was cloned into the NotI site of the
modified 8kb/pBS plasmid to create the final targeting vector, pTarVec (Figure
5.12). The overall strategy to successfully introduce loxP sites on either side of exon
1 of the Smad4 locus is shown in Figure 5.13.
5.2.3 Generation of correctly targeted embryonic stem (ES) cells
The pTarVec plasmid was transfected into bacteria such that 150pg of Clal linearised
plasmid DNA was ready for electroporation into ES cells. The cells were
electroporated as described in Chapter 2 and then plated. 24 hours after
electroporation the medium was removed and G418 selection medium added. Two
weeks later the colonies were picked, expanded and harvested. DNA was prepared
for Southern blot analysis.
5.3 Teviot Place Analyses
5.3.1 Southern Blot analysis of first round targeting
A Southern blot strategy was designed to detect correct integration of the targeting
vector at the 3' end of the region of homology. The ES cell DNA generated from























Apal (10716) PGK promoter
Thymidine kinase gene
Figure 5.12
pTarVec - the floxed Smad4 targeting vector
This figure shows the complete targeting vector within pBluescript. The
targeting vector consists of two loxP sites on either side of exon I of the
Smad4 locus and a floxed Neo/TK cassette downstream of exon I. There is
an HPRT cassette situated downstream of Smad4 exon 3 (HPRT exons 1 -
9).
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Ex2Ex3 (e) Deleted Smad4
allele
This figure shows the overall strategy employed to achieve conditional
deletion of the Smad4 allele. Homologous recombination between the
regions of DNA both upstream of the 5' loxP site and downstream of the
floxed selection cassette is required to integrate all three loxP sites into the
Smad4 locus. Embryonic stem cells with the structure shown in (d) will be
injected into blastocysts to generate mice bearing a "floxed" Smad4 allele.
Crossing of these mice to Cre-expressing transgenic animals will result in
deletion of the Smad4 ATG of the floxed allele, essentially making the locus
null for Smad4.
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endonuclease Apal and probed with a 2kb BamHI/MunI external probe obtained
from restriction digest of the original 15kb A, clone (see Figure 5.5 (d) for details).
The probe had been shown to bind to a 12kb Apal fragment generated from wild type
DNA and the correct integration of the floxed Neo/TK cassette would introduce a
number of new Apal sites which would shorten the Apal fragment to approximately
lOkb. Southern blot analysis in this way revealed that a number of ES cell clones
appeared to have both a wild type Apal fragment of 12kb and also a targeted allele
fragment of lOkb. 50 clones out of 200 hundred picked were analysed in this way
and of those approximately 40% contained the targeted allele (Figure 5.14).
A Southern blot strategy for the 5' region proved to be more difficult to design and to
date this region of the targeted allele has not been confirmed by Southern blot
analysis.
5.3.2 Administration of Cre recombinase to remove the floxed Neo/TK
Two approaches to the administration of Cre recombinase were taken. Both utilised
the PGK-Cre plasmid created by Dr Tom Gardner at the University of Edinburgh.
This plasmid was built from PMC-Cre by the addition of a PGK promoter-
Hygromycin resistance gene-PGK enhancer cassette from PHA57 (Figure 5.15). The
first approach (Teviot Place Protocol) was to transiently transfect the correctly
targeted first round ES cells with the piasmid using a iipid-based transfection agent.
Two clones from the first round of targeting, clone 1 and clone 21 were seeded at
low densities in 6 well plates (400 cells per plate and 4000 cells per plate) and
transfected with lpg of PGK-Cre plasmid using the Promega TfX-50 kit. The cells
were left in complete medium for one week and only then was medium containing
2p.M ganciclovir added. 10 days later colonies were visible to the eye and were
marked and picked as described before. DNA was made from the ES cells for PCR
analysis.
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Apa I digest Southern blot probed with 1.8kb BHI/MunI 3' probe
Figure (a) shows the first 19 samples of a Southern blot to detect correctly
targeted floxed Smad4 clones. The ES cell DNA was digested with Apal
and probed with an external 3' probe created from a restriction digest with
BHI and Muni. Apal restriction digest should give a 12kb wild type band
and lOkb targeted band via the introduction of a new Apal site within the
Neo/TK. From the clones tested approximately 40% were correctly
targeted by this criterion. Figure (b) shows an enlargement of a section of



















This plasmid was built from PMC-Cre by the addition of a PGK promoter-
Hygromycin resistance gene-PGK enhancer cassette from PHA57. The end
result can be used in the in vitro Cre steps involved to excise the floxed
Neo/TK from the targeted allele via recombination in the presence ofCre.
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The second approach (NPU protocol) was electroporation of the ES cells with the
circular PGK-Cre plasmid. The cells and the DNA were mixed together and
transferred to an electroporation cuvette where they were electroporated using two
pulses at 230V and 500 ^Fd.
The cells were left to rest at room temperature for 15 minutes before adding
complete medium containing LIF. The cells were plated out at 104 cells per 10 cm
plate and 6 days later LIF complete medium containing 2|uM ganciclovir was added
and the medium was changed as required. By day 15 colonies were visible so 50
colonies were selected from the plates and screened for the presence of the targeted
allele by PCR.
5.3.3 PCR Analysis of Cre-mediated deletion of the floxed NeoATK cassette
Two PCR analyses were carried out to detect a targeted clone which could be used
for injection into blastocysts. The first was to detect the presence of the 5' single
loxP site upstream of Exon I. This PCR is internal to the targeting vector but is still
important to confirm that there are two bands present to ensure that recombination
had occurred upstream of this loxP site and that this loxP site had therefore been
incorporated into the target locus; one wild type band and one targeted band. This
PCR utilised two primers designed from sequence data from either side of the single
loxP site. The primers "loxP up" and "380rev (2)" are designed to amplify a band of
approximately 220bp with wild type DNA and 280bp when a single loxP site is
present (Figure 5.16). The second PCR was designed to test that the floxed Neo/TK
had been excised properly after addition of the Cre recombinase. This PCR utilised
two primers designed from known sequence on either side of the cassette. "DPC4
Intron" and "DPC42" are designed to amplify a wild type band of approximately
230bp whereas the presence of a single loxP site remaining after recombination
between the two loxP sites at either side of the cassette should increase this band by
approximately 70bp to 300bp (Figure 5.17). No signal can be generated from the
Neo/TK-containing allele before recombination as this would involve PCR over a
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PCR with loxP up and 380rev (2) primers
This figure shows the results of a PCR to detect the 5' loxP site within the
targeted allele. ES cell clone 1 and 21 (both positive by Southern Blot
analysis) were tested after exposure to Ganciclovir to remove the floxed
Neo/TK. Clones correctly targeted at the 5' end show two bands, one WT










PCR with DPC4 Intron and DPC4 (21
This figure shows the results of a PCR to identify correctly targeted
clones which have lost the floxed Neo/TK cassette as a result of
exposure to Cre recombinase and selection in ganciclovir. Positive
clones will show two bands; one WT band of approximately 230bp and
the targeted allele band of approximately 300bp. The doublet in the
upper band is thought to be due to loxP secondary structure effects
during the PCR reaction.
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5kb region of DNA, which is unlikely with the short extension times used in this
PCR protocol.
The results of the PCR analyses on Teviot Place-derived ES cell clones were that
clone 1.29 was assumed to be correctly targeted with single loxP sites remaining
which flank exon I on one allele of the murine Smad4 locus. Clone 1.29 was
subsequently assessed for karotype.
5.3.4 Karyotyping correctly targeted ES cell clones
Standard methodology was used to karotype ES cell clones (See Chapter 2).
Preparation of metaphase spreads was achieved by fixing the cells and dropping
them on to a microscope slide from a height of about 30 cm. After staining the slides
with Giemsa it was possible to count chromosomes under the microscope.
Clone 1.29 had a modal chromosome number of 40, with approximately 65% of the
spreads counted having the modal number. 50 fields of cells were counted. This
figure gives an indication of the ability of the ES cell line to be germline competent.
Although only 65% of the cells counted have a normal modal chromosome number it
has been previously shown that HM-1 ES cells with karyotypes of this nature can
indeed produce good chimeras and can generate germline transmission of the
targeted allele (Manson J., personal communication).
Clone 1.29 was subsequently grown to yield a number of large flasks of cells for
freezing purposes. At this point the passage number of the clone was 23.
Mrs Jennifer Doig and Ms Tracey Higgins carried out blastocyst injections at the
department of Pathology, Teviot Place. A vial of ES cells was defrosted 2 days prior
to injection and grown in a 25cm2 flask in medium supplemented with LIF. The ES
cells were harvested as usual on the day of injection and injected into blastocysts
obtained from superovulated C57BL/6 pseudopregnant female mice. 15-30
embryonic stem cells were injected into each blastocyst and on average 10-15
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blastocysts were returned. From 6 injection sessions only one chimera was produced
with more than 25% chimerism (Figure 5.18). This one male was allowed to mate
repeatedly, but failed to produce any germline transmission of ES cell derived coat
colour markers. After this male had fathered 50 negative pups this chimera was
considered not to transmit ES cell coat markers and the situation re-assessed.
It was decided to re-target ES cells at the Neuropathogenesis Unit (NPU), Kings
Buildings, Edinburgh for a number of reasons; firstly non-targeted test ES cells at
Teviot Place were failing to colonise the germline even when excellent chimeras had
been produced, suggesting that there might be a problem with the ES cells, the
culture technique or the pseudopregnant females' blastocysts. Secondly, the NPU
had been consistently producing high quality chimeras (90%+) and subsequent
germline transmission using different protocols and methods even although their ES
cells were derived from the same stock as those being used at Teviot Place.
5.4 NPU Analyses
5.4.1 Targeting the Smad4 locus at the NPU
Targeting the Smad4 locus with the pTarVec floxed targeting vector commenced at
the NPU in late 1999/early 2000. I have outlined some of the differences in the
protocols used in the Materials and Methods section of this thesis (Chapter 2) but
essentially the main differences were the medium used, the electroporation protocols
and the in vitro Cre step (electroporation instead of transient transfection). However,
the same re-derived HM-1 ES cell line was used and the end result of the experiment
was effectively the same in terms of the number of correctly targeted clones at each
stage of the experiment. Re-derived HM-1 ES cells were electroporated with 150 pg
of linearised pTarVec plasmid as described in Chapter 2. Unfortunately a number of
dishes were destroyed by a fungal infection but of only ten ES cell clones picked 4
showed the presence of the targeted allele as described in section 5.3.1 of this
chapter. These targeted clones were then subjected to electroporation with the PGK-
Cre plasmid and from these a number of clones which survived selection in
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Figure 5.18
Teviot Place Chimera No. 1
This photograph shows a chimera generated from correctly targeted floxed
Smad4 ES cells. The animal is chimeric in coat colour only on the ventral
side and never produced germ-line offspring.
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ganciclovir were tested for the presence of the floxed Smad4 genomic structure using
the PCR described in section 5.3.3. One clone, numbered 49.8, was found to contain
the two loxP sites indicative of a floxed allele.
However, two differences were that the final clone. Clone 49.8, had a karyotype of
40 in 72% of cells counted (50 fields of cells counted) and the clone was frozen
down for blastocyst injections at a lower passage number - passage 19.
Dr Joe Mee of the Centre for Genome Research, Kings Buildings, Edinburgh (CGR)
carried out the ES cell injections into blastocysts from naturally mated C57BL/6
female mice and transferred them into pseudopregnant F1 recipient female mice.
From the first injection session 3 chimeras were produced, two of which were termed
"highly chimeric" on the basis of coat colour and one mouse demonstrated medium
to low chimerism. From a second injection session another 3 chimeras were
produced (Figure 5.19). The mice from the first injection session were then mated to
MF1 mice to identify germline transmission of the ES cell markers. Pups born from
these matings showed germline transmission of the ES cell markers in 50% of two of
the three litters and 100% of the third litter (Figure 5.20 (a)). Seven pups from a
total of 13 were tail-tipped and PCR analysis for the presence of the two loxP sites
on either side of exon I carried out from the tail tip DNA (Figure 5.20 (b) and (c)).
The results demonstrate that of the seven pups genotyped in this way, mouse
number 1 shows germline transmission of the floxed Smad4 allele, the pattern of
bands observed in the PCR being identical to those of the ES cells used for targeting,
clone 49.8.
5.5 Discussion
5.5.1 Floxed Smad4 mice - where next?
The generation of mice with a floxed Smad4 allele has been a major part of this
project and although this initial stage of this work is now complete, this marks the
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Targeted floxed Smad4 ES cells were injected into C57B1 blastocysts by Dr Joe
Mee at the Centre for Genome Research (CGR) at Edinburgh University. The
blastocysts were placed into the uterine horns of 2.5dpc pseudopregnant F1
mice and pups born approximately 18 days later. Three chimeras were
produced from the first injections, one chimera was classed as low to medium
levels of chimerism (pictures la,lb) and two of which were classed as having
high levels of chimerism (pictures 2a-3b). A second round of injections
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(C) M1234567M TV+Cre 49.8 -ve (H20)
500bp-
Figure 5.20
Germline Transmission of the Floxed Smad4 allele
This figure shows (a) pups born from a floxed Smad4 male chimera x
MF1 female, which resulted in three pups showing germline transmission
(grey pups). Figure (b) shows a PCR reaction to determine the presence of
the single loxP site upstream of exon I and Figure (c) shows a PCR reaction
to determine the single loxP site downstream of exon I.. Mouse no. 1 shows
the two bands identical to those observed in the ES cell clone 49.8
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beginning of the biological analysis. Germline transmission of the targeted Smad4
allele represents the first stage of a breeding programme required to create a null
Smad4 allele only in the mammary epithelium of the mouse. The next steps are:
1) Mating the Smad4+/n progeny of this cross to Smad4+/" animals.
2) Genotyping the progeny from this cross to determine which animals are
Smad4llA
3) Mating Smadd07" animals to BLG-Cre transgenic mice.
4) Analysing the progeny of this cross which should have deleted the floxed
allele and effectively be Smad"" in the mammary gland only.
Analysis of the mammary gland-specific null Smad4 animals will probably take on a
similar pattern to analysis of the BLG-Smad4 transgenic animals. This will involve
wholemount and H&E analysis of both wild type and Smad4 null mammary glands
and an extensive biochemical analysis of genes both related to and downstream of
the TGF-P signalling pathway. One of the first questions to be addressed will be
what levels of residual Smad4 are observed in the gland after exposure to Cre.
Previous studies have shown that the BLG-Cre transgene reproducibly delivers 80%
deletion of floxed genes (Chapman et al, 1999) and a similar level of recombination
is predicted for Smad4. Western blotting with a Smad4 antibody will be used to
determine exactly how much Smad4 protein remains in the mammary gland and
where it is located.
Predicting a phenotype for this experiment is difficult given that there are currently
no other mammary gland-specific floxed TGF-(3-related genes in the literature, and
the majority of conventional knockouts of TGF-P genes result in embryonic lethality.
However, given the widespread role of TGF-P in control of epithelial cell growth the
loss of Smad4 (and possible loss of some TGF-P signalling pathway components) is
predicted to lead to dysregulation of the mammary gland. How this dysregulation
presents itself is more difficult to predict as we currently have little information on
what role Smad4 actually plays in the mammary gland. However, the immediate
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hypothesis to be tested, given the observed up-regulation of Smad4 at the start of
involution (See Chapter 6) and the preliminary observation that over-expression of
Smad4 may lead to accelerated involution (See Chapter 4), is that loss of Smad4
will impair the normal programme of involution.
The availability of mice bearing a conditional Smad4 allele will also allow an
assessment of the potential of Smad4 to act as a tumour suppressor within any given
tissue, dependent upon the pattern of Cre mediated excision. Loss of Smad4 has
been reported to occur in a range of tumour types (Xu et al, 2000 and Schutte et al,
1996, Duff and Clarke, 1998), and it is clear that Smad4 is a potent tumour
suppressor in the murine intestine (Takagi et al, 1996, Takaku et al, 1999 and Xu et
al, 2000). The availability of mice bearing a conditional allele will allow these roles
to be dissected further in vivo. In particular, this strain will permit an analysis of
tumour suppressive activity within the mammary epithelium. Schutte et al (1996)
reported that Smad4 was lost in 12% of human breast cancers, suggesting that Smad4
may be important in preventing a subset of neoplasias in the breast. This data was,
however, derived from a limited analysis of tumour cell lines, and it is questionable
whether this truly reflects a role for Smad4 in suppressing neoplasias. Conditional
inactivation of Smad4 in the mammary epithelium will directly address this question
and may also generate a murine model for this subset of human breast cancers.
Numerous publications have demonstrated that loss of responsiveness to TGF-P is a
key factor in the progression to neoplasia (for review see Gold, 1999), and that this
may be mediated through both altered cellular proliferation and cell death. It is also
clear that functional Smad4 is an essential component of the normal TGF-P response.
The availability of mice bearing a conditional allele will allow a direct analysis of the
mechanisms through which perturbation of the TGF-P response can initiate and
promote neoplasia, and a precise assessment of the role of Smad4. The development
of these strains will not only permit a fundamental understanding of the significance
of signalling pathways in human cancer, but may also provide valuable models of
specific human cancers, such as of those of the breast and intestine.
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Chapter 6 - Smad-STAT Interactions in the Mammary Gland
6.1 Introduction
6.1.1 Mammary Gland Involution
As described in detail in Chapter 1 mammary gland involution proceeds through
two distinct stages and both these stages exhibit characteristic changes in gene
expression or activity. First stage changes include up-regulated expression of
sulphated glycoprotein-2 (SGP-2), tissue inhibitor of metalloproteinases-1 (TIMP),
interleukin -16 converting enzyme (ICE), and cell cycle control proteins (c-Jun,
junB, junD, c-fos and c-myc) and decreased expression levels of milk protein genes.
Second stage changes include increased expression levels of matrix
metalloproteinases gelatinase A and stromelysin-1 and serine protease urokinase-
type Plasminogen activator (Figure 6.1)
Programmed Cell Death (PCD) of individual alveolar cells during the first days of
involution is correlated with increased expression levels of the death inducers bax
and bcl xshort (bcl-xS) as compared to bcl-xlong (bcl-xL), both of which are
members of the bcl-2 family. Importantly, this phase of PCD is p53 independent.
Changes in activity of two STAT family members accompany mammary gland
involution: decreased activity of the prolactin signalling molecules STATSa and
STAT5b and activation of STAT3.
Recently the Smad gene family have been identified as mediators of TGF-P
superfamily signalling and have been implicated in mediating epithelial cell
apoptosis (Brodin et al, 1999, Yanagisawa et al, 1998 and Ishisaki et al, 1998). This
chapter aims to examine the in vivo potential for such a role during mammary gland














The two stages ofmammary gland involution
(1) In the first stage of involution alveolar cells undergo programmed cell
death, but there is no remodelling of the lobular-alveolar structure. First
stage changes include up-regulated expression of inhibitors of proteases,
apoptosis-associated genes and cell cycle control proteins and this is
concomitant with decreased expression levels of various milk protein genes
(2) During the second stage of involution the lobular-alveolar structure of the
gland is obliterated as proteinases degrade basement membrane and extra¬
cellular matrix (ECM).
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6.1.2 Smads and STATs and Apoptosis
Smads are the family of signalling intermediates involved in signal transduction from
Transforming Growth Factor (3 (TGF-(3) superfamily members (Massague 1998;
Heldin et al, 1997; Christian and Nakayama, 1999) and, as described in Chapter 1 of
this thesis, this group of proteins was discovered in 1996 when the first member of
the group. Mothers against decapentaplegic (Mad) was identified during a screen for
mutations which enhanced dpp mutants (Flahn et al, 1996). Smads have been shown
to play a multitude of important biological roles including the ability to function as
tumour suppressors (Duff and Clarke, 1998; Riggens et al, 1997). This ability may
arise as a consequence of having been shown to initiate a number of cellular
responses including apoptosis. This is perhaps not surprising, as members of the
TGF-P superfamily have long been implicated in the induction of cellular apoptosis
through activation of proteins associated with cell cycle arrest such as
p21WAFl/Cipl and p27/Kipl (Rosfjord and Dickson, 1999). Individual Smads have
also been shown to initiate apoptosis in vitro, thought to be mediated through an up-
regulation of p21 (Dai et al, 1999; Grau et al, 1997 and Chiao et al, 1999) and are
also up regulated during involution in the prostate (Brodin et al, 1999). Recently
Smads have been shown to interact with another family of intermediate signalling
molecules, STATs (Signal Transducer and Activator of Transcription). STATs are a
family of latent transcription factors which are activated in response to many
cytokines and growth factors (Schindler, 1998) and have been shown to be capable
of both activating and suppressing gene transcription (Fukada et al, 1998). Members
of the STAT family of transcription factors are present in species as diverse as
mammals, insects and slime moulds. Discovered as mediators of interferon-induced
signals, the STATs were later shown to drive many different ligand-induced
responses through receptor-induced tyrosine phosphorylation and dimerisation.
STAT1 also functions as a transcription factor, essential for the efficient constitutive
expression of certain genes, without needing tyrosine phosphorylation, and
phosphorylated STAT1 dimers mediate suppression - rather than activation - of
some genes. STATs are present in the cytoplasm of untreated cells in multiprotein
176
complexes, which might aid in their nuclear translocation and differential binding to
DNA, thus contributing to the specificity of STAT action. STATs are activated in
response to many different cytokines and growth factors, and they can function as
either growth suppressors (Kaplan et al, 1998) or growth promoters (Catlett-Falcone
et al, 1999) depending on the particular STAT and the promoter sequence to which it
binds. STATs regulate cellular functions as diverse as embryonic development
(Nemetz and Hocke, 1998) cell death (Kumar et al, 1997) and cell migration
(Mohanty et al, 1999) and to date at least seven mammalian STATs have been
identified, ranging in size from 90 to 115 kDa. The STAT signalling pathway has
been well defined as an archetypal membrane to nucleus signal transduction pathway
which utilises the Janus kinase (JAK) proteins to achieve a cascade of
phosphorylation signals leading to gene transcription. The classic activation pathway
involves the cytokine ligand IFNy which induces oligomerisation of the IFNy
receptor subunits, leading to phosphorylation and activation of the preassociated
JAKs, which then phosphorylate the IFNy receptor, allowing STATI to dock.
STAT1 is then phosphorylated and forms a homodimer that migrates to the nucleus
(Figure 6.2). TGF-(3 and Smads have been shown to be inhibited by the IFN-y/STAT
pathway (Ulloa et al, 1999). Here IFN-y inhibits the TGF (3-induced phosphorylation
of Smad3 and its attendant events, namely, the association of Smad3 with Smad4. the
accumulation of Smad3 in the nucleus, and the activation of TGF-(3-responsive
genes. Acting through JAK1 and STAT1, IFN-y induces the expression of Smad7, an
antagonistic Smad, which prevents the interaction of Smad3 with the TGF-(3
receptor. These observations were the first to indicate a possible mechanism of
transmodulation between the STAT and Smad signal-transduction pathways. A
second recent paper enforces this concept that Smad and STAT pathways are closely
linked with the observation that in vitro Smadl and STAT3 can interact through the










The classic activation pathway involves the cytokine ligand IFNy which
induces oligomerisation of the IFNy receptor subunits, leading to
phosphorylation and activation of the preassociated JAKs, which then
phosphorylate the IFNy receptor, allowing STAT1 to dock. STAT1 is then
phosphorylated and forms a homodimer that migrates to the nucleus
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6.1.3 Co-activators and Complexes
p300 and CBP are large proteins, which are structurally and functionally conserved
in mammals, C. elegans and Drosophila, and which have been demonstrated to serve
coactivator roles for several classes of transcription factors. p300 is a close
homologue of CREB- binding protein (CBP), a large protein discovered in 1998 to
associate with cAMP response element binding protein (CREB) in response to cAMP
signalling (Chrivia et al, 1993). p300 was purified as a cellular binding protein of the
adenoviral ElA protein (Eckner et al, 1994) and these two molecules have been
implicated in functions of a large number of regulated transcription factors based
primarily on two criteria; physical interaction and the ability to potentiate
transcription when overexpressed (Gerritsen et al, 1997). One reason for these
molecules' importance for so many different transcription factors may be the finding
that both CBP and p300 harbour histone acetyl transferase (HAT) activity (Bannister
and Kouzarides, 1996 and Ogryzko et al, 1996). Compact chromatin structure
imposes a repression effect on transcription in vivo. Histone acetylation results in
decreased affinity between core histone subunits and DNA, facilitating entry of core
transcription factors and is thus correlated with increased transcriptional activation.
Smadl, STAT3 and p300 were found to bind in a complex to the GFAP promoter in
neural cell types and this was the first indication that Smads and STATs can
physically interact (Nakashima et al, 1999). p300 was shown to interact physically
with STAT3 at its amino terminus in a cytokine stimulation-independent manner,
and with Smadl at its carboxyl terminus in a cytokine stimulation-dependent
manner. The formation of a complex between STAT3 and Smadl, bridged by p300,
was then elegantly shown to be involved in the cooperative signalling of LIE and
BMP2 and the subsequent induction of astrocytes from neural progenitors. A third
more recent paper has shown that Smadl interacts with p300 and that this interaction
can synergistically activate gene transcription (Pearson et al, 1999). This group
demonstrated that Smadl interacts with p300 and CBP both in vitro and in vivo. The
N- and C-termini of Smadl negatively interfere with binding to p300/CBP, and the
C-terminal half of Smadl harbours two interaction domains both binding
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to the same region near the C-terminus of p300/CBP. They showed that Smadl can
stimulate gene transcription in a cooperative fashion with p300/CBP and that
phosphorylation of Smadl enhances its binding to CBP and thereby further
stimulates Smadl-dependent transcription. These results were the first to provide a
mechanism of how a phosphorylated Smad might regulate gene activity by
interaction with p300/CBP and other factors associated with these bridging
coactivators.
STATs have been implicated in regulating apoptosis in several systems, but more
recently have been shown to be essential for co-ordinated mammary gland involution
where there is extensive apoptosis of the secretory epithelial cells (Chapman et al,
1999). This study utilised an animal model of conditional deletion of STAT3 in the
mammary epithelium during the time of lactation and involution. Following
weaning, a decrease in apoptosis and a dramatic delay of involution occurs in STAT3
null mammary tissue. No marked differences were seen in the regulation of STAT5,
Bcl-x(L), or Bax in the absence of STAT3. Functional activation of STAT1 and
increases in levels of p53 and p21 occurred and may act as compensatory
mechanisms for the eventual initiation of involution observed in STAT3 null
mammary glands. This was the first demonstration of the importance of a STAT
factor in signalling the initiation of physiological apoptosis in vivo.
I therefore chose to examine the regulation of Smads during normal mammary gland
involution and the interaction they may have with STATs in this environment during
that period. This investigation is based on the hypothesis that since STAT3 is known
to be important in mammary gland involution (Chapman et al, 1999) and TGF-(3 is
known to be both important in mammary gland biology and a known inducer of
apoptosis, and that Smads and STATs have been shown to interact; it seems possible
that Smads play a role in involution of the mammary gland and that if Smad-STAT
interactions are important in the context of mammary gland biology then disruption
of one of these components might affect the other. I chose to analyse the effect of
perturbed Smad-STAT interactions by utilising a strain of mice carrying a
conditional null STAT3 allele. This mouse model has been described before and
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briefly consists of a conditional deletion of the Stat3 gene using the Cre-lox
recombination system in which expression of Cre recombinase is directed
specifically to mammary epithelial cells by the promoter of the milk protein gene (3-
lactoglobulin (BLG) (Selbert et al. 1998). These BLG-Cre transgenic mice were
crossed with mice containing one null Stat3 allele and one floxed Stat3 allele in
which the loxP sites were inserted around the tyrosine phosphorylation domain to
create a functional knockout of Stat3 (Takeda et al. 1998).
6.2 Results
6.2.1 Smads are up regulated at the start of involution
TGF-(3-induced apoptosis of epithelial cell types has been well characterised. In
order to investigate the potential role of members of the Smad signal transduction
pathway in this process I examined levels of various Smads from day 10 of lactation,
at which point pups were weaned to induce involution, through to day 6 of involution
by Western blot analysis. See Figure 6.3 for a description of these stages by H&E
staining of mammary gland slides. A subset of the Smad proteins was analysed.
These comprised Smadl, as an example R-Smad implicated in BMP signalling,
Smad2 as an example R-Smad implicated in TGF-(3 and activin signalling; the
principal Co-Smad, Smad4; and the principal anti-Smad implicated in TGF-[3 and
activin signalling, Smad7. I also analysed levels of the activated R-Smad, phospho-
Smad2. Analysis of raw data shows that levels of Smadl, Smad2, phospho-Smad2
(R-Smads) and Smad4 (a Co-Smad) are all up regulated at day 2 of involution
compared to day 10 lactation. The highest fold induction is observed for Smads I and
2 at day 2 of involution. (Figure 6.4 (a).). In contrast to this, levels of Smad7, an
anti-Smad, remained relatively unchanged during involution, although a slight
reduction was seen at day 2 and day 6 (Figure 6.4 (b).). Data was also normalised to
keratin 18 levels, a marker for epithelial cells, to account for differences in the
epithelial cell content of the glands throughout involution attributable to the fact that
the STAT3 null mice involute approximately three days later than their wild type
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Figure 6.3
H&E stain ofmammary gland lactation to involution progression
This figure shows H&E staining of mammary gland in (a) virgin mice
where the gland is composed of branching epithelium and stromal
alveolar structures and (b) day 10 lactation where the alveolar structures
become filled with milk proteins and the epithelial walls expand. By day
3 (c) the lobuloalveolar structure of the gland has started to collapse due
to degradation of the extracellular matrix. And by day 6 (d), although
involution is not complete, the majority of the gland has been remodelled.
10 days after the start of involution (e) the gland resembles that of a
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Figure 6.4
Western blot analysis of Smads in wild type mammary gland
(a) Western blot analysis of R-Smadsl,2, activated Smad2 (phospho-Smad2)
and Smad4 in wild type mammary gland from day 10 lactation through to day
6 involution. Densitometry analysis was carried out on an average of two gels
and expressed as a percentage of the highest value for each blot
(b) Western blot analysis ofAnti-Smad, Smad7 in wild-type mammary gland
from day 10 lactation through to day 6 involution. Densitometry analysis was
carried out on an average of two gels and expressed as a percentage of the
highest value for each blot
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littermates. This analysis again showed levels of Smadl, 2 and phospho 2 to be
increased at day 2, levels of Smad 7 to be reduced at this time point and only
relatively minor changes in the levels of Smad4. When normalised to keratin 18
levels and compared to day 10 of lactation, increases in the levels of Smadl, 2,
phospho2 and 4 were seen at day 6.
Recently it has been established that Smads and STATs, specifically Smadl and
STAT3, interact in vitro in COS-7 cells (Nakashima et al, 1999). This interaction
takes place in the nucleus and involves the p300 co-activator molecule bound in a
ternary complex. I decided to investigate whether this interaction took place in vivo
during the course ofmammary gland involution, and if the interaction could still take
place in the absence of STAT3. It was decided to utilise a transgenic strain
conditional for STAT3 in the mammary gland to assess the significance of STAT3 in
this complex. This model utilises Cre-lox technology to render approximately 80%
of the gland null for STAT3 at full lactation (Chapman et al, 1999).
Immunoprecipitations with p300 were probed for Smadl and STAT3 in wild type
mammary glands and it was found that both proteins can interact with p300 in vivo
(Figure 6.5 (I) and (II)). Immunoprecipitation with Smadl and subsequent probing
with STAT3 implies that the Smad and STAT molecules are bound to the same p300
molecule in a ternary complex, as has already been demonstrated to occur in vitro
(Figure 6.5 (III)). In mice characterised by mammary gland specific deletion of
STAT3, immunoprecipitation with p300 and probing with STAT3 confirmed the
absence of STAT3 from the p30() complex throughout lactation and involution
(Figure 6.6 (a)). However, Smadl was found to bind p300 regardless of the presence
or absence of STAT3 (Figure 6.6 (b)). To further investigate Smad-STAT
interactions I also probed the p300 immunoprecipitations with STAT1 and found that














Immunoprecipitations with p300 and Smadl. probed with Smadl and STAT3
(I) Immunoprecipitation with p300 on wild type mammary gland tissue at
days 10 of
lactation and days 2, 3 and 6 of involution. This blot was probed with Smadl.
The large bands at approximately 50kDa and 25kDa reflect binding binding
to IgG heavy and light chains and are present in all the IP blots.
(II) Immunoprecipitation with p300 on wild type mammary gland tissue at
day 10 of lactation and days 2, 3 and 6 of involution, probed with STAT3.
(III) Immunoprecipitation with Smadl on wild type mammary gland tissue at
days 10 of lactation and days 2, 3 and 6 of involution, probed with Stat3.
Note: Immunoprecipitation with Smadl, probed with Smadl, confirmed that
immunoprecipitations were effective.
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Immunoprecipitations with p300 probed with STAT3. Smadl and STAT1
(a) Immunoprecipitation with p300 on wild type (+) and STAT3 null (-)
mammary gland tissue at day 10 lactation and days 2, 3 and 6 of involution,
probed with a STAT3 antibody. The large bands at approximately 50kDa and
25kDa reflect binding to IgG heavy and light chains and are present in all the
IP blots.
(b) Immunoprecipitation with p300 probed with Smadl, on wild type (+) and
STAT3 null (-) mammary tissues at day 10 lactation and days 2, 3 and 6 of
involution.
(c) Immunoprecipitation with p300, probed with STAT1 on wild type (+) and
STAT3 null (-) mammary tissues at day 10 lactation and days 2, 3 and 6 of
involution.
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6.2.2 Smad protein levels in a model of delayed involution, a conditional
STAT3 knockout
Mammary gland-specific STAT3 null mice have a phenotype of delayed involution
(Chapman et al, 1999). In these mice the mammary gland involutes approximately
three days later than in wild-type littermates and involves up-regulation of genes not
associated with normal involution. When levels of the Smads were compared
between wild type and STAT3-/- glands, an increase was seen in the absolute levels
of Smads 1, 2 and phospho2 in the absence of STAT3 at day 3 of involution. No such
differences were noted for Smad4 or Smad7 (Figure 6.7 (a)). However, these
differences must be interpreted in the context of altered involution in the absence of
STAT3. As has previously been shown (Chapman et al, 1999), STAT3 deficiency
causes a delay in involution which leads to a relative increase in the number of
epithelial cells during involution. Quantitation of Smad levels relative to the level of
keratin 18 (a marker of epithelial cells) suggests that any differences seen between
the wild type and the STAT3 null glands at day 2 and day 3 are due to the presence
of relatively more epithelial cells in the absence of STAT3 (Figure 6.7 (b)). At day 6
of involution, comparison relative to keratin 18 shows a marked increase in the levels
of all the Smads in the presence of STAT3.
6.2.3 PA1-1 and p21/WAF1/Cip1 levels in the mammary qiand
Several recent studies have used Plasminogen Activator Inhibitor-1 (PAI-1) as a
functional readout of Smadl, 2 and 3 activity as the PAI-1 promoter contains
multiple Smad binding elements (SBE) which can be activated by these R-Smads
(Pearson et al, 1999 and Dennler et al, 1998). It was therefore considered likely that
if Smad-STAT interactions play an important part in the induction and maintenance
of involution of the mammary gland then the absence of STAT3 from the p300
complex might alter the functional readout in terms of known downstream gene
expression. Consequently I decided to examine PAI-1 protein levels in normal and
STAT3-/- mammary glands. PAI-1 levels were compared from wild type and STAT3
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Figure 6.7
fa) Western blot analysis of Smadl. Smad2, phospho-Smad2 and Smad4 in
wild type (+) and STAT3 null (-) mammary gland tissues throughout
lactation and involution.
Densitometry analysis was carried out on an average of two gels and
expressed as a percentage of the highest value for each blot. Solid bars
represent wild type and open bars represent STAT3 null. The raw
densitometry data was then normalised to keratin 18 data to compensate for
epithelial cell content.
fbl Western blot analysis of Smad7 in wild type (+) and STAT3 null (-)
mammary gland tissues during lactation and involution.
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was found that in normal involuting mammary gland absolute levels of PAI-1 were
high at the start of involution, began to decrease by day 3 and were very low at day 6
of involution. In contrast to this the absolute levels of PAI-1 increased throughout
involution in the STAT3 null glands to day 3 but dropped by day 6 (Figure 6.8 (a)).
It is necessary to normalise these results to keratin 18 levels to account for
differences in the epithelial cell content of wild type and mutant glands. This
normalisation process showed PAI-1 levels to be unaffected by STAT3 deficiency
and that even in wild type mammary glands they did not parallel the levels of the
Smads, as might be expected if they are accurate downstream markers of gene
activation.
To continue with this approach I chose to examine protein levels of p21/WAFl/Cipl,
another cited readout of Smad activity. This cell cycle arrest protein is commonly
activated in response to TGF-P induced growth arrest and has been shown to be
downstream of the Smad4 signalling molecule (Grau et al, 1997) with direct
evidence for Smad interactions with the p21 promoter region (Moustakas and
Kardassis, 1998). Comparison of p21 protein levels in the wild type and STAT3 -/-
glands shows that p21 is massively up regulated in the null animals but not in the
wild types, both by analysis of raw data and following normalisation to keratin 18
(Figure 6.8(b)). Thus, examination of two commonly cited readouts of Smad activity
(PAI-1 and p21) has shown that in vivo levels of PAI-1 do not parallel levels of the
R-Smad proteins as might have been predicted, and that these levels of protein
expression are unaffected by STAT3 status. However, these experiments have also
shown that p21 levels markedly increase in the absence of STAT3 compared to the
very low levels in wild types, and that the peak of p21 expression coincides with the
induction of Smads 1, 2 and phospho2 at day 2 of involution.
6.2.4 DNA Binding Activity of Smads in the Mammary Gland
The data obtained from the analysis of PAI-1 and p21AVafl/Cipl expression levels
therefore gives apparently contradictory readouts of the effects of STAT3 deficiency
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Figure 6.8
(a) Western blot analysis of Plasminogen Activator Inhibitor-1 (PAI-1) in
wild type (+) and STAT3 null (-) mammary gland tissues during lactation and
involution.
Densitometry analysis was carried out on an average of two gels and
expressed as a percentage of the highest value for each blot. Solid bars
represent wild type and open bars represent STAT3 null. The raw
densitometry data was then normalised to keratin 18 data to compensate for
epithelial cell content.
fb) Western blot analysis ofp21/Waf-l/Cipl in wild type (+) and STAT3 null
(-1 mammary gland tissues during lactation and involution.
Densitometry analysis was carried out on an average of two gels and
expressed as a percentage of the highest value for each blot. Solid bars
represent wild type and open bars represent STAT3 null. The raw
densitometry data was then normalised to keratin 18 data to compensate for
epithelial cell content
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likely that expression levels during involution of the tissue are affected by factors
other than the Smads. Hence, although these are the only currently recognised
functional readouts of Smad activity they probably do not accurately reflect Smad
activity within the involuting mammary gland. For this reason I decided to examine
Smad DNA binding activity and directly determine if this was altered in the absence
of STAT3. This question was addressed using an Electrophoretic Mobility Shift
Assay (EMSA). The MH1 domains of Smads are known to bind to specific DNA
sequences that contain 5'-AGAC-3' sequences, termed Smad Binding Elements
(SBEs). EMSA analysis of wild type and STAT3 null mammary gland nuclear
extracts showed strong binding to the SBE (GTCTAGAC) in the STAT3 nulls but
extremely weak binding in wild type samples. Notably this increased binding was
demonstrated for the time point characterised by maximal p2i induction, at day 2 of
involution. No binding occurred in either sample with a mutant SBE oligonucleotide
demonstrating that this binding was specific to the SBE (Figure 6.9 (a)). Supershift
analysis with Smadl and Smad4 showed supershifts with both antibodies in the
STAT3 null samples and evidence of a much weaker supershift in the wild type
samples (Figure 6.9 (b))
6.3 Discussion
This work has shown that in the normal murine mammary gland Smadl, Smad2 and
phospho-Smad2 are all up regulated at the start of involution, both by the analysis of
raw data and when calculated relative to keratin 18. Levels of Smad4, the co-Smad,
increase only moderately at the start of involution. By contrast, the I-Smad, Smad7,
is decreased during this period. These observations suggest that the Smads may be
involved in regulating epithelial cell apoptosis which commences at approximately
day 2 of involution. Although the changes in protein levels reported here are
relatively modest (up to 4-foid induction) these increases are comparable with
changes in expression levels known to have important biological consequences.
Examples of these include haploinsuffiency of the Pax genes (Ostrom et al, 2000),










Electrophoretic Mobility Shift Analysis (EMSA) of wild type (+) and
STAT3 null (-) nuclear extracts from mammary gland tissue at day 2 of
involution.
(a) Shows part of an EMSA gel where nuclear extracts from wild type (+)
and STAT3 null (-) mammary glands have been incubated with either a wild
type SBE radiolabelled oligonucleotide or a mutant SBE radiolabeled
oligonucleotide.
(b) Shows part of an EMSA gel where nuclear extracts from wild type (+)
and STAT3 null (-) mammary glands have been incubated with a
radiolabelled wild type SBE oligonucleotide plus either Smad2 or Smad4
antibodies.
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the most extreme phenotype with haploinsufficient Eya-1 animals lacking ears and
kidneys (Xu et al, 1999).
Nakashima and colleagues (Nakashima et al, 1999) recently demonstrated Smadl,
STAT3 and p300 form a ternary complex in vitro. This prompted an investigation to
determine if this complex was intact in vivo in the mammary gland during lactation
and involution. Immunoprecipitation studies show that p300 can bind both STAT3
and Smadl throughout lactation and involution, strongly suggesting that this
complex is intact in vivo in wild type mice. Assuming that immunoprecipitations are
only semi-quantitative there is no conclusive change in binding to the complex over
this period. Immunoprecipitation with Smadl followed by probing with STAT3
implies that the Smadl and STAT3 molecules are both bound to the same p300
molecule, indicating that this is probably a tripartite complex with p300 acting as a
bridging molecule as has been previously been shown in vitro by Nakashima et al.
The function of this complex remains unknown but Smadl binding to p300 has
recently been shown to synergistically facilitate transcriptional activation (Pearson et
al, 1999).
The data suggesting that Smads may be involved in the regulation of involution and
that Smads and STATs can interact in the mammary gland in vivo prompted an
enquiry to examine how loss of one of these components, namely STAT3, would
affect the process of involution and give insight into the importance of the Smad-
STAT complex. The results show that the pattern of Smad protein expression over
the course of involution was altered in the absence of STAT3, the principal
difference being observed at day 3 of involution. These conclusions are drawn from
an analysis of raw densitometric measurement. However, these measurements can be
misleading, as the mammary gland is a dynamic tissue which is undergoing massive
deconstruction and remodelling during involution. This is particularly relevant to the
analysis of STAT3 deficiency as this leads to persistence of the mammary
epithelium. It was therefore necessary to normalise all densitometry data against a
marker of epithelial cell content, namely Keratin 18, so compensating for variations
in epithelial cell content between wild type and STAT3 null glands. This analysis
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revealed that, relative to the epithelial cell content, levels of the Smads were
unaltered in the absence of STAT3 for the first three days of involution, but that
marked differences were observed at day 6. It can be concluded from this that the
Smads are not targets of STAT3 in the first three days of involution, and the
differences at day 6 must be interpreted with caution because at this time point the
vast majority of the gland is composed of non-epithelial cells.
Immunoprecipitation with p300 shows as expected that very little STAT3 binding
occurs in the STAT3 null mammary glands. The residual level of binding observed
probably reflects the fact that in this model STAT3 deletion occurs only in the
epithelial cells of the gland such that some STAT3 will remain in stromal cells.
Immunoprecipitation with p300 and subsequent probing with Smadl shows that
Smadl can, however, bind the p300 molecule in the absence of STAT3. It can be
concluded therefore that STAT3 is not absolutely required for the Smadl/p300
complex to form. This also suggests that the p300 molecule is acting as a bridge and
that Smadl and STAT3 may not be directly linked, confirming the data presented by
Nakashima et al (1999). I have also shown that STAT1 can bind the p300 molecule
in both the presence and absence of STAT3. It has been observed that up-regulation
of STAT1 protein levels occurs in the absence of STAT3 (see Chapman et al, 1999).
This raises the possibility that STAT1 may be compensating for STAT3 loss. The
immunoprecipitations performed here do not support increased STAT1 binding;
however these can only be considered semi-quantitative.
In order to ascertain if functional activity of the Smads was affected by disruption of
the p3()0/Smad/STAT complex I then analysed expression of two commonly cited
readouts of Smad expression, namely Plasminogen Activator Inhibitor-1 (PAI-1) and
p21AVafl/Cipl. PAI-1 plays an important part in mammary gland involution as it is
one of many protease inhibitors produced by epithelial cells which are down
regulated to allow proteolytic degradation of the gland (Zavizion et al, 1996). The
PAI-1 promoter contains Smad Binding Elements (SBE) in its promoter sequences
which have been shown to be targets of transcriptional activation by the Smad
proteins. The PAI-1 promoter is commonly used in vitro assays to determine Smad2
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and 3 activities and very recently was shown to be an appropriate marker for Smadl
activity (Pearson et al, 1999). It therefore seemed logical to analyse PAI-1 protein
levels as a functional readout of Smad activity in the mammary gland. Once
normalised to the keratin 18 content the data shows that in the absence of STAT3
PAI-1 levels remain unaltered relative to wild type levels seen in the glands during
involution. Notably, however, changes in PAI-1 expression do not parallel changes
in Smadl, 2 and phospho Smad2 expression suggesting that in this context PAI-1
expression is not an accurate indicator of Smad activity. This raises important issues
regarding the use of this molecule as a suitable readout in vivo for the Smads. It is
hardly surprising that in the context of massive mammary gland proteolytic
degradation and reconstruction that an inhibitor of proteases is down regulated to
allow involution to commence and my findings strongly suggest that there are many
more factors other than the Smads acting upon it. A second cited readout of Smad
transcriptional activity is p21. Western blot analysis shows that in wild type glands
p21 levels remain relatively low and constant throughout lactation and involution. In
contrast p21 levels are dramatically increased during involution in the STAT3 null,
peaking at day 2 of involution. This pattern of expression only correlates with
changes in Smad protein levels in the absence of STAT3 suggesting that STAT3 may
normally function by repressing Smad transcriptional activity in the mammary gland.
Use of PAI-1 and p21 protein levels as readouts of Smad activity is potentially
flawed because levels of these proteins are likely to be affected by other factors. This
may explain the apparently contradictory results obtained for these proteins here. I
therefore also investigated if the ability of the Smads to bind target DNA sequences
in the mammary gland was altered by disruption of the p300/Smadl/STAT3
complex. EMSA analysis with a consensus SBE oligonucleotide, but not a mutant
SBE oligonucleotide, showed that binding occurred much more strongly in the
absence of STAT3 than in wild type mammary extracts, supporting the concept that
STAT3 can play an inhibitory role in this complex. In order to rule out the possibility
that the observed binding to the Smad oligonucleotide was an artefact supershift
analysis with anti-Smad antibodies was carried out, confirming that both Smadl and
Smad4 are bound to the complex. The possible mechanism of repression of Smad
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binding by STAT3 is currently not known but STAT3 is known to both enhance and
repress transcription, one example of which is the effect STAT3 has on the G1 to S
transition phase. Here STAT3 has been shown to up regulate cyclins D2, D3 and A
whilst concomitantly down regulating p21 and p27. This particular paper suggests
that such contradictory signals regulating cell cycle progression could be
simultaneously delivered via STAT3 and Smad-STAT interactions could well play a
role in orchestrating this kind of balance. (Fukada et al, 1998) Another example
shows STAT3 repression of c-myc and c-myb and expression of junB and IRF1. In
this system blocking of STAT3 activation resulted in inhibition of the repressed c-
myb and c-myc (Nakajima et al, 1996). Repression of DNA binding can occur via
many means including conformational changes and "squelching" - that is
sequestration of associated transcriptional proteins. As both Smad and STAT
transcriptional complexes are only beginning to be elucidated it remains to be seen
which of these possibilities could account for the observed increase in DNA binding
by Smads in the absence of STAT3 (Figure 6.10).
In conclusion, this work has shown that R-Smadsl, 2 and phosphorylated Smad2 are
modestly up regulated during involution of the normal mammary gland. The data
presented is consistent with the presence of a p300/Smadl/STAT3 complex during
mammary gland lactation and involution and further shows that another member of
the STAT family, STAT1, is also capable of binding this complex. Analysis of the
effect of removing STAT3 from this complex using mice bearing a conditional
STAT3 null allele showed that in the absence of STAT3, Smadl and STAT1 are still
capable of binding p3()(), showing clearly that STAT3 is not required for the binding
of these proteins to the complex. STAT3 deficiency does not alter levels of the Smad
proteins over the first three days of involution, however protein levels of p21 (one of
the transcriptional targets of the Smads) are markedly elevated in the absence of
STAT3 during this period, suggesting that SFAT3 may be inhibiting Smad activity.
By contrast, levels of PAI-1, the only other commonly cited readout of Smad activity
are unaffected by STAT3 deficiency and do not parallel the pattern of Smad protein
expression. This finding questions the usefulness of PAI-1 as an in vivo readout of
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Possible model for Smad-STAT Interactions
This figure shows a possible model for Smad-STAT interactions where
STAT3 may act as an inhibitor to Smad binding to SBEs within promoter
sequences of DNA. This model shows the simplest type of steric inhibition
with (a) showing that when there is no STAT3 present the complex of R-
Smad, Co-Smad, p300 and various co-activators can bind the SBE and
initiate transcription of genes such as PAI-1 and p21. In (b) the diagram
shows how STAT3 may bind preferentially to the p300 molecule thus
sterically inhibiting binding of the Smad molecules to the SBE.
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be affected by STAT3 status, EMSA analysis was performed upon samples from
wild type and STAT3 null glands. This showed that Smad binding to an SBE
oligonucleotide was up regulated in the absence of STAT3. Taken together, this data
implicate the Smads in regulation of the normal physiology of the mammary gland
and show that in this tissue they interact with STAT3, and specifically that STAT3
can mediate repression of Smad DNA binding ability.
198
Chapter 7 - Discussion
7.1 Introduction
In this thesis I have examined the role of Smad4 in the murine mammary gland by a
number of in vitro and in vivo analyses including the use of two transgenic
approaches. I have reported that over-expression of various Smad cDNA expression
constructs in murine embryonic stem cells results in both the induction of apoptosis
and a G1 arrest; this work was then extended to an examination of the role of the
central mediator, Smad4, in the induction of mammary gland epithelial cell apoptosis
via the production of both a Smad4 mammary gland transgenic model and a Smad4
conditional deletion. The final analysis was an investigation into Smad-STAT
signalling interactions within the mammary gland and an examination on how
disruption of one pathway may affect the other.
7.2 Smads and Apoptosis
The initial study to address the question of what role Smad4 might play in mammary
gland epithelial cell apoptosis (involution) was based on the known facts that TGF-(3
plays many important roles in mammary gland physiology including apoptosis
during involution, and that Smads had been shown in a number of different cellular
environments to be capable of initiating apoptosis. To investigate if different human
Smad cDNA sequences were capable of initiating apoptosis in murine ES cells these
constructs were transfected and Annexin V levels analysed as an indicator of early
apoptotic events. Surprisingly, this experiment showed that only over expression of
the central mediator, Smad4 could initiate statistically significant increases in the
number of apoptotic cells. This phenomenon had been shown previously where over
expression of wild-type Smud4, but not Smad3, in MDCK cells strongly increased
the basal level of the p3TP-Lux reporter expression plasmid and initiated apoptosis
as determined by TUNEL analysis (Atfi et al, 1997). My finding confirms the
hypothesis that Smad4 has an important central role to play in the induction of
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cellular apoptosis. In an effort to elucidate what mechanism may potentiate this
apoptosis I examined cell cycle distributions from ES cells in which the human Smad
cDNAs had been over expressed. Previous workers have shown a slight increase in
the number of cells in G1 concomitant with Smad4 associated apoptosis (Dai et al,
1999) and I was able to confirm that this also occurred in ES cells. However, this
finding must be interpreted with caution as TGF-/3 induced apoptosis has been
associated with many different factors, pathways and causative agents and there is no
direct evidence that cell cycle arrest is a causative factor in the induction of
apoptosis. Nevertheless, this initial study into the role of Smad over expression
prompted an investigation of the in vivo role of Smad4 in mediating apoptosis
through the production of two transgenic models.
7.3 Transgenic Animal Models
In order to understand what contribution to mammary gland epithelial apoptosis
Smad4 might make, two systems were generated to examine over expression and loss
of the Smad4 protein in the same cell types of the mammary gland. This approach
involved the production of a Smad4 mammary specific transgenic strain and a
Smad4 mammary specific conditional deletion strain. Both approaches utilise the
same promoter to obtain Smad4 gene expression/deletion with the same cell
specificity. I report here the successful creation of both models and, although the
questions to be addressed by these remain as yet mostly unanswered, some potential
future analyses are discussed.
7.3.1 Creation of the BLG-Smad4 Transgenic
Both models utilise the ovine beta-lactoglobulin (BLG) promoter and it is hoped that
the benefits of using this will become apparent when more data is available. The
BLG promoter was used to create the Smad4 transgenic and the presence of FLAG-
tagged Smad4 protein in the transgenic cohort reflects human Smad4 cDNA over
expression. Preliminary analysis suggests these mice show a phenotype of
accelerated involution and completion of these analyses together with further
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biochemical analysis should be very revealing. The phenotype of the BLG-Smad4
transgenic animals involves no gross abnormalities of the gland which might result in
undernourishment of the pups, for example. Instead, initial insights might be drawn
from H&Es collected from the transgenic animals, which appear to be further
advanced through involution than control mice at the same stage, and it is hoped that
further biochemical analyses will confirm this finding. Although these comparisons
are made with non-littermate F1 controls, and it remains undetermined whether this
observation will hold with F2 littermate control mice, it is unlikely that the use of F1
control animals will alter the final analysis. It is therefore hypothesised that if Smad4
plays an important central role in involution of the gland then over expression of this
protein will lead to altered involution. Whatever the final outcome of the phenotype,
the model itself will provide valuable information on the precise role of Smad4
during this period.
Determination of expression levels of the human FFAG-tagged Smad4 cDNA will be
carried out by Northern blot analysis on the polyA tail of human Smad4 and
compared to expression of endogenous mouse Smad4 RNA. There remains a
possibility that expression of the transgene is too low to cause a strong phenotype
and there are a number of possible reasons as to why this might occur; it has been
shown previously that in some cases mammalian cDNAs are not expressed as well as
genomic DNAs (Clark et al, 1997). For example when the ovine BFG promoter was
used to drive expression of some mammalian cDNAs or a CAT reporter sequence it
failed to be expressed in the majority of transgenic lines generated. I analysed a total
of 10 lines and only one, EK6, expressed the FLAG-tagged transgene. It could well
be that this particular cDNA will be poorly expressed in the majority of lines and that
a greater number of founder animals would need to be generated in order to
overcome this.
Another potential reason for low expression of the transgene might be the absence of
a 5'UTR in the BFG promoter (£. Whitelaw, personal communication). Although
there is currently no evidence to support this idea regarding the efficiency of
expression of this particular ovine BLG promoter, it has been shown that 3'UTRs
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can aid in the stability of the RNA during processing (Kocarek et al, 2000) where the
poly(A) tail and sequences contained within the 3' UTR appear to be important for
protecting mRNA from RNase activity associated with the translation machinery.
BLG is one of the few promoters which has been shown to be remarkably non-
susceptible to position effects (Whitelaw et al, 1992). Chromosomal position effects
can influence strongly the transcription of foreign genes in transgenic animals and
this results in low frequencies and levels of gene expression and, in some cases, in
aberrant patterns of expression. It is assumed that transgene arrays integrate into the
host genome in a random manner where the integration site often influences the level
or pattern of expression of the transgene which may therefore be prone to position
effects (Al-Shawi et al, 1990). However, expression of heterologous genes from the
BLG promoter can result in either no expression (e.g. BLG/CAT as described above)
or expression levels unrelated to copy number. In an attempt to overcome this
problem, a transgene "rescue" strategy has been devised (Clark et al, 1992) based on
co-injection with genomic BLG constructs which has been found to result in a higher
frequency of expressing lines. This was successful in a number of cases but is not
universally applicable suggesting that genomic BLG sequences have the ability to
insulate transgenes from position effects in some chromosomal locations but not in
others. This "rescue" strategy was not applied to my pronuclear injection sessions (as
both were carried out outwith the Roslin Institute) and may be a useful strategy to
employ when utilising the BLG promoter in the future.
7.3.2 Future Work with the BLG-Smad4 Transgenic
Future work with this model will be carried out by other workers and will centre on a
biochemical analysis of Smad proteins (R-Smads 1, 2 and phospho-2 and the I-
Smads 6 and Smad7), downstream targets such as p21 and PAI-1 and STAT proteins,
specifically STAT3. Western blot analysis will attempt to determine if over-
expression of Smad4 in the mammary gland affects levels of the other Smads, if
Smad4 levels are self-limiting, or if R-Smads are the limiting factors. Another
possibility is that levels of I-Smads may be up-regulated to help "squelch" activated
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R-Smad levels (if indeed these are up-regulated) and in these studies it is hoped to
address the question of how central Smad4 is to the propagation and regulation of
TGF-(3 superfamily signalling - the initial experiments presented in this thesis
suggest that Smad4 may be the limiting factor in the pathway, and although
experiments with Smad4 null cells have shown that the presence of Smad4 is not
always necessary for transcription to occur (Dai et al, 1999; Sirard et al, 2000), and it
is possible that Smad4 may not be the only limiting factor in this pathway, this model
may help to elucidate how regulation of Smad4 by other Smads might occur.
Analysis of downstream marker genes such as p21and PAI-1 (and associated
problems in this analysis as discussed in Chapter 6) will provide information on
whether over expression of the transgene results directly in increases in transcription.
This study will enable us to address the question of whether other nuclear signals
might be involved (for example nuclear transcriptional co-repressors like TGIF
(Wotton et al, 1999) although it is currently difficult to assess exactly which
molecules due to lack of availability of antibodies.
Analysis of STAT protein levels follows on from my observations (in Chapter 6)
that Smads and STATs can interact in the context of mammary gland lactation and
involution and that STAT3 may be inhibitory to the Smadl transcriptional apparatus.
If this phenomenon of STAT inhibition is truly a mechanism of Smad transcriptional
control then it might be expected that a STAT protein could be up regulated to
compensate for the increase in Smad signals resulting from the transgene.
It is hoped that the transgenic cohort can be rapidly expanded to the required number
of animals such that these experiments and others can help elucidate what role
Smad4 plays in mammary gland lactation and involution. However, this question can
be addressed in parallel using the converse animal model, that is a conditional
deletion of Smad4 in the mammary gland.
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7.3.3 Creating the Conditional allele of Smad4
I have reported in this thesis the successful germ line transmission of a conditional
allele of the murine Smad4 gene. This method of analysis of Smad4 function in the
mammary gland was chosen based on the knowledge that conventional Smad4 gene
targeting has resulted in an embryonic lethal phenotype (Sirard et al, 1998).
Therefore, in order to study loss of Smad4 in the gland this approach was deemed
highly appropriate. One factor, which strengthened the argument to embark on such a
potentially risky and lengthy project, was the immediate availability of well-
characterised mammary gland Cre transgenic animals for mating to the "floxed"
mouse (Selbert et al, 1998).
7.3.4 Future work with the Conditional "Floxed" Smad4 Model
Due to time constraints the analysis of loss of Smad4 in murine mammary gland
epithelium lies outwith this project. The immediate next step is to mate the floxed
Smad4 mice (with one wild type allele and one "floxed" allele, termed Smad4+/fl) to
animals heterozygous for Smad4 (Smad4+/~) (Sirard et al, 1998) to create animals
with one floxed allele and one null allele (Smad4n/ ). The second step is to mate the
Smad4fl/" mice to our BLG-Cre transgenic animals (Selbert et al, 1998). These
animals have already been demonstrated to express Cre from late gestation until late
involution and, as soon as piogeny are available, it is hoped to begin characterisation.
This will comprise firstly, the kinetics and degree of deletion of Smad4 occurring in
the gland and secondly, the phenotype of loss of Smad4 in the murine mammary
gland. Analysis of the phenotype will concentrate on histological and wholemount
analysis of the mammary glands and on a biochemical analysis of related and
downstream target genes, similar to those used to analyse the phenotype in the
Smad4 transgenic animal model.
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7.4 Smad-STAT Interactions in the Mammary Gland
I have shown here for the first time that the STAT family of signal transduction
factors/transcription factors can inhibit Smad initiation of transcription in the
mammary gland, and confirm that this inhibition occurs through a complex formed
with the co-activator/repressor molecule p300. I have also shown that the commonly
cited readout of Smad activity, PAI-1, is not entirely appropriate in analysis of the
mammary gland in vivo as PAI-1 is likely to be a target of many of the protease
pathways active during the involution stage of mammary gland progression. This fact
also brings into question the suitability of using p21 as a marker of Smad activity in
vivo as this molecule is undoubtedly also a target of many of the active signalling
pathways at this time point. Studies in progress in collaborative laboratories where
mammary-specific floxed STAT3 mice have been crossed to p53 null animals will
determine if p21 is indeed a suitable marker for Smads in vivo. The fact that these
two molecules are the only commonly cited targets of Smad activation has made this
analysis difficult but the combination of this and EMSA analysis with an SBE
oligonucleotide strongly suggests that STAT3 is indeed inhibitory to Smads in the
context of mammary gland involution, and that this inhibition is generated through a
complex containing Smadl, STAT3. p300 and probably Smad4.
7.5 Conclusions
In this thesis I have attempted to describe an analysis of the role of Smad4 in the
murine mammary gland. This analysis centred on the use of transgenic technology to
create potentially useful models of both over expression and loss of Smad4 in the
same types of cell within the gland, the epithelial cells. Other analyses have included
an in vitro investigation into how Smad4 can cause cell death when inappropriately
expressed in embryonic stem cells, and an in vivo analysis of Smad-STAT
interactions within the mammary gland, which has shown inhibition of Smads by
STATs for the first time. Characterisation of the animal models will be a lengthy
process which lies outwith the realms of a 3-year Ph.D. However, in the near future I
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hope that information can be gained from both models which will be constructive in
determining what role Smad4 plays in mammary gland lactation and involution.
The evidence presented in this thesis allows several conclusions to be drawn on the
role of Smad4 in the induction of apoptosis. These conclusions are; first, that Smad4
is capable of inducing cellular apoptosis (as determined by transient transfection
experiments in embryonic stem cells) and that this induction of apoptosis is
associated with a G1 arrest; second, that Smad4 levels are up-regulated during the
normal programme of apoptosis associated with mammary gland involution and that
this up-regulation is concomitant with an increase in the expression of the cell cycle
cdk (cyclin dependent kinase) inhibitor p21/Wafl/Cipl, known to inhibit all cdks
involved in theGl —> S transition. This data strongly supports the notion that p21 is a
direct target of the Smad pathway and that altered p21 expression can induce cell
death. Finally, preliminary analysis of transgenic mice expressing Smad4 specifically
within the mammary epithelium has suggested that this may result in accelerated
involution compared to wild type controls. Taken together, this data strongly
suggests that Smad4 can modulate the programme of apoptosis and that it plays an
important role in both the initiation and maintenance of mammary gland involution.
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Appendix A - solutions and distributors
L-Broth
Bactotryptone (DIFCO) lOg/L
Yeast Extract (DIFCO) 5g/L
NaCl (Sigma) 10g/L
In de-ionised H2O, autoclaved
Supplemented with 50pig/ml ampicillin where stated
Supplemented with 1.2% w/v Bactoagar for plates
Solution PI
Tris-HCl, pH 8.0 50mM
EDTA (Sigma) lOmM
Rnase A (Sigma) 100|ig/ml
Should be stored at 4°C after addition of Rnase A
Solution P2
NaOH (Fislier Scientific) 200mM
Sodium Dodecyl Sulphate (SDS) (ICN, US) 1%
Should be stored at room temperature
Solution P3
Potassium acetate, pH 5.5 (Fisher) 3.0 M




MOPS, pH 7.0 (Sigma)
Isopropanol (Fisher)





Should be stored at room temperature.
Buffer OC
NaCl (Sigma)





Should be stored at room temperature.
Buffer OF
NaCl (Sigma)





Should be stored at room temperature.
10 x TBE Buffer:
TRIZMA base (Sigma)
Boric Acid (Sigma)





Make up to 1L with double distilled water
10 x Loading Buffer
Bromophenol blue (Fisher) 0.25%
Glycerol (Sigma) 25%
Make up in double distilled water
Sequencing Gel Solution
Urea (Sigma) 250g
19:1, 40% acrylamide stock (Severn Biotech Ltd. UK) 75mls
10 x TBE 50mls
Double distilled water 175mls
Tail Lysis Buffer













1M HEPES pH 7.4 (BDH) O.lmls
1M NaCl {Sigma) 1.4mls
1M CaCB^IDO (Sigma) 25jil
Double distilled water 8.5mls
Propidium Iodide 50pg/ml in PBS
Citrate Buffer
Sucrose (Fisher) 85.5g
Trisodium citrate (Fisher) 11.76g
Double distilled water 800ml
DMSO (Sigma) 50mls
pH to 7.6 with 5M HC1
Stock Solution
Tri-sodium citrate (Sigma) 2g
TRIZMA base (Sigma) 121 mg
Spermidine tetrahydrochloride (Sigma) 1044mg
Nonidet P40 (Sigma) 2mls
Double distilled water 2L
Adjust pH to 7.6 with 5M HC1
Solution A
Trypsin (Sigma) in 500mls Stock Solution, store frozen 15mg
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Solution B
Trypsin inhibitor (Sigma) 250mg
Ribonuclease A (Sigma) 50mg
In 500mls Stock Solution, store frozen
Solution C
Propidium iodide 208mg
Spermidine tetrachloride in 500mls (Sigma) 500mg
In 500mls Stock Solution, store frozen
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